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Abstract
Five derivatives of 15,16-dihydrooyolopenta[a]phenanthren-17-one were 
synthesised bearing 5-6 atom-long linker arms terminating with carboxyl groups. 
Linkage at C-3 and C-11 was through 0-butyryl ethers, at C-15 by way of an S- 
ether with thiopropionic acid, at C-16 via a hemisuccinate ester, and at 0-17  
through a carboxymethyloxime. These hapten acids were allowed to react, as 
their active N-hydroxysuccinimide esters, with the lysyl e-amino groups present 
on BSA to form physiologically stable conjugates suitable for antibody production.
These conjugates were independently used as antigens for the production 
of polyclonal antibodies. Rabbits were inoculated and serum collected at monthly 
intervals; the resultant sera were assayed by a direct ELISA assay procedure 
described, and the immunisation profile per animal, per antigen are presented.
A competition assay designed to probe human biofluids directly was 
developed and up to 60 compound analytes tested against each of the 5 
polyclonal sera generated, with the view to characterising the respective antibody 
specificity. The data was normalised between assay plates and polyclonal sera, 
and a direct comparison of the D-ring linked antigen derived polyclonal sera 
carried out. The polyclonal (17-N-linked serum) was shown to recognise most of 
the carcinogens tested, these included 11-methyl- and 7-methyl-15,16- 
dihydrocyclopenta[a]phenanthren-17-one,3-m ethylcholanthrene, and 
benzo[a]pyrene, in addition to other closely related compounds. Both the 15-S­
and the 16-Olinked derived antibodies demonstrated specificity toward 
cyclopenta[a]phenanthrene analogues they were designed to recognise. The 
sera raised against antigens derived from conjugates linked directly through the 
aromatic rings via the 3- and 11-positions, showed remarkable specificity toward 
their target antigens.
A collaboration was set up with Mr John.H.Davies (surgeon) at the Royal 
Surrey County Hospital and two affinity-purified anti-sera raised against C-11(11- 
O-linked) and C-17(17-N-linked) were employed in a competitive ELISA assay on 
human urine and blood samples. Having carefully eliminated recognition of 
human serum albumins closely homologous with the antigen BiSA carrier protein, 
one of the sera gave positive results with 10 out of 46 urine samples tested. 
When a minimum 10% cross-reaction threshold was applied to the analysis of 
data, only two of these urine samples were positive, one by a margin of 2% and 
the second patient displayed an activity of about 100 times that of the other 
positives.
Collection of further samples from this patient confirmed the ELISA activity. 
It was demonstrated that the activity was partially extracted into organic solvent 
(ethyl acetate) suggesting it to be a small hydrophobic molecule. HPLC analysis 
of the ethyl acetate extract revealed a peak having a U.V spectrum consistent 
with that expected for a cyclopenta[a]phenanthrene. This peak has not been 
identified or shown to be responsible for the ELISA activity.
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Chapter 1
Introduction
Introduction.
In the 1950’s a hypothesis was proposed by G.F.Marrian suggesting in-vivo 
loss of the 18-methyl group from an oestrogenic steroid hormone may result in the 
complete aromatisation of the oestrogen fused ring system, to generate a 15,16- 
dihydrocycIopenta[a]phenanthren-17-one analogue whose structure was dependant 
on the initial oestrogen and the mechanism of modification. This led to an 
extensive study of the biological activity of these polyaromatic compounds with 
special references to their carcinogenic and mutagenic activity in mammalian and 
bacterial systems .
Their is no evidence to date of the presence of this type of compound in 
mammalian biofluids or tissue. The aim of this study was to develop an assay 
procedure to be used for direct screening of human blood, and urine, for some of 
the biologically important members of this ketonic polycyclic aromatic hydrocarbon 
series.
Before discussing the strategy it is necessary to review the background and 
reasoning for this study and put it into perspective with other work being undertaken 
in the field of chemical carcinogenesis.
Historical background
The early observations of Percival Potts (1 7 7 5 )2 , suggesting that the 
chemical components in soot were responsible for the high incidence of scrotal 
cancer exhibited by chimney sweeps, was the first serious attempt to associate 
cancer with a chemical causation. It remained impossible to evaluate this further 
until a suitable animal model system was developed to allow a systematic study of 
the carcinogenic agents responsible for tumour formation. Such a model system 
was not made available until 1915 when Yamagiwa and Ichikawa^ showed that 
repeated skin painting of coal tar onto the ears of rabbits resulted in tumour 
formation at the site of application. Following a similar procedure on the more 
practical laboratory animal the mouse, it was soon shown that many pyrolysates of 
carbon containing compounds generated carcinogenic activity. Clar’s^ synthesis 
of dibenz[a,h]anthracene and later isolation of benzo[a]pyrene from gas works 
pitchS, afforded pure and structurally defined chemicals exhibiting carcinogenic 
activity6,7. This work set the direction of cancer research and confirmed the role of 
polycyclic aromatic hydrocarbons as a probable cause of cancer in man.
Parallel studies on the structural chemistry of natural steroids, revealed that 
these biologically important molecules shared a similar polycyclic carbon ring 
arrangement to that of cyclopenta[a]phenanthrenes. Diels et ai 8 demonstrated 
that selenium dehydrogenation of cholesterol and many other sterols, generated 
polycyclic aromatic hydrocarbons which included chrysene(l) and 16,17-dihydro-
17-methyl-15H-cyclopenta[a]phenanthrene (2), later named Diels' hydrocarbon (fig 
1), and the reaction became an important diagnostic test for the steroid carbon 
ring structure.
Figure 1
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This and other chemistry indicated a structural relationship between steroids, 
cyclopenta[a]phenanthrenes and other polycyclic aromatic hydrocarbons bearing 
the phenanthrene ring arrangement, and led to speculation that these compounds 
may well show biological activity because of their potential interaction with steroid 
binding sites. Further evidence to support this structural relationship was the early 
chemical synthesis of the carcinogenic polycyclic aromatic hydrocarbon 3- 
methylcholanthrene [5] by pyrolysis of the bile acid 12-oxocholanic acid [3], the 
sodium salt of which underwent an internal Perkin reaction with decarboxylation 
generating the hydrocarbon [4] which on further dehydrogenation gave 3-methyl- 
cholanthrene[5]9, found to be a potent carcinogen 10,11,
Figure 2
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The chemical synthesis of a carcinogenic polycyclic aromatic hydrocarbon from a 
natural steroid posed the question could this be achieved in vivo under 
physiological conditions.
The oestrogens which included oestradiol [9],oestrone [8], and oestriol [6], 
identified as female sex hormones 12, were considered likely candidates for in vivo 
conversion into polycyclic aromatic hydrocarbons sharing the same carbon 
skeleton, as they already had an aromatic [A] ring within their structure.
Figure 3
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Evidence for in vivo aromatisation was provided by Heard etal'^^ and Bagget et 
a / .  14 who demonstrated that [14c] labelled androstenedione was converted to 
oestrone[8] and finally oestradiol [ 9 ]:-
Figure 4
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Aromatisation involved the loss of the C-19 methyl group, achieved by NADPH 
mediated oxidation to generate the 19-hydroxylated analogue; this was isolated by 
IV Ie y e r 1 5 .1 6 ,  Further oxidation to the aldehyde occurs, énolisation and concerted 
oxidation of 0-1 with (3 -  elimination of the C-1 equatorial hydrogen as the hydride 
(probably by F e Q 2 +  in the presence of an oxidase). Formic acid is liberated to 
form oestrone which requires further reduction of the 17-carbonyl to produce 
oestradiol.
Marrian speculated that loss of the C-18 methyl group was a necessity to 
achieve formation of an aromatic C-ring generating the 15,16-dihydro-3- 
hydroxycyclopenta[a]phenanthren-17-one [40] see figure 5.
The first step occurs in-vivo\ investigations by Loke and M a r r ia n  17 identified 
an oestrogen containing a C-18-hydroxyl [69]in human urine. It was demonstrated 
in-vitro that this compound readily lost formaldehyde in the presence of base to 
generate 18-noroestrone[70]. It is not known whether the final dehydrogenation 
step can occur enzymatically.
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The discovery of the oestrogen equilenin [7] containing a naphthalenic structure 
i.e., aromatic [A] and [B] rings, isolated from pregnant mares urine"! 8, added 
weight to this hypothesis. Later work confirmed C-18 hydroxylation as a routine 
adrenal function and other hydroxylated steroids such as corticoid aldosterone^^ 
have been isolated. Additionally aromatisation of 19-hydroxyandrostanes^0,21. 
have been achieved by microbiological conversions.
Isolation of the anti-fungal viridin from the common soil fungus Trichoderma 
viride was carried out in the 1940’s by Brian and M c G o w a n 2 2 ,  the structure of this 
anti-fungal agent was later shown to be a s t e r o id 2 3 , 2 4  with an aromatic C-ring:-
Figure 6
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Recent interest in this compound stems from its inhibition at nanomolar 
concentrations of phosphatidylinositol-3-kinase in growth factor mediated cell 
transformation and mitogenesis^S. This compound represents a naturally occurring 
C-ring aromatised steroid; indicating that naturally occurring mechanisms exist for 
this transformation.In addition the conjugation exhibited by this compound 
suggests that further aromatisation to yield a cyclopenta[a]phenanthrene derivative 
is a real possibility.Thus a link is established between cyclopenta[a]phenanthrenes, 
the biologically important steroid hormones and polycyclic aromatic hydrocarbons. 
Nomenclature.
The nomenclature used to describe polycyclic aromatic hydrocarbons is not 
the same as employed for cyclopenta[a]phenanthrenes. As polycyclic aromatic 
hydrocarbons especially benzo[a]pyrene have been instrumental in defining many 
of the current theories concerning chemical carcinogenesis, an outline of polycyclic
aromatic hydrocarbons nomenclature is included using benzo[a]pyrene as the 
representative example.
Figure 7
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Following the I.U.P.A.C. rules^G
The largest component fused ring system within the molecule defines its primary 
name, in the case of figure 7A and fig 7B this is a pyrene ring system. The pyrene 
ring system (leaving out the aromatic character to allow face designation) is 
numbered as illustrated in figure 7 and the Roman letters designate the ring faces. 
Additional rings or functional groups prefix the major fused ring component name, 
thus in the above benzo (substituent) precedes pyrene. The isomers are identified 
by lettering the peripheral sides of the component ring system alphabetically, as 
already indicated for pyrene, note that side 1,2 starts the lettering to give face a_. 
Therefore the face of the pyrene ring system to which the benzo ring is fused, is the 
a face and is designated by inclusion of this letter in between square brackets to 
give the name benzo[a]pyrene.
In order to number the newly formed ring system the molecule is rearranged 
on paper, to give the maximum number of fused rings in a horizontal row, with as 
many as possible of the other rings above pointing towards the right hand of the 
molecule see figure 7A. If more than one arrangement meets this requirement then 
the structure with the minimum number of rings occupying the lower left hand side 
is chosen. The system is numbered starting from the carbon atom not involved with 
ring fusion in the most counter clockwise position for the ring occupying the top 
most right hand side. This is illustrated for the positional arrangement in figure 7A 
and the numbering arrangement in figure 7B. Atoms common to two or more rings 
are not numbered but Roman letters are added to the number of the position 
immediately preceding it, the interior atoms follow the highest number, taking a 
clockwise sequence wherever there is a choice. When there is a choice carbon 
atoms common to two or more rings follow the lowest possible numbers. See figure
7B. This numbering system applies to all polycyclic aromatic hydrocarbons with the 
exception of phenanthrene, anthracene, and cyclopenta[a]phenanthrene.
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Figure 8 illustrates the numbering system applied to cyclopenta[a]phenanthrenes.
Structure [11] represents the labelling system used to identify the site of attachment 
of the fused 5-membered ring to the phenanthrene i.e. the compound represented 
by structure [10] has the 5-membered ring attached to the [a] face and this site of 
attachment is designated by the letter a placed between square brackets as 
described above. Note that the numbering of the phenanthrene differs from the 
numbering with other PAHs since the 1,2 site does not occupy the most counter 
clockwise position on the top right hand ring (i.e. 1.2 position using polycyclic 
aromatic hydrocarbon numbering nomenclature represents the [b] face on a 
cyclopenta[a]phenanthrene see fig 8 [11]) therefore the site of the a face differs 
also. The close structural relationship between cyclopenta[a]phenanthrenes and 
steroids has resulted in the adoption of the steroid numbering system in their 
nomenclature as indicated by structure [10]. In a steroid ring the methyl group 
attached to carbon atom 13 is C-18 and the methyl group attached to the carbon 
atom 10 is 0-19.
The description of the fused five membered ring, prefixes (the site of 
attachment [a]) and the substituents are arranged in alphabetical order. The basic 
structure has the maximum number of double bonds as shown in compounds [12] 
and [13]. The extra hydrogen at position 17 for [12] and 15 for [13] are prefixed and 
italicised :-
[12] 17H- cyclopenta[a]phenanthrene.
[13] 15H- cyclopenta[a]phenanthrene
8the unsaturated compounds are therefore considered dihydro derivatives, thus 
structure [10] is 16,17-dihydro-15H- cyclopenta[a]phenanthrene. The replacement 
of the hydrogen by a double bond functional group such as a carbonyl at the 17- 
position results in the omission of the H  prefix to give the name 15,16- 
dihydrocyclopenta[a]phenanthren-17-one or 15,16-dihydro-17-oxo-cyclopenta[a]- 
phenanthrene whereas in the case of Diels’ hydrocarbon (which does not have a 
double bond containing functional group at 17-position) this prefix is retained as 
indicated i.e. 16,17-dihydro-17-methyl-15H- cyclopenta[a]phenanthrene. 
Carcinogenic activity mode of action.
Investigations into the mode of action of chemical carcinogens have largely 
involved the study of structure activity relationships, which have resulted in the 
synthesis of a large number of polycyclic aromatic hydrocarbons with subtle 
chemical alterations, and the development of tests to measure their activity.
It was considered that a requirement for carcinogenic activity was that the 
molecule contained at least four fused aromatic rings following the angular 
phenanthrene arrangement. It had also been established for some hydrocarbons 
that méthylation of particular sites had a dramatic effect upon carcinogenic activity. 
Diels’ hydrocarbon proved to be n o n - c a r c i n o g e n i c ^ ^ ,2 8  supporting the four ring 
hypothesis. Synthesis and measurement of carcinogenic activity (using a mouse 
model) of the aryl monomethyl analogues of 16,17-dihydro-15H-cyclopenta[a]- 
phenanthrene were undertaken by Butenandt and D a n n e n b e r g 2 8 , 1 a .  The 1 - , 2 - , 4 -  
,6-, 1 2 - ,  1 7 -  methyl compounds proved to be non-carcinogenic, but the 7- and 1 1 -  
methyl analogues showed very weak activity.
Marrian’s hypothesis that in vivo aberrant metabolism of the oestrogens 
may result in the formation of substituted cyclopenta[a]phenanthrene products, was 
the subject of Coombs et ai  ^ research programme at the Imperial Cancer 
Research Fund. The general model for these studies was 15,16-dihydrocyclopenta- 
[a]phenanthren-17-one[14], although the most likely product of the oestrogen 
aberrant metabolism is the 3-hydroxy compound [40].
Following a similar programme to that carried out by Butenandt and 
I Dannenberg29, using the model ketone[14], a complete range of mono aryl methyl 
j compounds i.e. 1 - , 2 - , 3 - , 4 - , 6 - , 7 - ,  11 - ,  12 -  m e t h y p O  and many other modifications 
were synthesised and tested. The unsubstituted ketone was found to be non- 
carcinogenic in the mouse model 31 but was mutagenic when subjected to the 
Ames’ t e s t 3 2 .  The monomethyl analogues followed the carcinogenicity profile 
observed by the Butenandt study, with the exception that both the 1-methyl and 7- 
monomethyl analogues were weakly active ( 1 -methyl hydrocarbon was inactive in 
the Butenandt study) and both the 15,16-dihydro-11 -methylcyclopenta[a]- 
phenanthren-17-one[60] and the 15,16-dihydro-7,11 -dimethylcyclopenta[a]-
9phenanthren-17-one proved to be potent carcinogens, suggesting that four fused 
rings were not a necessary requirement for carcinogenicity.
Other 11-substituted analogues of the cyclopenta[a]phenanthrenes showed 
varying degrees of activity. The poorly soluble 11-hydroxy compound proved to be 
a weak carcinogen which is an important finding with regard to Marrian’s 
hypothesis, since 11-hydroxylation of steroids is also a routine biosynthetic pathway
i.e. deoxycorticosterone hydroxylated to corticosterone by adrenal p e r f u s i o n 33. 
Additionally micro-organisms such as members of the Rhizopus 3 4 , 3 5  family carry 
out this difficult chemical step (difficult because of steric hindrance at this site), and 
these organisms are routinely used for the commercial manufacture of 11- 
hydroxylated steroids. Clearly any steroid containing this modification, undergoing 
full aromatisation to yield the respective polycyclic aromatic hydrocarbon would be 
a candidate for carcinogenic activity.
DNA and Protein Binding.
To change the growth characteristics of the cell, a defining feature of any 
cancer, it is necessary to modify directly or indirectly growth controlling macro- 
molecules i.e. DNA, RNA or proteins.
It has been demonstrated that mixing polycyclic aromatic hydrocarbons 
(referred to as RAM’s) with DNA,RNA,or proteins in the test tube does not of itself 
result in covalent binding without the aid of either metabolic activation 36,37 or free 
radical initiation.
Initiation of covalent binding by a free radical mechanism is not to be 
considered in any depth, as no evidence for such a mechanism has been 
proposed for cyclopenta[a]phenanthrenes. For historical purposes a few examples 
are presented to show that this approach has been validated for other RAM’s. 
Electron spin studies on benzo[a]pyrene incubated with skin homogenates 38  ^with 
the inclusion of free radical initiators such as Ig or M202 /  F e 3 +  and a light source 
when mixing benzo[a]pyrene with DNA39, indicate that an independent free radical 
mechanism operated in these instances to give covalent binding.
Metabolic activation.
The binding of RAM’s to d N A 4 0 . 4 1 , 4 2  and p r o t e i n s 4 4 , 4 5 , 4 6 , 4 7  at the site of skin 
painting has been well established. Two independent groups Grover & S i m s 3 6  and 
G e l b o i n 3 7  showed that incubation of a number of RAM’s with liver microsomal 
mixed function oxidase enzyme system, followed by the addition of DNA resulted 
in the RAM-DNA covalent binding, suggesting that in order to achieve covalent 
linkage an activated metabolite was required .
Figure 9
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B o y la n c |4 7  had proposed that an epoxide intermediate would be expected to 
meet the criteria of many of the metabolites isolated; the electrophilic nature of the 
epoxide made it a good candidate for reaction with nucleophilic sites on proteins, 
and DNA, RNA. Evidence for this hypothesis was later presented by Boyland and 
S i m s 48, who identified a number of metabolites of benz[a]anthracene [ 6 8 ]  from rat 
liver homogenates, figure (9). Similar findings were observed for dibenz[a,h]- 
anthracene49. Epoxidation occurred at the site referred to as the K- region, a 
position of high electron density and is prone to electrophilic attack.
Pullman, who gave the term K-region, attempted to explain the carcinogenic 
behaviour of the 4 , 5  position (K-region) in benzo[a]pyrene [67] using quantum 
mechanical c a l c u l a t i o n s ^ 9 , 5 1  This theoretical study combined with the fact that 
metabolites for a variety of PAHs had been isolated, most of them from K-region 
sites showed the importance of this region.
The hypothesis that the K-region epoxide was the proximal carcinogen was 
challenged when Baird et al 1975^2 showed that although the K-region epoxide of 
benzo[a]pyrene-4,5-oxide resulted in DNA, RNA and protein binding, the adducts 
formed were different from those obtained when cells were treated with parent 
benzo[a]pyrene. Additionally it had been demonstrated that the K-region epoxide 
was less mutagenic and carcinogenic than the parent hydrocarbon which was
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inconsistent with the K-region epoxide being the proximate carcinogen. B o r g e n ^ S  
activated benzo[a[pyrene with Syrian hamster liver microsomes and isolated the 
dihydrodiol-epoxide metabolite. Sims et al 54 proposed the 7,8-dihydrodiol-9,10- 
epoxide of benzo[a]pyrene was the precursor to DNA binding and therefore 
considered to be the ultimate carcinogen. This has subsequently been synthesised 
55,56 and shown by several groups to be more potent, both in terms of 
carcinogenic and mutagenic properties than the parent benzo[a]pyrene and also 
gives the DNA adducts shown by benzo[a]pyrene itself. 
17-Keto-cyclopenta[a]phenanthrenes binding to DNA.
A comparative in vitro metabolic study by Coombs et a i , using hepatic 
microsomes from 3-methylcholanthrene induced rats followed by a DNA binding 
profile, compared the effect of two carcinogens and two non-carcinogens:-
1. 15,1 G-dihydrocyclopenta[a]phenanthren-17-one [14] non-carcinogen 
but a mutagen .
2. 15,16-Dihydro-11 -methylcyclopenta[a]phenanthren-17-one[ 60] 
carcinogenic and mutagenic
3. 15,16-dihydro-12-methylcyclopenta[a]phenanthren-17-one [61] non­
carcinogen but is only weakly mutagenic.
4. 15,16-dihydro-11,12-dimethylcyclopenta[a]phenanthren-17-one [63] 
carcinogenic, mutagenic.
(Carcinogenic in the mouse model system, mutagenicity as measured by the Ames’ 
test52.)
Unlike benzo[a]pyrene no K-region metabolites were observed in any of the 
studies undertaken with cyclopenta[a]phenanthrene analogues, even though the 
chemical epoxidation of the 6 , 7  double bond does occur and is the favoured region 
of a t t a c k 5 7 .  The main metabolites of the unsubstituted compound (non­
carcinogen) were analogous to those of the carcinogenic 11-methyl compound 
(Hadfield et al 198458); table 1 illustrates the relative amounts of major metabolites 
observed for these analogues following in vitro metabolism with hepatic rat 
microsomes. The actual identity of the metabolites are not important for this review, 
only the fact that relative proportions of the same metabolites were expressed for 
both the carcinogenic and the non-carcinogenic analogues. Metabolite (e) was 
identified as the trans-[3R,4R]diequatorial diol precursor to the major DNA binding 
adducts via the proposed 1,2-epoxide intermediate (ultimate carcinogen).
Binding studies in vitro revealed that the unsubstituted compound bound to DNA to 
a lesser extent than the 11-methyl analogue[60], but yielded the same pattern of 
adducts, as did the 12-methyl analogue[61], which showed a 15% reduction in 
binding compared with the 11-methyl compound[60] 59.
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Table 1
Metabolite Compound and amount of metabolite as % of total ethyl acetate extractable
radioactivity.
17-ketone f141 11-Me [601 12-Me [611 11.12-diMe[631
a 11.2 8.0 5.2 0.9
c 9.2 5.7 12.1 6.3
d 4.2 4.0 6.6 5.3
e 11.6 9.2 7.7 11.1
f 4.3 10.8 1.7 9.2
other 35.7 38.1 39.1 42.1
unchanged compound 23.8 24.2 27.6 25.1
Taken from Coombs & Bhatt 
The 12-methyl analogue was originally assigned non-mutagenio status, but 
was later shown to be weakly mutagenic with Salmonella typhimurium TA100 50, 
In vivo DNA binding studies to mouse skin resulted in the following 
comparison where DNA binding was measured as nmol of compound per mole of 
DNA phosphorus.
Ta ble 2
Compound DNA binding
unsubstituted -17- ketone [141 19
11 - methyl -17- ketone [601 458
12 - methyl -17- ketone [611 155
11,12 - dimethyl -1 7 -ketone [631 974
Taken from Coombs and BhatflG
The unsubstituted compound failed to bind covalently to any extent (4% in relation 
to the 11-methyl analogue) with the DNA in vivo, which may help explain its lack of 
carcinogenic activity. Significant binding of the 12-methyl analogue[61] was 
observed but this represented only a third (34%) of the level exhibited by the 
carcinogenic 11-methyl compound[60] and by itself does not explain its failure to 
produce tumours.
The stereochemistry of the respective cyclopenta[a]phenanthrene-DNA 
adducts was investigated to establish whether this could shed light on the observed 
biological activity. Passage of the major adduct B from the column down a 
Sephadex LH20 column using borate b u f f e r ^ S ,  as the gradient for each of the 
analogues resulted in both the 11-methyl and 12-methyl adducts eluting early, an 
indication that these adducts were derived from the anti -diol-epoxide (this shift in
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Rf in the presence of borate was the result of a c/s-diol borate complex, which is 
the stereochemical consequence of nucleophilic attack of an anti -diol epoxide). 
The unsubstituted ketone showed no such reduction in retention time suggesting 
that this adduct was derived from the syn-diol-epoxide. The result for the 
unsubstituted 17-ketone [14] was consistent with data observed for benzo[a]pyrene 
adducts sharing the syn -configuration, as both the syn- diol- epoxide of the 17- 
ketone [14] (assignment of stereochemistry is not absolute in this case, but is 
based on retention time data from HPLC, and is consistent with the findings of other 
studies) and benzo[a]pyrene51 have been shown to be non-carcinogenic in mouse 
model systems, but both are mutagenic in suitable bacterial systems. Whilst 
explaining the non-carcinogenic but mutagenic behaviour of the unsubstituted 
compound this did not resolve the inactivity of the 12-methyl compound which 
showed significant binding and the adducts shared the same apparent 
stereochemistry as its carcinogenic analogue the 11-methyl compound[60].
The work of Abbot and C r e w ® 2  investigated the rate of formation and 
subsequent clearance of DNA adducts in vivo by skin painting, and or 
intramuscular injection, of the 11-methyl-17-ketone [60]. DNA lesions of skin, lung 
and liver were measured, it was found that a maximum binding was achieved 
within 1-2 days of treatment. After this period the adducts declined with a half life 
of skin and lung of about 7-days (these are the target tissue for this carcinogen) 
and liver 2.5 days. Further studies indicated that repair of the carcinogen lesions in 
the target organs was limited whereas they were rapidly removed from the liver. 
Repeat studies by Russell ef a /5 9  established that rapid clearance of the 12- 
methyl -17-one[61] was observed in skin (half life of 3.5days). Failure of this lesion 
to survive a cell division necessary to achieve permanent DNA modification within 
the target cell clones, would explain the non-carcinogenic behaviour of this 
compound.
Examples of protein modification.
Miller and Miller reported that the dye 4-dimethylaminoazobenzene [DAB], 
(common name butter yellow) reacted with rat liver protein in vivo 53  ^ Sorof et ai 
54 later identified the DAB covalently bound protein and named it protein h. Some 
years later it was reported that polycyclic aromatic hydrocarbons were found to 
covalently bind to h-protein in mouse epithelial c e l l s 4 7 , 65,66,67 and that the protein 
was modified by PAHs in transformable mouse prostate fibroblasts, but was 
undetectable in chemically transformed cells58. Evidence pointed to protein h as 
being the same molecule as L ig a n d in 57,69 an important hepatic determinant for the 
uptake of small molecules70. Ligandin was later shown to be identical to 
glutathione transferase b71- Protein h is also known to show glutathione 
transferase activity72. The role of glutathione transferases is largely concerned
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with detoxification of the hydrophobic electrophilic molecules. They all have a 
sulfhydryl group which exhibits enzymatically enhanced nucleophilicity making 
them very efficient electrophile predators.
Nuclear proteins have an influence on the presentation of DNA tertiary 
structure, which in turn plays a role in the control of expression. Covalent binding 
to these proteins would be expected to alter this control mechanism, Moses efa /73  
have reported the binding of polycyclic aromatic hydrocarbons to nuclear 
subtractions of AKR mouse embryo cells, it has also been established that 
benzo[a]pyrene covalently binds to DNAase sensitive chromatin74, The nuclear 
envelope has been shown to contain enzyme activities capable of activating 
benzo[a]pyrene 75,76,77,
General conclusions.
In conclusion the metabolic activation of polycyclic aromatic hydrocarbons 
and subsequent covalent linkage of these metabolites to DNA are the primary 
initiating events leading to cancer. In order for these events to generate a 
permanent change leading to malignant transformation, the modified DNA is 
required to undergo replication resulting in the production of a stable mutant DNA 
product cell line, which ultimately effects the mechanism of cell growth. The type 
of DNA modifications that have been identified which result in mutant DNA damage 
are base deletions, base additions,( often the result of repair of chemical lesions), 
base alteration (i.e. U.V.damaged thymidine dimer formation), base translocation to 
other regions of the genome. Modifications of the chromosomes by the formation 
of PAH -nuclear protein lesions effect the expression of the DNA.
Aim of the study.
The objective of this study was to test Marrian's hypothesis:-
“That cyclopenta[a]phenanthrenes may be generated as a result of aberrant 
metabolism of steroids".
The model compounds used in the study were derived from 15,16- 
dihydrocyclopenta[a]phenanthren-17-one as these are the expected products of 
aberrant steroid metabolism. The presence of molecules bearing this structure 
motif have not been reported in living tissue or biofluids to date.
The first stage in such a study is to develop an assay capable of detecting 
these molecules in human biofluids. If found the second stage is to establish the 
source of the molecules(i.e.incorporation such as diet, smoking or constituents of 
other forms of environmental pollution, or as described by the proposed 
hypothesis). The final stage is to use the information accrued , to treat (i.e. 
develop drug design) or prevent cancer or related medical problems from occuring. 
Finally from an academic point of view their presence are of importance in the 
understanding the stages leading to chemical carcinogenesis in humans. The aim
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of this programme of work is to address the first question “ the development of an 
assay procedure capable of probing large numbers of blood or urine samples with 
the purpose of identifying the presence of these analogues”.
The primary interest in these compounds are their potential involvement in 
cancer. With this in mind an initial assumption is made, which states, “that if these 
molecules are involved in tumourigenic events, they must be present in either their 
original state (to provide a source for continued carcinogen production) or as 
metabolites both inactive and active within the body for long periods of time”. This 
is based upon the requirement that repeated dosage of any carcinogen is 
necessary to achieve malignant transformation in the animal models studied to 
date.
The biological properties of these compounds being well understood and 
described, give a number of possible options for the development of such an
assay:-
a. To assay the cyclopenta[a]phenanthrene analogues directly.
b. To probe for specific metabolites.
c. To identify specific protein or DNA lesions.
Attempts to target specific metabolites such as suitable diols and diol- 
epoxides pose a number of problems which include the synthesis or isolation of the 
metabolites in suitable quantity for use as standards. Synthetic methods for 
achieving cyclopenta[a]phenanthrene metabolites are available i.e. both diol and 
d io l - e p o x id e s 7 8 ,7 9  also preparative is o la t io n 8 0 , 8 1 , 6 0 , 5 8  from animal sources are 
possible. Both procedures are impractical for the development of a chemical or 
biological assay procedure within the time scale of this thesis, therefore a method 
was required for the identification of the original compounds.
Because of the high molar absorption coefficient (range from 1Q4- 
1Q5moles/litre ) exhibited by these molecules U.V detection methods have been, 
regarded as the most sensitive procedures available to date and high pressure 
liquid chromatography (H.P.L.C.) is the method of choice for separation and 
identification of these c o m p o u n d s G O ,81,60,58, jh e  solubility of the model ketone 
in water is about 0.5nmoIes/mL and is therefore an approximation of the upper 
limits of detection necessary to obtain useful data; this represents the limiting range 
of sensitivity available using U.V flow cells.
Gas liquid chromatography using either flame ionisation, or electron capture 
detection systems, are also a potential methods of analysing these compounds 
chemically but have the disadvantage that many of the compounds such as 
hydroxylated analogues may require derivatisation to achieve separation or 
maintain stability at the temperatures required.
16
Mass spectrometry is the most sensitive chemical technique available and is 
flexible enough to achieve unambiguous identification of the compounds both by 
molecular weight and fragmentation studies; but purification using either of the 
chromatographic methods described is necessary prior to mass spectroscopic 
analysis. However the cost of these approaches make them impractical for the 
routine assay of large numbers of samples.
An alternative approach was to develop an immunoassay involving the 
production of specific antibodies to the molecules to be assayed, and the approach 
has several advantages over the chemical methods. Immunoassays are fast, 
simple to carry out and require small sample aliquots; they can be carried out 
directly on biofluids if designed with care, negating the need for expensive 
purification procedures; last but not least they are more sensitive than chemical 
procedures with the exception perhaps of mass spectrometry. The disadvantage of 
the immunoassay over chemical approaches is that antibody recognition of a 
molecule is not itself sufficiently specific for this criteria to be unambiguously 
acceptable as proof of identity. It is therefore necessary at some stage to confirm 
by chemical means the true identity of an antibody positive; but care taken in 
antigen preparation and subsequent characterisation of the antibodies used in the 
final assay will enable mass screening of specific molecules with confidence.
Immunoassay can be adapted to target either small molecules such as 
cyclopenta[a]phenanthrenes in solution, protein conjugates, or DNA adducts.
I 1. Food industry use ELISA (Enzyme Linked Immunosorbent Assay)I assays for the identification of smali molecule toxins such as o c h r a t o x i n 8 2 .  The 
jplant metabolites derived from Quassin isolated from the tree Quassia amara\ 
[Simaroubaceae were also synthesised and studied using immunoassays, an 
[e)densiye review of both of these studies was written by Morris and Clifford 83,
2. Enzyme linked immunosorbent assay and the ultra sensitive 
enzymatic radioimmunoassays have been developed to look at benz[a]pyrene DNA 
adducts and 0.1-0.4 fmole was detected in Img of DNA 84,85,86, 87,88,89.
3. The advantage of antibody production is that by suitable labelling of 
the antibodies they can be used as a probes for the identification of target antigen 
geography on cells or tissue 89,90, or for labelling molecules for visualising under 
the electron microscope i.e. Fab-benzo[a]pyrene-deoxyguanosine fragments, were 
modified with ferritin labelled anti-rabbit Fab fragments and visualised by electron 
microscopy 30.
4. Other applications of specific antibodies is to inhibit activity by using 
them against the biologically active molecule, for example benzo[a[pyrene- 
antibody inhibited in vitro cytotoxic and mutagenic activity of benzo[a]pyrene in rat 
embryo fibroblast and a rat cell- mediated mutagenisis system 31.,
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5. R a d i o i i m u n o a s s a y s 3 2 .  have been successfully used to detect 
steroids in biological preparations and biofluids by many workers over a number of 
years.
The development of an assay based upon immuno-chemical methods is the 
primary objective of this work, the production of sera and their antigen structure 
recognition characteristics, using the large number of closely related compounds 
and precursors synthesised by Coombs"* «over the years, as well as steroids and 
hydrocarbons sharing similar geometry make it possible to characterise such sera 
with confidence.
Arrangement of thesis.
A large number of cyclopenta[a]phenanthrenes were used in this study each 
having complex chemical names. In order to aid identification each compound is 
numbered and the number is presented as an emboldened numeral enclosed in 
square brackets. A table is included at the end of this chapter showing the 
chemical structures and their relevant numbers, a second loose leaf-copy of this 
table is included in the bound thesis to be used for continual reference. An 
additional loose leaf sheet is included; this defines the nomenclature used for the 
protein conjugates and antigens sera.
Presentation does not represent the order in which the work was 
undertaken, only the defined steps required for its conclusion. The thesis is divided 
into five chapters:-
1. Introduction
2. Synthesis of the antigens.
3. Production Purification and direct ELISA assay of Polyclonal 
antibodies.
4. Competition Assay Studies
5. Preliminary application of assay procedure on human biofluids.
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Chapter 2
Synthesis of Antigens
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General considerations concerning the synthesis of antigens.
Small molecule such as steroids and cyclopenta[a]phenanthrenes 
are not immunogenic, that is they do not stimulate an immune response 
when introduced into an animal's blood stream. This was first demonstrated 
by the work of Landsteiner and L a m p | 9 3 ,  who showed that when p- 
azobenzenearsonate was injected into a rabbit it failed to produce 
antibodies to the inoculum. When the p-azobenzenearsonate was covalently 
attached to a protein (globin) before inoculation, the modified conjugate 
inoculum generated antibodies that were specific to the 
azobenzenearsonate and which did not recognise the unmodified carrier 
globin. Thus in general when a small molecule is attached to a larger 
immunogenic molecule such as a protein it becomes visible to the immune 
system. The resultant population of antibodies generated against this 
protein conjugate include some which are specific to the bound small 
molecule referred to as a hapten, and these antibodies react specifically 
with this hapten even when it is not covalently linked to a protein.
It therefore follows that in order to achieve the production of 
antibodies specific to cyclopenta[a]phenanthrenes, it is necessary to 
synthesis suitable cyclopenta[a]phenanthrene - protein conjugates.
Covalent attachment of small molecules to proteins.
Proteins are polymers that are built from up to 20 different amino acid 
monomer units. Unlike synthetic polymers the sequences of the individual 
monomers, i.e. the amino acid sequence, is singularly defined, with the 
result that each protein is a unique molecule with a definite size and shape. 
The side chains of each amino acid used to make up the protein determines 
the available chemistry for the potential covalent linkage of haptens to it; 
table 1 identifies some of the groups and chemical methodologies utilised by 
a variety of workers to prepare modified protein conjugates.
Diazotisation was used by Landsteiner but was not considered 
practical for our purposes because of the aromatic nature of the linkage 
amino acids, i.e. histidine, tryptophan and tyrosine. The planarity of these 
amino acids and their close proximity to the cyclopenta[a]phenanthrene 
target molecule (hapten) may result in problems of separating the linker 
molecule response from the target antigen response. Cystein or synthetic 
sulphydryl containing linker molecules for covalently linking the target 
antigen to the protein through a disulphide bond was considered. Recent
Table 1
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Amino acid Reactive site Reaction or product Reference
Cystein Sulphur 1.Maleimide addition to give thioether 
linkage.
2.Disulphide bond formation
98,99
94,95,96,97
Lysine e-amino 1. Amide formation using carbodiimide 
chemistry.
2. active ester methodology
100,101,
102.
105
Histidine Imidazol Diazotisation 93
T ryptophan Indol Diazotisation 93
Tyrosine Phenol Diazotisation 93
Aspartic 
/Glutamic acids Carboxyl
Carbodiimide activation and reaction with a 
primary amine
100,101,
102,
work of Thorpe et a /34 showed that the disulphide bond between a lysyl 
amide linked through a 2 - p y r id y l t h io | 3 5 , 9 6 ,  attached to an antibody and the 
sulphydryl group present on a ricin molecule, had a limited life span under 
physiological conditions; within 3  days it was chemically reduced 
separating the carrier immunoglobulin from the ricin molecule. Since a 
hyperimmunisation schedule was to be used to produce sera for assay 
purposes over a prolonged period of time it was essential that the antigen 
complex was stable under physiological conditions.
The formation of an amide bond between the linker molecule 
attached to the cyclopenta[a]phenanthrene and the protein was attractive. 
This chemistry is well established and the resultant product is 
physiologically stable. Two approaches were available for achieving this 
aim these include:-
1. in situ activation of a protein bound p-aspartic and p-glutamic 
acid carboxyl groups and their subsequent reaction with an amine 
modified cyclopenta[a]phenanthrene.
2. Chemical activation of a linker molecule terminated with a 
carboxyl group, followed by reaction between this activated derivative 
and the e-lysyl residues present in the protein.
23
In situ activation of carboxyl groups using water-soluble carbodiimides 
mixed with the protein required for conjugation, have been successfully 
applied‘^ 00. The disadvantage of this approach lies in the fact that the 
activated carboxyl groups react with primary amines to form both 
intermolecular and intramolecular products resulting in the formation of 
protein dimers, internally cross linked proteins in addition to the required 
conjugate. Also other side reactions can occur between the carbodiimide 
and other protein containing functional groups which include s u l f h y d r y l ‘• 0 3  
and to a lesser extent t y r o s i n e " *  0 4 ^  all of which pose additional and 
unnecessary problems which resulted in the In situ activation procedure not 
being considered further.
Method of choice
Figure 1
O
+
NH2 — (CH2)4 — Protein
X(CH2)nCONH(CH2)4 -  Protein
General procedure for the attachment of 
Cyclopenta[a]phenanthren-17-one to proteins.
The chemistry of the linker molecule is defined by the site of 
attachment on the cyclopenta[a]phenanthrene and the required spacing 
necessary to allow good visibility to the immune system; usually a 
hydrocarbon spacer of between 2 or 3 methylene groups length and the 
functionality required for linkage to the carrier protein are needed. In our 
case an activated carboxyl group is the method of choice. The carboxyl 
group is activated for reaction with a primary amine by preparation of the N- 
hydroxysuccinimide ester, which can be purified and characterised prior to 
being used for modification of the protein"* 05 when the N- 
hydroxysuccinimide ester of the respective cyclopenta[a]phenanthrene is 
added to the protein in aqueous buffer containing a few percent of dioxan to 
aid small molecule solubility, a reaction will generate largely the e-lysyl-
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cyclopenta[a]phenanthrene modified protein and hydrolysis products of the 
activated ester. No inter- or intra-molecular cross linking can occur within or 
between proteins, but modification of other nucleophilic sites may occur 
such as the formation of serine, threonine 0-esters, cystein thio-esters etc. 
although these can be largely avoided by good control of the pH. 
Attachment of the linker molecule to the 15,16-dihydrocyclo- 
penta[a]phenanthren-17-one.
Early immunochemical s t u d i e s ' * 06,107,108^ have shown that the 
region of the antigen furthest away from the protein (the most exposed 
region) is immunodominant and therefore largely responsible for defining 
the antibody recognition site or epitope.
The primary objective of this work was to produce an assay capable 
of selectively identifying cyclopenta[a]phenanthrenes as a class of 
analogues including some with substituents and D-ring modifications. 
Since a single presentation of the model antigen is inadequate by itself to 
achieve this goal, a number of antibodies needed to be prepared, each of 
which is capable of recognising different regions of the model antigen or the 
important substituent analogues closely associated with it. In this way the 
collective data from each serum probe can be pooled to compare and 
contrast the resultant cross reactions expected with those observed. This 
combined data will enable confident identification of the sample.
The choice of antigen as a suitable model was the 15,16- 
dihydrocyclopenta[a]phenanthren-17-one. The chemistry of the linker 
molecules and the reasoning for the choice of particular antigenic options 
finally applied are outlined in figure 2, and discussed below.
Figure 2
= N0CH2C00H
H00C(H2C)30^  f
^  O 17
i  IL /  1^ " ^ “  -00CCH2CH2C00H
-SCH2CH2C00H 
H00C(H2C)30'^
Site and chemistry of conjugation of protein to the model compound.
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An sp2 carbon at C-17 is important in influencing the carcinogenic 
activity of the cyolopenta[a]phenanthrene molecule. Introduction of the 
16,17-carbon carbon double bond 31,109 revealed compounds containing it 
to be weakly carcinogenic using skin painting and injection studies in mice. 
These studies and others led to the conclusion that two structural features 
were necessary to acquire carcinogenic activity; these were methyl 
substitution at C -11 or C-7 and conjugation of the | cyclopenta[a]phen- 
ianthrene D-ring system.
Coombs and C r o f t 3 1  found that repeated skin painting treatment of 
mice using as a quantitative measure of tumour appearance the (ball 
index:-
Iball index = % of animals with tumour $ x 100
Mean latent period in days
$ based upon the number of animals alive at the time of the appearance of the first skin 
tumour in the group, (taken from Coombs and Bhatt
resulted in the conclusion that D-ring unsaturation and 11-methyl 
substitution were additive. This is illustrated by the following data taken from 
the review"! G and is modified to show the 17-carbon atom bond status .
Table 2
Compound Iball index
C-17 
bond status
46 sp2
OH
23 sp3
3 sp3
27 sp2
0 $ % 5 sp3
The 17-carbonyl group is an obvious candidate for attachment of a 
bifunctional molecule, since it can be directly modified retaining its sp2
26
status or reduced to an alcohol for bifunctional estérification or éthérification 
changing the C-17 carbon bond status to sp3. The oxime was the 
functionality of choice because this maintains the sp2 bond integrity of the 
17 carbon atom; whilst meeting the physiological requirements for the 
production of antibodies, as indicated by its use in the preparation of serum 
against steroid conjugates"! 10,111,91,112.
As already mentioned the 11-position is of major biological 
importance as it has been demonstrated that modification of this bay region 
site is usually accompanied by carcinogenic activity^lJOO,"!"!3,124, Table 
3 illustrates a number of examples of the varying carcinogenicity of 11- 
substituted cyclopenta[a]phenanthrene analogues. Identification of some of 
these analogues is clearly of great importance since their presence marks 
the possible initiation of cancer in a patient.
The final choice of linker molecule for the 11-position was the -0-butyric acid 
ether, although estérification was also investigated.
Table 3
Compound Iball index Comments
Cpp-17-one 0 non-carcinogenic
11 -methvl-cpp-17-one 57 strongly carcinogenic
7,11 -dimethvl-cpp-17-one 66 strongly carcinogenic
1,11 -methano-cpp-17-one 33 moderately carcinogenic
11 -methoxv-cpp-17-one 32 moderately carcinogenic
11 -ethoxv-cpp-17-one 23 moderately carcinogenic
11-n butoxv-cpp-17-one 5 non-carcinogenic
11 -hydroxymethyl-cpp-l 7-one 16 carcinogenic
Selected data taken f ro m l f ,  Initiating activity of some 15,16-  
dihydrocyclopenta[a]phenanthrene-17-ones in the two-stage regime using croton oil as 
a tumour promoter.
The potential aromatisation of oestrogens following oxidative 
cleavage of the 18-methyl group suggested by Marian and discussed in the 
introduction was considered to be an important question relating to the 
design of this project. As the expected aromatisation of natural steroids 
would result in a product which is substituted at the 3-position (all common 
natural steroids contain a substituent at this position), then it was considered 
necessary to include a 3-linked antigen within the series, a hydroxyl group 
was considered the most likely candidate and linkage through an 0-butyryl 
acid ether was the proposed method.
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Figure 3
R = H or Methyl
Primary metabolites of 11- H or 11-methyl-15,16-dihydrocyolopenta[a]phenananthren-17-
one.
Both the 16-hydroxy and particularly the 15-hydroxy substituent positions 
are important, as these are the primary metabolites generated in wVo^l. 
Further metabolism occurs by epoxidation and hydroxylation of the aromatic 
rings to give modifications resulting in substantial loss of aromatic character. 
These non-planar epoxide or polyhydroxylated A-ring metabolites are 
unlikely to be recognised by sera targeted against the largely planar 
cyclopenta[a]phenanthrene molecule and their synthesis or metabolism are 
too complex and time consuming to consider within the framework of this 
project.
The 16-hydroxy-15 ,16-dihydrocyclopenta[a]phenanthren-17-one 
analogue was synthetically available, therefore hemisuccinylation was 
considered a possible route of bifunctional linker molecule attachment.
The 15-position for reasons described later was attached via a thio- 
ether-propionic acid using a thioether bond to achieve this aim.
Results and discussion
Ketone A was the main starting material for most of the subsequent 
reaction schemes reported in this thesis and was prepared by the method of 
Coombs e f  a / 1 ^4,115_
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Figure 4
NOCHpCOOH NOCH2COO
BSA-17-oxime conjugate 
A.3
Synthesis of the 17-N-carboxymethyloximidocyclopenta[a]phenanthrene 
bovine serum albumin conjugate.
The synthesis of oxime [A.1] was carried out using the procedure 
described by C a m e r o n 92 in  the synthesis of 20a-hydroxy-5a- pregnan-3-(
carboxymethoxy) oxime which was based on the method of Erlanger et a/  ^  ^0. in 
the Cameron study two product isomers were obtained, these were the result of 
restricted rotation about the N=C double bond and were identified by 1H NMR as 
anti 70%, syn 30% but were not separated. In our case the product (see figure 5 
for expected isomeric products)
Figure 5
CH3CH2 OOCCH2 O .OCHgCOOCHgCHg
A.4b antiA. 4a syn
[A.1] showed poor solubility properties in most of the common organic 
solvents tried; and the chromatographic procedures employed were not 
useful in demonstrating the presence of one or more isomers. The proton 
NMR data showed a single sharp methylene signal at 4.5ppm, the shift 
upfield caused by the deshielding effect of the [adjacent ether oxygen.
The sharpness of the signal suggested that it was a single isomer and not 
a mixture.
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When [A.1] was suspended in 3NHCI(4pts) containing ethanol(lpt) it
dissolved slowly, and after an hour at room temperature needle shaped 
crystals were obtained and filtered off. Concentration of the mother liquor 
generated further crystals which were kept separate and independently 
characterised in case they proved to be different isomers separated by 
selective crystallisation. Both products were unambiguously characterised 
as the ethyl ester and were identical ( melting point and IR spectrum). The 
rapid facile estérification may be explained by the influence of the electron 
withdrawing =N-0- linkage attached to the methylene group adjacent to the 
carboxyl resulting in increased acidity.
As the two respective isomers (see figure 5) would be expected to 
present a completely different view of the cyclopenta[a]phenanthrene when 
linked to a protein it became important to establish the orientation about the 
C=N bond.
The crystalline nature of the ester A.4 suggested that its structure may be 
unambiguously established using X-Ray crystallography. An X-Ray study 
was set up in collaboration with Dr Jonathan Davies, who carried out the 
structural analysis and whose data is presented.
The morphology of the crystals presented some initial problems, their 
narrow width was considered, after inspection under a polarising 
microscope, to be insufficient to give a useful diffraction pattern. Attempts to 
improve the nature of the crystals using the standard crystallisation method
i.e. involving the preparation of saturated solutions at elevated temperatures 
and allowing the solutions to cool and crystallise yielded the same crystal 
shape for methanol, ethanol, isopropanol, ethyl acetate and n-propanol. 
The problem was overcome by dissolving the compound in a large volume 
of ethyl acetate and leaving it open (using a sintered glass conical with a 
small piece of card between the ground glass joint and its stopper to allow 
slow evaporation of the contents) to the atmosphere over the week end, the 
slow crystallisation resulting in a few crystals with sufficient width to meet the 
requirements. The repeating unit cell of the crystal A.4 is presented in figure 
7. Complete structural data is presented in tables 7,8, 9 and 10 in the 
methods section of this chapter. Figure 6 illustrates the final structure using 
thermal ellipsoids to describe the anisotropic motion around the constituent 
atoms. From this data the single isomer has been unambiguously identified 
as the as the anti - configuration about the C=N double bond, and this also 
confirms the structure of the precursor acid A.1 to be anti since estérification
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C I S
Figure 6
The structure of flnrM7-ethyloarbonylmethyloximidocyclopenta[a]phenanthrene
(A.4b)
Figure 7
Unit cell of crystal A.4
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does not involve breaking the C=N double bond.
Synthesis of the 16-Hydroxy-15H-cyclopenta[a]phenanthren-17- 
one[B.2].
The 16-hydroxy-opp-17-ketone [B.2] was the key starting material for 
linkage to the protein at this position and was synthesised by a modification 
of the method of Coombs e ta / ^16,
Cpp-17-one l[A.,14]
Figure 8
OCOCH3
OCOCH3
[B] [B.1] [B.2.,21]
Synthesis of 16-hydroxy-15,16-dihydrocyclopenta[a]phenanthren-1 Tone
Following the literature procedure compound [B] was obtained as described, 
but the oxidation step resulted in multiple spots on tic and gave a poor yield 
of product, suggesting overoxidation. It was decided to monitor this reaction 
by U.V spectroscopy, both the spectra of the starting material [B] and the 
product [B.1] have been published"C*G i.e.:-
Table 4
Compound Àmax(nm) Àmax(nm) Comment
Enol acetate B 268 272 doublet
16-0-acetvI-17-one B.1 265 - sinqlet
These spectral changes indicated that oxidation was complete within 
SOmins after addition of Imole equivalent of lead tetra-acetate under the 
described conditions to give product [B.1] as a single spot.
Acid hydrolysis of [B.1] gave [B.2] in addition to further by products 
which were removed by flash chromatography on a silica column. The 16- 
hydroxy-cpp-17-one was subjected toj hemisuccinoylation following the 
procedure of Erlanger et a /110,117, which involved stirring [B.2 ]in pyridine
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with an excess of succinic anhydride at room temperature resulting in the 
formation of [B.3] in high yield. Synthesis of [B.4] is to be discussed later.
Figure 9
0C0(CH2)2C00H
[B.2.,21 ]
OCO(CH2)COO-N^
[B.4]
Formation of N-hydroxysucoinimidyl-16-O-hemisuooinoyl- 
oyoIopenta[a]phenanthren-17-one.
Synthesis of 15-iinked Cyclopenta[a]phenanthren-17-one.
15-position
Figure 10
Inspection of the 15- position reveals two synthetically useful 
characteristics:-
1. The position is benzylic to the aromatic C-ring.
2. The position is p to the 17-carbonyl group.
A potentially useful reaction for alkylation of this position is the benzylic 
bromination. Bromination at this position occurs readily under electrophilic 
conditions, both the 15- mono and dibromo cornpounds are^formed prior to 
aryl bromination at the 6 and 7 positions"! 18. | Attempts by Coombs efa/"!"!8 
to displace the 15-halide by nucleophilic attack with an acetate ion 
generated the 16-0-acetyl analogue instead of the 15-0-acetyl derivative as
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expected. M.M C o o m b s ^  18 proposed the following mechanism to explain 
this unexpected result:-
Figure 11
>Ac
OHOH
OCOCHg
Proposed mechanism for rearrangement of 0-acetyl when used to displace a 15-halide
A similar rearrangement may be expected if an ambidentate nucleophile 
were used for the purpose in hand, therefore an alternative strategy was 
required.
An alternative approach to the problem was suggested by the work of 
Weinstein who linked a thiopropionic acid to the 7-position of a
series of 4,6-di-unsaturated steroids of the androgen family:-
Figure 12
Base
o
P .0
R = OH, C=0,
-OH
In our compound [A] the 15-position is p to the 17-carbonyl group and 
therefore the generation of a 15,16-double bond would make a p - addition a 
practical proposition.
Synthetic route to 15-S-thlopropionlc acid derivative.
Bromination of the 16-position using N-bromosuccinimide in carbon 
tetrachloride and light to assist free-radical formation was used, as 
described by Coombs eta l  118, and [0.1] was obtained in good yield.
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Compound [0.1] was dissolved in benzene and the U.V. spectrum 
measured at X max 281 nm; on addition of triethylamine the X max shifted to 
313nm see figure 14.
Figure 13
SCH2CH2C00 SCH2CH2COOH
BSA-conjugate 
[C.5]
Synthesis of N-hydroxysuccinimidyl-15-(3-carboxyethylthio)-15,16- 
dihydrooycIopenta[a]phenanthren-17-one [C.4j.
with the formation of the 15,16 carbon carbon double bond to give 
cycIopenta[a]phenanthren-17-one [0.2]. Compound [0.2] readily forms an 
insoluble product when left standing at room temperature, a reaction which 
has not been fully characterised, but according to Coombs e f  a /  "118 the 
close similarity in structure of the C and D rings in 
cyclopenta[a]phenanthren-17-one with that of indenone, suggested that the 
insoluble product may be the result of polymerisation, analogous to that 
demonstrated for in d e n o n e " !  20_
No attempt was made to work up [0.2] after U.V spectroscopy had 
confirmed its formation; an excess of mercaptopropionic was added and 
within 15 minutes the U.V. spectrum shifted to 279.Inm indicating the 
formation of [C.3.] The presence of the sulphur at C-15 was confirmed by its 
"!hnMR spectrum where a downfield shift of 0.4ppm was observed for H-7 
and an approximate downfield shift of 1.8 ppm was observed for the H-15 in 
both the acid [C.3.] and the N-hydroxysuccinimide ester [C.4.]
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Figure 14
U.V spectrum showing the reaction progress in benzene, of the formation of [C.3] from [C.1]
via the transient intermediate [C.2]
2 , 5 t
1 . 5  •-
1.0 • -
450400350200 250 300
Synthesis of 11-and 3-linked 15,16-dihydrocyciopenta[a]phen- 
anthren-17-one.
Figure 15
o
H00C(CH2)2C00 
 ►
Hemisuccinylation of the 11-hydroxy-15,16-dihydrocyclopenta[a]phenanthren-17-one
Attempts to react succinic anhydride with the 11-phenol failed, even after 
refluxing for Iweek. If the mechanism of attack of the succinic anhydride 
follows a similar mechanism as proposed for the hydrolysis of acetic
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anhydride in p y r i d i n e ^  21,122,123, the resultant proposed intermediate 
would be implied:-
Figure 16
Q °  *  0
this somewhat bulky intermediate is unlikely to get sufficiently close to the 
sterically hindered bay region hydroxyl, to generate an ester.
Attention was switched to the 3-phenol, after estérification with 
succinic anhydride in pyridine, a shift in the U.V. from Xm ax266.1nm , 
296.Inm, 365.6nm for compound [E.1], to a new value of Xmax 278nm, 
324nm was observed and reaction was complete within 2hrs. The IR 
spectrum revealed an ester carbonyl at 1740cm-1, which was consistent 
with hemisuccinate formation, but attempts to work up this product generated 
largely starting phenol indicating that rapid hydrolysis was taking place. This 
facile hydrolysis, possibly involving intramolecular attack of the 
hemisuccinate carboxyl anion on the ester, made its use as a potential linker 
molecule unreliable and was therefore abandoned.
An alternative route for attachment through both the 3-and 11- 
phenols was required. A number of alkoxy derivatives of the 11-phenol 
were prepared by Bhatt et a / 124 following the procedure of the Williamson 
synthesis :-
Figure 17
RX + -OR' — ------- ► ROR'
1. X = halide
2. OR = phenol or alkoxyl
Williamson Synthesis
This involved preparation of the 15,16-dihydro-11-hydroxycyclopenta[a]- 
phenanthren-17-one anion in the presence of a suitable alkyl halide, with 
the subsequent formation of an alkoxy ether. Ethers are particularly stable 
both chemically and physiologically; the demonstration that quite bulky
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alkoxy analogues (up to pentyl) have been substituted at this sterically 
hindered position makes this chemistry very attractive. A literature survey 
revealed that chloroacetic acid was successfully used to etherate trityl phenol 
using sodium hydroxide as the base (see figure 1 8 )  Narang e f  a / 1 2 5 .
Figure 18
OH + CICH2COOHHO OHHOOCCHO
Ethérification of trityl phenol with chloroacetic acid using the method of Narang 
Chloroacetic acid was unsuitable for our purposes because it was 
considered that a minimum of two or three spacer atoms were required to 
achieve visibility of the bound antigen to the immune system. Following 
essentially the same procedure using as our potential linker molecule the 
alkyl halide 4-bromobutyric acid and later 3-bromopropionic acid, with a 
variety of different bases(see methods), we were unable to achieve 
éthérification. The literature revealed that intra-molecular lactonisation was 
the preferred reaction for these bromoalkanoic acids under the conditions 
used, reactions which have been extensively studied with regards to their 
kinetics by Mandolini e f  a / 1 2 6 , 1 2 7
Figure 19 
Br(CH2)3C00Na+ ►
Base mediated lactonisation of bromobutyric acid 
The successful éthérification of chloroacetic acid by Narang e f  a / 1 2 5  was 
because formation of a three membered lactone was not an energetically 
favoured reaction.
In order to prevent intramolecular lactonisation, the carboxyl required 
protection against ionisation in the presence of base. Therefore ethyl-3- 
bromopropionate was used as the ester protected form of ambidentate alkyl 
halide, again | without success; as base hydrolysis of the ester occurred, 
clearly a more stringent protection regime was necessary.
Nitriles presented a potential mode of protection as these can be 
converted to carboxyl groups using both acid and base mediated
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hydrolysis 128,129,130,131 _ As illustrated in figure 20 hydrolysis of the 
nitrile occurs via the intermediate amide, which loses j ammonia to generate 
a carboxyl.
Figure 20
R— CN
NHg
p
OH
Hydrolysis of a nitrile under acid or basic conditions to generate a carboxyl via an
intermediate amide.
Proposed synthetic route to the 11-and 3-linked analogues.
Figure 21
o
NC(CH2)30.
NC(CH2)3Br + r II > K2CO3
[D.1.,41]
fO
N 0 0 C (C H 2 )3 0
o
H 0 0 C (C H 2 )3 0
[D.4]
BSA-conjugate [D.6]
Because of the formation of the amide intermediate hydrolysis conditions 
necessary for this modification would be expected to be more stringent than 
required for base catalysed éthérification. Using this new strategy for the 
attachment of alkanoic acids to both the 3- [40] and 11-hydroxyl[41] 
containing cyclopenta[a]phenanthren-17-ones, figure 21 outlines the 
synthetic route up to conjugation, using the 11-hydroxy analogue as the 
example.
The same reaction scheme applies to the 3-analogues, but the letter 
coding used to identify the intermediates for the 11-series represented by 
the letter [D] was replaced by the letter [E] for the 3-analogues.
To reduce the possibility of base hydrolysis of the nitrile under 
éthérification conditions, a weak base potassium carbonate was employed; 
this proved successful in both the synthesis of ethers [D.2] and [E.2].
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Conversion of the alkyl nitrile ethers to their respective alkanoic acids used 
acid hydrolysis (6N HOI in glacial acetic acid). Base catalysis was 
considered to be deleterious to the integrity of the 5-membered ring‘d9. 
Synthesis of N-hydroxysuccinimide esters.
A modified version of the method of Anderson et al ^05 was used for 
this preparation, which involved transient activation of the acid via an O- 
acylurea, or by symmetrical anhydride formation, using the dehydration 
agent dicyclohexylcarbodiimide (DOG), in the presence of N- 
hydroxysuccinimide with the resultant formation of the respective N- 
hydroxysuccinimide ester. Because of the insoluble nature of the acid 
precursors for this reaction a suspension was allowed to react with the 
soluble DOG and N-hydroxysuccinimide and left for long periods of time 
sometimes up to a week; reaction progress was monitored by thin layer 
chromatography and the formation of the finely divided precipitate of 
dicyclohexylurea. Removal of the urea by filtration and subsequent 
extraction of the excess DGG and N-hydroxysuccinimide, followed by 
crystallisation or precipitation of the product was the general method of 
preparation.
The 11-N-hydroxysuccinimidyl ester [D.4 ] was subjected to further 
purification using flash chromatography on a silica gel column. Two 
fractions were isolated; the first fraction gave a comet shaped spot on tic 
and had an Rf spread of between 0.29 to 0.56 while the second fraction had 
a more discrete circular appearance with an Rf of 0.48. When these two 
fractions were co-spotted as described in the methods section, they 
generated a stepping effect see figure 22,
Figure 22
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(an effect which was observed at a variety of concentrations) suggesting that 
the former fraction was a mixture of two components and the later fraction 
was a single compound, they both shared identical IR spectra consistent 
with [D.4] and each gave the correct analysis for an N-hydroxysuccinimide 
ester of the empirical formulae represented by [D.4]. Inspection of the 
molecule [D.4] using Drieding scale models revealed that the close 
proximity of C.1 proton to the ether oxygen implies restricted rotation about 
the 11-position possibly generating two conformers. The 11-nitrile [D.2] 
gave only a single spot on tic, the acid [D.3] was not chromatographically 
resolved, and the cyclohexylamide derivative [D.5] also indicated a single 
compound. Presumably if the hypothesis that the two spots represent the 
respective conformers is correct; the bulky, but essentially planar N- 
hydroxysuccinimide ester has aided chromatographic separation of the two 
forms, whereas the bulky cyclohexylamide ring which occupies various 
conformation states chromatographs as a single spot.
Conjugation Studies
The efficacy of the N-hydroxysuccinimide ester as a suitable vehicle 
for activation of a carboxyl group within the context of this study was 
considered necessary prior to attempting protein, cyclopenta- 
[a]phenanthrene conjugation reactions. Following the reaction scheme 
represented by figure 23, cyclohexylamine was allowed to react with the 11- 
alkanoic-N-hydroxysuccinimide [D.4] as a model reaction. The product was 
isolated in good yield and was unambiguously characterised as the correct 
structure for [D.5], confirming this approach to be of practical value.
o
^ 0
NH2 .
Figure 23
N O O C (C H 2)30*v ^ ^ N s ^  H N 0 C (C H 2 )3 0
[D.4] [D.5]
Model activated N-hydroxysuccinimide ester reaction, between compound [D.4] and the
primary amine cyclohexylamine 
The successful use of BSA as a carrier protein for the production of 
antisera against steroids by a variety of independant workers, in the
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developement and use of radioimunoassays is well documented ^2 
Conjugation properties of this protein have made it the carrier of choice for 
use in this study.
As the problem of solubility of the two reagents, namely the 
hydrophobicity of the activated cyclopenta[a]phenanthrene analogues and 
the hydrophilicity of the protein, was the first problem to be addressed, a 
compromise between the two systems was sought. As it was not necessary 
to retain the integrity of the 3-dimensional protein structure of the carrier 
protein, providing the partially denatured conjugate retained good solublity 
characteristics, it was possible to use water-soluble organic solvents to 
achieve the solubilisation of the cyclopenta[a]phenanthrene activated ester. 
Essentially, the activated ester dissolved in dioxan was added dropwise to 
the rapidly stirred protein solution containing 0.1 M phosphate buffer with 
10% dioxan and left at room temperature overnight. The resultant 
suspension was centrifuged and passed down a G-25 desalting column to 
remove low molecular weight material. Figure 24 clearly shows the 
enhanced UV absorption at 254nm caused by the attached 
cyclopenta[a]phenanthrene molecules to the early eluting protein fraction 
indicating bound cyclopenta[a]phenanthrene. The UV spectrum of the 
product protein fraction in this case gave a typical 15,16-dihydrocyclopenta- 
[ajphenanthrene -17-oxime profile (see figure 25).
Figure 24
The reaction between BSA and compound [A.2] to give the 17-oxime-BSA conjugate 
[A.3].
a. Elution of BSA only (dotted line) through the G-25 column.
b. The same concentration of BSA after conjugation with [A.2] through the 
same column (continuous line).
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UV spectrum of the protein fraction after passage down a G-25 desalting column 
for the BSA-17-oxime conjugate A.3
Figure 25
In order to reduce side reactions involving nucleophilic attack of the ester by 
other protein side chain nucleophiles, such as threonine(OH), serine(OH), 
cystein sulphydryl etc it was necessary to buffer the reaction at neutral pH 
7.0.
To establish covalent linkage between the cyclopenta- 
[ajphenanthrene and the protein, as opposed to hydrophobic or ionic 
association, both 16-hemisuccinate-BSA con]ugate[B.5] and the 17-oxime- 
BSA conjugate [A.3] were independently subjected to dialysis at pH 4.8 . 
At this low pH both conjugates slowly denatured and precipitated out of 
solution; they were left overnight after which time the bags were transfered to 
a solution of phosphate buffer 0.1M, pH7.1 and redialysed. In both cases 
the insoluble conjugates redissolved as the pH adjusted to 7.0. Analysis of 
the contents of the bags by UV spectroscopy showed that the expected 
cyclopenta[a]phenanthrene chromophores had been retained as shown in 
figures 26 and 27, suggesting a covalent link between the respective 
partners for each conjugate.
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Figure 26
UV spectrum of 16-hemisuocinate-BSA conjugate [B.5]
Spectrum was obtained after dialysis under acid pH4.5 followed by dialysis at pH 7.0.
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Figure 27
UV spectrum of 17-oxime-BSA conjugate [A.3]
Spectrum was obtained after dialysis under acid pH4.5 followed by dialysis at pH 7.0
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Further evidence of covalent linkage was the retention of the 
cyclopenta[a]phenanthrene spectra when the conjugates were extracted 
with ethyl acetate see figure 28.
Figure 28
UV spectrum of BSA-15-S-cpp 
after passage through a G-25 
desalting column followed by 
ethyl acetate extraction.
1 . 5 "
0 . 5 ”
200 250 300 350 400nm
To establish the extent of covalent linkage between the two moieties an 
assay for both the protein content and the cyclopenta[a]phenanthrene 
content was required.
Protein Assay
The protein assay used in these studies was originally developed by 
Smith etal ‘•32. and was based on the Biuret reaction:-
Protein
Figure 29
Alkaline Tartrate RCH
Cu+^ SO^
N
.+1 o =
f=0  X  "v RCH
NH
I
Taken from Biuret reaction (Creighton^
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In the presence of protein under basic conditions Cy2+ is reduced to 
the less stable Cu1+ oxidation state as indicated, and the formation of this 
oxidation state is a direct measure of the protein concentration. Smith et al 
132 used the Bicinchoninic acid complex with Cu "*+ to stabilise this 
oxidation state and generate a measurable chromophore which absorbs at 
562nm.
+1
-Cu:;
00 c
000
COD'
000"
Cu"*+ Bicinchoninic acid complex(taken from Smith efa/134 
Figure 30
The advantage of this assay over the commonly used Lowry approach lies in 
the stability of the coloured complex, which is stable up to one week at room 
temperature, or if the protein is difficult to handle under these conditions the 
assay can be used at elevated temperatures such as 37°c and eo^c. In 
addition the complex is resistant to commonly used solubilising agents, such 
as detergents and to dénaturation agents such as 4M guanidine 
hydrochloride and 3M urea. The complex is susceptible to interference with 
reducing sugars and chelating agents. The reagent is commercially 
available from Pierce.
Cyclopenta[a]phenanthrene content of conjugates
The high molar absorbtivity of cyclopenta[a]phenanthrene analogues 
(see table 13 chapter 4 of this thesis), and inspection of the UV data so far 
presented for the protein conjugates ( Figures 25,26,27,28) indicate the 
value of UV spectroscopy as a practical choice for the estimation of 
cyclopenta[a]phenanthrene content of these conjugates.
The first stage in the assay was to determine the relative contribution 
of the protein and cyclopenta[a]phenanthrene absorbances in the total 
conjugate spectrum.
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U.V profile of added cpp(A.2) to fixed concentration of BSA
Figure31
A standard curve of variable cyclopenta[a]phenanthrene concentration in the 
presence of fixed protein concentration versus the optical density 
contribution of the cyclopenta[a]phenanthrene was prepared for each 
conjugate mix. A typical U V profile figure 31. using as the example 17- 
oxime NHS ester [A .2 ] dissolved in dioxan and added at fixed 
concentrations to a known invariant concentration of BSA. Where total 
optical density minus BSA optical density contribution equals the optical 
density contribution for the oxime, expressed on the y-axis used to plot the 
standard curve (see table 13, page 61 ).
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Standard curve for 17-oxime-cpp(A.2) 
in the presence of BSA.
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Graph 1
This and all of the curves (used for other conjugate studies) showed a linear 
relationship over the entire range of concentrations sampled. In the above 
example a blue shift of 6nm was observed as the concentration of oxime 
Increased over the relatively diminishing concentration of BSA, until the 
spectrum was Identical to the precursor oxime [A.2].
From the protein assay and the total optical density measurement of a 
typical cpp-protein conjugate an optical density contribution for the protein 
can be estimated (based upon the O.D measurement of the protein of known 
concentration used to prepare the standard curve). This value when 
subtracted from the total optical density measurement gives the optical 
density contribution of the cyclopenta[a]phenanthrene which Is used to read 
off Its concentration from the standard curve. The relative molar ratios of 
cyclopenta[a]phenanthrene to protein were calculated. Table 5, shows the 
ratio of cyclopenta[a]phenanthrene to protein for a number of BSA 
conjugates used In the production of antisera In rabbits. BSA contains a 
maximum of 60 lysine residues not all of which are available for reaction 
because of steric constraints, the maximum observed modification was 42, 
for a 17-oxlme BSA conjugates.
Table 5
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BSA conjugate Protein concentration 
U, mole /  litre
Cpp-concentration 
^ mole /  litre
Ratio of 
cppiBSA
17-oxime la 6 188 31
17-oxime 1b 12.3 420 34
17-oxime 1b, after dialysis 12.3 365 30
17-oxime 2 14.8 625 42
16-hemisuccinate 1 11 89 8
16-hemisuccinate 1 
after dialysis
11 138 12.5
15-thioether 112 1040 9
3-ether 18 384 21
11 -ether 19 285 15
The 17-oxime - BSA conjugate labelled la  and 1b were derived from the 
same reaction, which was unequally divided into two fractions each of which 
were subjected to a different work-up procedure; the ratios (31 and 34) 
indicate the good reproducibility of the assay procedure.
The 17-oxime sample (1b) and the 16-hemisuccinate were subjected 
to dialysis using dénaturation conditions (as described), and it was assumed 
that the protein concentration was the same after dialysis as before since 
BSA would not pass through the dialysis membrane. The 17-oxime 
indicated measurable losses of cyclopenta[a]phenanthrene suggesting 
hydrophobic interactions, but a large proportion of this hapten was retained 
giving a final ratio alteration from 34:1 to 30:1. The protein estimate for the 
hemisuccinate conjugate was less accurate as the relative ratio of 
cyclopenta[a[phenathrene to protein was increased from 8:1 to 12.5:1 again 
indicating good retention of cyclopenta[a]phenanthrene under dénaturation 
conditions. Both groups of data provided further evidence of significant 
covalent bond formation for each of the conjugates studied, and in the case 
of the 17-oxime some hydrophobic interactions between the two moieties 
were observed.
Table 6 shows the molar ratio for other protein cyclopenta[a]- 
phenanthrene conjugates, which were to be used in the assay procedure.
Table 6
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Protein conjugate Molar protein 
concentration 
U mole/litre
Molar Cpp 
concentration 
u mole/litre
Ratio of cppiprotein
17-oxime-cpp-
ovaibumin
11.2 149 13.3
17-oxime-cpp-
thvroglobulin
1.42 137 96
15-thioprop-cpp-
thyroglobulin
2 262 118
3-0-cpp-
thyroglobuiin
3 150 46
11 -0-cpp- 
thyroglobulin
2 242 120
The cyclopenta[a]phenanthrene values presented represent an 
average concentration, as each protein conjugate mixture consists of a large 
number of protein chains differing only in the degree of cyclopenta- 
[ajphenanthrene substitution.
In conclusion the described chemistry has provided us with good 
quality well defined cyclopenta[a]phenanthrene-BSA conjugates suitable for 
antibody production. Other conjugates based upon this chemistry involving 
alternative proteins are used for the presentation of bound antigen 
(a) direct assay used to characterise the products of antibody production as 
described in chapter 3, and (b) in the final competition assay described in 
chapters 4 and 5.
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MATERIALS AND METHODS
The starting cyclopenta[a]phenanthrene derivatives employed i.e. [14,A], 
[40,E.1], [41,D.1], and [21,6.2] used as a standard for identification 
purposes, were all available from previous syntheses. A sample of [40,E.1] 
was a generous gift from Professor R. G. Harvey.
Ultraviolet spectra were recorded in ethanol solutions unless otherwise 
stated and are expressed as Xm ax.(logic e) where e is the molar absorption 
coefficient in mole/litre. Infrared spectra were measured as a Nujol mull or a 
neat film on a sodium chloride disc. "IH N.M.R. spectra were run with CDCI3 
solutions (unless otherwise specified) on a Bruker instrument at 300 MHz; 
chemical shifts are measured in p.p.m. downfield from tetramethylsilane.
Preparation of a/7f/-15,16-dihydrocyclopenta[a]phenanthren-17- 
one carboxymethyloxime (A.1)
15,16-Dihydrocyclopenta[a]phenanthren-17-one (A.0.59g) was 
dissolved in boiling ethanol (lOOmL). A solution of carboxymethoxyamine 
hydrochloride (0.8g) in 2N potassium hydroxide solution (4mL) was added 
and boiling was continued overnight. The almost colourless solution 
containing white solid was concentrated to about 4mL, water (lOOmL) was 
added, and the mixture was shaken with ether, leaving white solid at the 
interface. This was collected, washed well with water and dried (0.73g, 
94%yield). It recrystallised from a large volume of boiling ethyl acetate as 
small prisms, mp 225°C (decomp) elemental analysis: (Found; 0, 74.3; H, 
4.8; N, 4.75. C19H16O3N requires C, 74.5; H, 5.25; N, 4.6%), I.R: 1736 
(C=0) and 1634 (C=N) cm-1, UV: Xmax 270.8(4.71), 283.7sh(4.67), 
286.9(4.50), 295(4.37), 300.7(4.40), 308.8(4.21), 332.6(3.14), 348.5 (3.41), 
356.8 (2.90), 366.2 (3.47) nm, ^HNMR: ^H (300M H z de- DMSO T M S  ref) 
12.7(1 H,s,acid,H), 8.84(1 H,d,Ji,2 7.75Hz,1-H), 8.77(1H,d,Ji 1,12 8.7Hz,11- 
H), 8.1-7.95(2H,m,aryl-H), 7.79(1 H,d,Ji 1,12 8.7Hz,12-H), 7.72-7.65 
(3H,m,aryl-H), 4.71(2H,s,side chain methylene protons), 3.4(2H,m,16-H), 
3.05(2H,m,15-H)
Synthesis of anti -17-ethylcarbonylmethyloximidocyclopenta- 
[ajphenanthrene (A.4b)
!Compound [A.1 j was suspended in 3N HCI (4pts), ethanol (i pt) and 
stirred at room temperature for 1 hour. It,slowly dissolved and needle- 
shaped crystals of the ethyl ester separated and were collected, m.p.169- 
1700c elemental analysis: (Found; 0 , 75.65; H,5.7; N,4.3. C21H 19NO3
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requires C,75.65; H,5.75; N,4.2%), IR: 1754 cm-1 (ester C=0), no OH signal,
UV: X m ax 2 6 9 .7 (4 .8 6 ) ,  2 9 5 (4 .6 1 ) , 3 0 7 .9 (3 .4 0 ), 3 3 1 (3 .3 3 ), 3 3 9 .7 (3 .1 1 ),
347.5(3.57), 355(3.09), 365.2 (3.61) nm. 1h NMR Sr  (300MHz,CDCl3sat)
8.68 (1H,d,H-1), 8.61(1H,d,H-11), 7.6-8.0(6H,m,aryl-H), 4.79(2H,slnglet,
CH2-18), 4.29(2H,quartet,CH2-20), 3.41(2H,dd,CH2-15), 3.2(2H,dd,CH2-
16), 1.32(3H,trlplet,CH3-21)
X-Ray crystallography data 
Table 7
Atomi Atom2 Distances Atom 1 Atom2 Distances Atomi Atom2 Distances
01 019 1.166(9) 04 05 1.402(8) 012 013 1.385(8)
02 N1 1.417(6) 05 06 1.423(8) 013 014 1.367(9)
02 018 1.415(9) 05 010 1.419(9) 013 017 1.455(7)
03 019 1.329(9) 06 07 1.330(7) 014 015 1.514(8)
03 020 1.426(10) 07 08 1.424(8) 015 016 1.538(8)
N1 017 1.289(8) 08 09 1.429(8) 016 017 1.491(9)
01 02 1.351(8) 08 014 1.407(7) 018 019 1.506(10)
01 010 1.410(8) 09 010 1.438(7) 020 021 1.436(13)
02 03 1.381(10) 09 O il 1.417(9) - - -
03 04 1.354(10) O il 012 1.365(8) - - -
Numbers in parentheses are estimated standard deviations in the least significant digits.
Table 8
Table of Positional Parameters and their Estimated Standard Deviations
Atom X y X B(A2) Atom X y X B(A2)
01 -0.4217(3) 1.0000(9) 0.1152(3) 9.8(2) C9 0.0358(3) 0.896(1) 0.1596(3) 3.6(1)
02 - 0.3480(3) 0.8732(9) - 0.0005(3) 7.5(1) CIO 0.1217(3) 0.900(1) 0.1983(3) 3.9(2)
03 - 0.4988(3) 0.6804(9) 0.0961(2) 7.9(1) O il - 0.0205(4) 0.727(1) 0.1741(3) 4.3(2)
Ml - 0.2733(3) 0.798(1) 0.0480(3) 5.9(2) 012 -0.1027(4) 0.728(1) 0.1391(3) 4.4(2)
01 0.1587(4) 0.733(1) 0.2514(3) 4.7(2) 013 - 0.1307(3) 0.900(1) 0.0868(3) 4.0(2)
02 0.2391(4) 0.747(1) 0.2880(3) 5.7(2) 014 - 0.0802(3) 1.070(1) 0.0700(3) 3.9(2)
03 0.2886(4) 0.927(1) 0.2743(4) 6.4(2) 015 -0.1266(4) 1.235(1) 0.0109(3) 4.4(2)
04 0.2563(4) 1.090(1) 0.2226(4) 5.8(2) 016 -0.2172(4) 1.153(1) -0.0032(3) 5.2(2)
05 0.1729(3) 1.084(1) 0.1839(3) 4.1(2) 017 -0.2146(4) 0.940(1) 0.0431(3) 4.8(2)
06 0.1390(4) 1.253(1) 0.1287(3) 5.0(2) 018 -0.4129(4) 0.739(1) 0.0162(4) 6.9(2)
07 0.0599(4) 1.247(1) 0.0920(3) 4.5(2) 019 -0.4419(4) 0.827(1) 0.0829(4) 6.7(2)
08 0.0042(3) 1.074(1) 0.1067(3) 3.6(1) 020 - 0.5385(5) 0.738(2) 0.1547(4) 10.5(3)
Table 9
Table of Positional Parameters and their Estimated Standard Deviations
Atom X y X B(A2) Atom X V X B(A2)
HI 0.1243 0.5996 0.2619 5* H16B -0.2395 1.1164 -0.0572 5*
H2 0.2631 0.6256 0.3261 5* H16A -0.2528 1.2748 0.0127 5*
H3 0.3479 0.9382 0.3023 5* H18A -0.4610 0.7413 -0.0281 5*
H4 0.2930 1.2167 0.2118 5* H18B -0.3931 0.5757 0.0264 5*
H6 0.1757 1.3788 0.1169 5* H20B -0.5679 0.8888 0.1424 5*
H7 0.0388 1.3669 0.0529 5* H20A -0.4954 0.7517 0.2021 5*
Mil 0.0007 0.6005 0.2111 5" H210 -0.5672 0.4106 0.1743 5*
H12 -0.1414 0.6082 0.1510 5* H21A -0.6236 0.6065 0.2036 5*
H15A -0.1212 1.3990 0.0294 5* H21B -0.6397 0.5477 0.1146 5*
H15B -0.1057 1.2239 -0.0358 5*
Starred atoms were refined isotropically.
Anisotropically refined atoms are given in the form of the isotropic equivalent thermal 
parameter defined as (4/3) * [a2*B(1,1)+b2*B(2,2)+c2*B(3,3)+ab(cos gamma)*B(1,2) +ac(cos
beta)*B(1,3)+bc(cos alpha)*B(2,3)]
Table 10
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Atom 1 Atom2 Atom3 Angle Atomi Atom2 Atom3 Angle
N1 02 018 107.1(5) 01 010 09 123.7(5)
019 03 020 117.4(6) 05 010 09 119.1(5)
02 N1 017 109.1(5) 09 O il 012 122.4(5)
02 01 010 121.8(6) O il 012 013 118.1(6)
01 02 03 120.9(6) 012 013 014 122.9(5)
02 03 04 119.5(6) 012 013 017 128.4(6)
03 04 05 121.8(6) 014 013 017 108.7(5)
04 05 06 121.8(6) 08 014 013 119.9(5)
04 05 010 119.0(5) 08 014 015 128.2(5)
06 05 010 119.1(5) 013 014 015 112.0(5)
05 06 07 121.9(6) 014 015 016 104.2(5)
06 07 08 121.8(5) 015 016 017 104.8(5)
07 08 09 118.6(5) N1 017 013 120.3(6)
07 08 014 122.6(5) N1 017 016 129.7(5)
09 08 014 118.8(5) 013 017 016 110.1(5)
08 09 010 119.4(5) 02 018 019 113.2(6)
08 09 O il 117.9(5) 01 019 03 125.6(7)
010 09 O il 122.6(5) 01 019 018 126.4(7)
01 010 05 117.1(5) 03 019 018 107.8(6)
03 020 021 109.9(7)
Numbers in parentheses are estimated standard deviations in the least significant digits.
Synthesis of 17-Acetoxy-15H-cyclopenta[a]phenanthrene(B)
Following the procedure of Coombs eta l  ‘• ‘•®;ketone [A ](1 .116g ,
4.81 mmole) was dissolved in isopropenyl acetate (ISOmL) and p-toluene 
sulphonic acid (0.65g, catalytic amounts) and the mixture refluxed overnight. 
The UV spectrum showed a Xmax shift from 265nm(single major peak), to a 
doublet 268nm and 272nm; the isopropenyl acetate was removed under 
reduced pressure and the residue dissolved in dichloromethane and 
partitioned with a saturated sodium bicarbonate solution to remove the acid. 
The organic layer was combined with further dichloromethane washings, 
dried over anhydrous magnesium sulphate, filtered and evaporated to 
dryness and the residue was recrystallised from benzene 1.28g 
(93.4%yield).
Elemental analysis; Found C,83.16; H,5.20, calculated C,83.19: H, 5.14.
Synthesis of 16-Acetoxy-15,16-dlhydrocyclopenta[a]phen- 
anthren-17-one-(B.1)
Modified procedure of Coombs e t a l  1 1 6 ,  Com pound
B(1.51 g,5.51 mmole) was suspended in glacial acetic acid (60ml) containing
lead tetraacetate (2.44g, 5.51 mmole), and the reaction was stirred under
2x150Watt light bulbs and monitored by UV spectroscopy (see table 4,
Results and Discussion for spectral changes). TLC (4%EtOH/CHCl3) after
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à 20 minute reaction time revealed a single spot Rf 0.6 (deep brown char with 
H2SO4), where as the starting end ether had an Rf 0.46 and gave a greenish 
yellow colour with H2SO4 , indicating complete oxidation. The product co-migrated 
using the above tic system with authentic [B.1] derived from the analytical sample 
prepared by Coombs The reaction was stopped by addition of 5% sodium
thiosulphate and extraction into dichloromethane followed by sodium bicarbonate 
wash, drying over magnesium sulphate, filtration and evaporation.
Synthesis of 16-Hydroxy-15,16-dlhydrocyclopenta[a]phen- 
anthren-17-one |b .1]
Compound B2 was dissolved in 5 M H2SO4 : methanol(1:1v/v)(80mL) 
and refluxed for 3h, the product was partitioned between chloroform and 
saturated sodium bicarbonate solution and the organic layer was removed 
and dried over anhydrous magnesium sulphate, filtered and reduced in 
volume to approximately 20mL This product was passed down a silica flash 
column using a chloroform gradient up to 10%methanol/ chloroform 0.433g 
of white crystalline solid was obtained which showed a single spot on tic 
(4% M e O H /C H C l3) Rf 0.54. 1RNMR (300M Hz. CDCI3 sat, TMSref) 
8.79(1H,d,aryl,11-H), 8.72 (1H,d,aryl,H-1), 7.8(6H,m,aryl,2,3,4,6,7,12-H), 
4.75-4.85(1 H,dd,16H gem to OH), 4.2(2H,m,15H cis to OH), 5H 3.20- 
3.30(1 H,dd,15H trans to OH).
Preparation of 15,18-dihydro-16-hydroxycyclopenta[a]phen- 
anthren-17-one 16-hemisuccinate (B.3).
Dry15,16-dihydro-16-hydroxycyclopenta[a]phenanthren-17- 
one110,111 .(50mg) was dissolved in anhydrous pyridine (Im L) and 
succinic anhydride was added. After four days at room temperature the 
pyridine was removed by repeated co-evaporation with benzene and the 
resulting solid was dissolved in ethyl acetate. Extraction of the latter with 
sodium bicarbonate solution and acidification gave a solid which was again 
extracted into ethyl acetate. This solution was dried and evaporated to yield 
the acid (B.3) as a white solid (65mg). showing the expected (C = O) bands 
in the I.R, 1740 (ester), 1700 (acid), and 1685 (ketone) cm"1, and 
5H(300Mhz d6 DMSO TMS ref) 12.3 (IH , s, acid H), 8.97 (2H, dd, 1- and 11- 
H), 8.2-7.75 (6H, m, aryl-H), 5.10 (IH , dd, 16-H), 4.10 (IH , dd, 15-H), 3.40 
(IH , dd, 15-H), 2.65 and 2.52 (2H each, m, side chain methylene protons).
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Synthesis of 16-Bromo-15,16-dlhydrocyclopenta[a]phenanthren- 
17-one-(C.1)
Ketone A(1.07g, 0.46mmole) was dissolved in carbon tetrachloride 
containing N-bromosuccinimide (0.98g, 5.5mmole) and the mixture refluxed 
for 5hours under the light generated by two by 150Watt light bulbs. The 
product was filtered, evaporated to dryness and recrystallised from 15mL of 
benzene, 0.9g (63%yield), mpt 173°c with decomposition, co-elutes with 
analytical sa m p le (C .I) synthesised by Coombs e f  a /  118,  using 
dichloromethane.
Preparation of 15-(3-carboxyethylthio)-15,16-dihydrocyclopent- 
[a]phenanthren-17-one (0.3)
16-Bromo-15,16-dihydrocyclopenta[a]phenanthren-17-one118 
(0.24g,0.67mmole), dissolved in dry benzene (50mL) was treated at room 
temperature with triethylamine (0.5mL, 3.6 mmole) to form 0 .2  which was 
not isolated. After 15 min 3-mercaptopropionic acid (0.25mL, 2.4mmole) was 
added to the deep yellow solution of the 15(16)-en-17-one(0.2), Xmax 313 
nm; the colour paled, and after 2hrs the ultraviolet spectrum disclosed 
complete conversion to product Im ax 279 nm(0.3). Water was added and 
the aqueous layer was acidified with dilute hydrochloric acid and re­
extracted with dichloromethane. The combined organic layers, beginning to 
deposit brown solid, were evaporated to dryness. The resulting solid was 
dissolved in hot n-butanol which on being cooled gave cream rosettes of 
needles of the thioether (0.3) (0.12g). A sample recrystallised twice from n 
-butanol had mp 206°. (Found: 0 , 71.2; H, 5.0. C20H 16O3S requires 0, 
71.4; H, 4.8%), I.R. v max 1738(acid 0= 0 ) and 1679(ketoneC=0) cm"1, U.V. 
X max 270.4, 299.7, 353.1, 370.7nm, 1RNMR (300MHz, De DMSO,TMSref) 
8H 12.35 (1H,s,acid-H), 8.95 (1 H ,d ,Jn ,i2  8.6Hz,11-H), 8.9(1H,m,1-H), 
8.4(1 H,d,Je,7 8.8Hz, 7-H), 8.05(2H,m,aryl-H), 7.82(1 Hd,Je,7 8.8Hz,6-H), 
7.78(2H,m,aryl-H),5.3(1H,d,Ji5,i6 6.5Hz,15H), 3.45(1 H,dd. J l5 ,16 6.5Hz, 
Jl6,16 19.2Hz, 16-H), 2.95(1H,d,Jie,16 19.2Hz,16-H) and multiplets at
2.84(2H) and 2.72(2-H) due to side chain methylene groups.
Attempted synthesis of 11 (Succinoyl)-15,16-dihydrocyclopenta- 
[a]phenanthren-17-one
Compound D ( 0.5g,2mmole) was dried by co-evaporation with 
anhydrous pyridine and dissolved in pyridine (lOmL) containing succinic 
anhydride (0.3 g, 3mmole), the mixture was stirred for 3 days at room
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temperature, both monitoring by UV spectroscopy and tic indicated no 
change; the mixture was refluxed for 1 week, again with no change. 
Attempted synthesis of 3-(Succinoyi)-15,16-dihydrocyclopenta- 
[a]phenanthren-17-one
Compound E ( 0.5g,2mmole) was dried by co-evaporation with 
anhydrous pyridine and dissolved in pyridine (10mL) containing succinic 
anhydride (0.3 g, 3mmole), the mixture was stirred for 2hours at room 
temperature, after this period a UV spectrum revealed a shift from X max 
266.1,296.1 and 365.6nm for E, to Xmax 278,324nm for the product. 
Treatment of the product in the UV cell with sodium hydroxide regenerated 
the starting phenol spectrum. The pyridine was removed under vacuum and 
the residue was partitioned between saturated sodium bicarbonate and 
ethyl acetate , the bicarbonate fraction was acidified and re-extracted with 
ethyl acetate, the ethyl acetate fraction was dried over anhydrous 
magnesium sulphate, filtered and evaporated to dryness wt 0.191 g 
(27%yield) IR spectrum Broad C =0 at 1690,1740cm" 1 which indicates both 
COOH,and keto-C=0, broad hydroxyl at around 3000cm" 1 confirms the 
presence of a carboxyl.
Preparation of 11-(3-cyanopropoxy)-15,16-dihydrocyclopenta[a]- 
phenanthren-17-one (D.2)
15,16-Dihydro-11 -hydroxycyclopenta[a]phenanthren-17-one124,( D,1 )
(3.0g) and dry potassium carbonate (2.5g) were heated under reflux with 
4-bromobutyronitrile (5.3g) in acetonitrile (250mL) for 44h when TLC 
indicated absence of the phenol. The solution was filtered from the 
precipitated potassium bromide, the latter was washed with a little 
acetonitrile, and the combined solutions were concentrated to about 
50mL. The yellow crystals that separated from the cooled solution were 
collected and dried (3.4g). A specimen recrystallised from the same 
solvent had mp 178° (Found: 0 , 79.95; H, 5.4; N, 4.95. C21H 17O2N 
requires 0 , 79.95; H, 5.45; N, 4.50%), v m a x 2 2 4 8  (C=N) and 1694 cm- 
1 (C=0). 1 HNMR(300MHz,CDCl3,TMSref)9.6(1 H,m,aryl1 -H),7.65-8.0 (5H, 
m, aryl not in order, 2, 3, 4, 7, 12), 7.22(1 H,m,aryl,6-H), 4.3(2H,m,18-H), 
3.3(2H,m,H-20), 2.72(2H,m,16H), 2.7(2H,m,19H), 2.4(2H,m,15H).
Hydrolysis to 11-(3-carboxypropoxy)-15,16-dihydrocyclopenta- 
[a]phenanthren - 17-one (D.3 )
This nitrile (D.2) (1.6g) was dissolved in hot glacial acetic acid (100 
m l) giving a golden solution which became deep red following the addition
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of an equal volume of cono. hydrochloric acid. The mixture was boiled under 
reflux for 35 min, cooled, and the yellow crystalline solid filtered off and dried 
(1.28g). A specimen recrystallised from acetic acid had m.p. 222- 
2230.(Found: C, 75.6; H, 4.95 C21H18O4 requires C, 75.45; H, 5.4%), v max 
1730 (acid C=0), 1665 cm-1 (ketone C=0).
3-(3-Cyanopropoxy)[E.2] and 3-(3-carboxypropoxy)-15,16- 
dihydrocyclopenta[a]phenanthren-17one [E.3].
This nitrile (E.2) was prepared from the 3-hydroxy-17-ketone(E.1) as 
described for the 11-analogue(D.2). It formed yellow needles, m.p. 175° 
(Found: N, 4.2%), vmax 2250 (C = N) and 1698 (C=0) cm-1.
Acid hydrolysis of the nitrile (0.17g) as before, gave brick red needles of 
the acid (E.3) (0.15g) lacking this infrared CN absorption, v max 1728 (acid 
C=0) and 1652 ( ketone C=0) cm-1. A, ^ax  221 (3.52), 268.3 (3.94), 278.7 
(4.01), 292.7 (3.66), 323.8 (3.44), 348.8 (3.15), 365.6 (2.74) nm, 
lHNMR(300MHzd6-DMSO,TMSref) ÔH 8.74 (2H, t,1-and 11-H), 7.97 (IH , d, 
J e j  8.95 Hz, 6- or 7-H), 7.88 (IH , d, J Q j  8.95 Hz, 6- or 7-H), 7.76 (IH , d, 
v/11,12 8.6 Hz, 12-H), 7.33 (IH , d, J 2,4 2.4 Hz, 4-H),7.26 (IH , dd, J l ,2  8.9 
Hz, J 2,4 2.4 Hz, 2-H), 3.45 (2H, m, 16-H), 2.79 ( 2H, 15-H), 2.5-2.3 (6H, 
multiplets, side chain methylene protons ).
Preparation of N-hydroxysuccinimide esters
The 17-oxime-acid (A.1) (0.3g ) was stirred in dry dioxan (50mL) with 
N-hydroxysuccinimide (0.9g) and dicyclohexylcarbodiimide (0.36g, DCC) at 
room temperature for 4 days. The white finely divided precipitate of 
dicyclohexylurea was removed by filtration and the mother liquor was 
evaporated to give a gum. The latter was dissolved in the minimum volume 
of dichloromethane and precipitated by the addition of hexane; this 
procedure was repeated until a drop of the dichloromethane solution, dried 
as a film on an NaCI plate, no longer showed the presence of DCC by its 
strong infrared absorption at 2120cm-1.The resulting glass (0.46g) was 
crystallised from ice-cold dichloromethane to yield the NHS ester (A.2) 
(0.121g), m.p. 178-1830 with decomposition, vmax1810,1780cm-1. A, max 
(measured in dichloromethane) 270.8(4.71), 283.7(4.67), 286.9(4.50), 
300.7(4.40), 332.6(3.14), 348.5(3.41), 356.8(2.90), 366.2(3.47) nm, 
1hNMR(300MHz, CDCIs.TMS ref)8H 8.71 (IH , d, 1-H), 8.65 (IH , d, 11-H),
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8.0-7.6 (6H, m, aryl-H), 5.10 (2H, s, side chain methylene protons), 2.85 (4H, 
s, succinimide ring protons).
The 16-hemisuccinate (B .3 ) (75 mg), subjected to the same procedure, 
afforded the NHS ester (B .4 ), m.p. 162-1670c, v m ax"!814, 1783, 1736 
(ester C=0), and 1726 (ketone C=0) cm-1. X max (in dichloromethane) 
268.3(5.06), 286.7(4.71), 300.1(4.62), 338(3.42), 354.9(3.61), 372.9(3.62) 
nm, lHNMR(300MHz,CDCl3,TMSref) 6h 8.75 (2H,dd,1- and 11-H), 8.05- 
7.70 (6H, m, aryl-H), 5.68 (IH , dd, J 15,16 7.7 and 4.2 Hz, 16-H), 4.15 (IH , 
dd, J15,15 17.1, J15,16 7.7 Hz, 15-H), 3.38 (IH , dd, J 15,15 17.1, J l5 ,1 6  
4.2 Hz, 15-H), 3.04 and 2.96 (2H each, m, side chain methylene protons),
2.82 (4H, s, succinimide ring protons).
The thioester acid (C .3 ) (0.49g) was treated as described above to 
yield the NHS ester ( C .4 )  which was crystallised from ice-cold 
dichloromethane, v m a x i820, 1790, 1740, and 1720 (ketone C =0) cm-1, 
Amax (in dichloromethane) 273.3(4.80), 301.5(4.43), 353(3.27), 371.6(3.30) 
nm,lHNMR(300MHz,CDCl3,TMSref) 5 r  8.82 (1H, d, J n , i 2 8.6 Hz, 11-H), 
8.73 (IH , dd,1-H), 8.37 (IH , d, J 6,7 9.0 Hz, 7-H), 8.0 (3H, m, aryl-H), 7.7 
(2H, m, aryl-H), 5.12 (IH , dd, J i5 ,1 6  1-3 and 6.9 Hz, 15-H), 3.40 (IH , dd, J  
15,16 6.9, J 16,16 19.2 Hz, 16-H), 3.17 (IH , dd, J 15,16 1.3, >/16,16 19.2 Hz,
16-H), 2.85 (4H s, succinimide ring protons), 3.05-2.80 ( 4H, m, side chain 
methylene protons).
The 3-ether acid (E .3 ) (0.15g) on treatment by this procedure yielded 
the NHS ester (E .4 ) as a yellow resinous solid , vmax 1811, 1775, 1735, 
and 1680 cm-1. Am ax ( in dichloromethane) 205.5, 277.0 and 320.0 nm.
The 11- ether acid (D .3 ) was subjected to these conditions and after 
removal of the excess of DCC the oil which gave a 1HNMR consistent with 
an NHS ester ; 1hNMR(300MHz, CDCl3,TMSref)5H 9,76 (IH , dd, 1-H), 7.95 
(3H, m, aryl-H), 7.73 (2H, m, aryl-H), 7.42 (IH , s, 12-H), 4.45 (2H, t, 16-H), 
3.42 (2H, t, 15-H), 3.70, 3.00 and 2.52 (2H each, m, side chain methylene 
protons), 2.85 (4H, s, succinimide ring protons).was further purified by 
chromatography using a silica gel flash column (50g) in dichloromethane 
with increasing amounts (2-20%) of ethyl acetate. Two fractions were 
collected, running on tic as discrete, but overlapping spots. Both fractions 
had elemental analyses consistent with the expected NHS ester (D .4 )  
(Found: fraction 1, C,69.30; H,4.8; N,3.2 ; fraction 2, C,69.35; H,4.95; N,3.2. 
C25H21O6N requires C,69.6; H,4.9; N,3.25%), v max 1811, 1781, 1733, 
1688 cm-1, A portion of the oil before chromatography was stirred overnight
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in dioxan (10 mL) with cyclohexylamine (0.3 mL). The reaction mixture was 
diluted with dichloromethane which was washed successively with dilute 
sulphuric acid , water, saturated aqueous sodium hydrogen carbonate, and 
water, and dried over anhydrous magnesium sulphate. Evaporation left a 
solid which was recrystallised from hot ethanol as pale yellow needles of 
the cyclohexylamide (D.5), m.p. 207-2080C (Found; C,78.15; H, 7.0; N, 
3.25. C27H28O3N requires C,78.05; H,7.05; N,3.35%), vmax 3290 (N- 
H),1690 (ketone C=0), 1640(amide C=0) cm-1, Amax 263.0 (5.02), 293.6 
(4.64), 3.03 (4.49), 346.1 (3.56), 363.6 (4.21), 381.9 (4.23) nm, IH N M R  
(300MHz,CDCl3,TMSref)0H 9.75 (IH , dd, 1-H), 8.0-7.8 (3H, m, aryl-H), 7.70 
(2H, m aryl-H), 7.33 (IH , s, 12-H), 5.35 (IH , d, NH), 4.30 (2H, t, 16-H), 3.77 
(IH , m, methine-H), 3.35 (2H, t, 15-H), and side chain and cyclohexane 
multiplets at 2.82 (2H), 2.47 (4H), 1.85 (2H), 1.6 (3H), 1.32 (2H), 1.05 (3H).
Preparation of protein conjugates
To bovine serum albumin (108 mg, 1.66 mmole) dissolved in 0.1M 
phosphate buffer (pH7.1, 50 mL) containing dioxan (2mL) was added 
dropwise with stirring the oxime active ester (A.1) (lOmg, 24.9 mmole) 
dissolved in dioxan (4mL), and stirring was continued overnight at ambient 
temperature. Small molecular weight materials were removed by passing 
the cloudy solution down a G25 exclusion column (44cm x 3cm diam.). The 
protein, eluted first with 0.1M phosphate buffer (pH7.1), possessed the 
strong ultraviolet absorption characteristics of the oxime (A.1).
Dialysis of conjugates A.3 and B.5 under dénaturation 
conditions.
Each of the respective conjugates were dialysed following identical 
protocols but were treated independently.
Various lengths of dialysis tubing ( Visking size 2-18/32” ) were soaked 
in distilled water for 2hrs at room temperature and each tube was sealed at 
one end with three tight knots to form a bag. lOmL aliquots of the respective 
conjugate was poured into the bag via a glass funnel, the air removed above 
the liquid level by compressing the tubing with two fingers prior to tying the 
tubing, using an identical knot arrangement as used before. Both ends of the 
bag were attached to a weight and immersed in a 1 litre beaker containing 
denaturing buffer , 0.1 Molar sodium dihydrogen orthophosphate pH 4.5
59
(500mL) and the contents of the beaker stirred magnetically overnight at 
room temperature. Both protein conjugates formed a white precipitate within 
the dialysis sack. The sacks were removed and transferred to a second 
1 litre beaker containing 0.1M phosphate buffer pH7.1(500mL) and dialysis 
was repeated overnight at room temperature, again both conjugate solutions 
within the respective dialysis sacks redissolved to give a homogeneous 
solution.
Protein assay protocol
This follows the procedure described by Pierce as part of their assay kit. 
A standard BSA (2mg/mL) solution was used to prepare a series of 
standard solutions see table 11.
Reagent A. Bicinchoninic acid buffered with sodium bicarbonate,sodium 
carbonate and sodium tartrate as supplied was diluted to 1 litre with water. 
Reagent B.
4% Copper sulphate solution.
Reagent 0
Volume of BSA Volume of water Protein concentration 
in ng per mL
0.1 0.9 200
0.2 0.8 400
0.3 0.7 600
0.4 0.6 800
0.5 0.5 1000
0.6 0.4 1200
Taken from the Pierce (1989) Handbook and general catalogue p210-212
Table 11
These standards were freshly prepared for each assay carried out; triplicate 
repeats of 0.1 mL aliquots of these standard solutions, sample or 
blanks(buffers used to dissolve the protein) were added to 2mL of freshly 
prepared reagent 0  . After mixing these solutions were left for a minimum of 
2hours at room temperature after which time the colour was read at the fixed 
wavelength of 562nm. The data was averaged and the mean blank 
absorbencies were subtracted from the mean sample absorbencies and a 
plot of the mean sample absorbence versus protein concentration in pg/mL 
was prepared.
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Table 12 ,graph 2, represents assays carried out at different times 
which were used to establish protein contents for a variety of conjugates. As 
described each assay was accompanied by an independent set of 
standards with the respective sample runs.
Table 12
A series of standard curves used to calculate protein concentration for the
Protein cono 
in n g/mL
Optical density 
curve A
Optical density 
curve B
Optical density 
curve 0
Optical density 
curve D
Optical density 
curve E
0 0 0 0 0 0
200 0.174 0.187 0.202 0.283 0.308
400 0.325 0.378 0.361 0.506 0.522
600 0.380 0.528 0.519 0.724 0.667
800 0.612 0.705 0.612 0.945 0.840
1000 0.813 0.819 0.709 1.190 1.056
1200 0.845 0.982 0.903 1.290 1.235
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Cyclopenta[a]phenanthrene assay.
Preparation of standard curve for BSA-17-oxime-cpp conjugate, an 
example of the general procedure used for A.3,B.2,C.3,D.4,E.4, data from 
this experiments and the others are included in tables 13 and 14.
Two solutions were prepared; (a) BSA containing Img/mL of protein 
in 0.1M phosphate buffer pH7.1, (b)15 ,1 6-dihydrocyclopenta-
[a]phenanthren-17-one-N-(-2-succinimido-carboxymethyloxyoxime at 1 mg
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/mL in dioxan. A 2nriL aliquot of the protein solution A was added to a 5mL 
silica cuvette and the U.V. spectrum of this solution was recorded. A 
lOplitre aliquot of solution B was added to the cuvette and the contents 
thoroughly mixed and the spectrum read. This addition of lOplitre aliquots of 
solution B followed by measurement of the spectrum was repeated until the 
optical density readings exceeded the scale of the spectrophotometer.
Table(13)
Vol Concentration of 
cpp/ml corrected for 
volume in nmole /  mL
Protein /  cpp 
Total optical density 
per mL
Protein/cpp optical 
density /  mL cpp 
contribution
Wavelength
nm
in ml A.3 B.2 0.3 A.3 B.2 0.3 A.3 B.2 0.3 A.3 B.2 0.3
2.00 0 0 0 0.607 0.691 0.518 0 0 0 278 279 278
2.01 12.39 7.98 5.87 0.817 1.018 0.761 0.210 0.327 0.243 278 270 274
2.02 24.65 11.91 11.67 1.095 1.296 1.045 0.488 0.605 0.527 278 270 274
2.03 36.80 15.80 17.42 1.408 1.537 1.432 0.801 0.846 0.914 274 270 273
2.04 48.82 19.66 23.12 1.558 1.796 1.591 0.951 1.105 1.073 273 270 273
2.05 60.73 23.48 28.76 1.876 2.018 1.932 1.269 1.327 1.414 273 270 272
2.06 72.52 27.26 - 2.130 2.222 - 1.523 1.531 - 272 270 -
2.07 84.20 31.00 - 2.399 2.444 - 1.792 1.753 - 272 270 -
2.08 95.77 34.71 - 2.674 2.611 - 2.067 1.920 - 272 270 -
2.09 107.2 38.38 - 2.842 2.816 - 2.235 2.125 - 272 270 -
Results in table (13) represent the data used to derive the standard curve for
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17-oxime-cpp(A.2) in the presence of BSA (presented in the results and 
discussion section Graph 1 (page 47) and obtained from the UV profile figure 
33 page 46). Graphs derived from data B.2 and C.3 are exhibited in graph 3 
above.
Standard curves for 16-hydroxy-15,16-dihydrooyclopenta[a]phenanthren-17-one(B.2) and 
15-(3-oarboxyethylthio)-15,16-dihydroGyclopenta[a]phenanthren-17-one.[C.3]
Table 14
Vol Concentration of cpp/ml 
corrected for volume in 
nmole /  mL
Protein /  cpp 
Total optical density 
per mL
Protein/cpp optical 
density /  ml cpp 
contribution
Wavelength
nm
in mL D.4 E.4 D.4thy D.4 E.4 D.4thy D.4 E.4 D.4thy D.4 E.4 D.4thy
2.00 0 0 0 0.624 0.567 1.483 0 0 0 279 279 279
2.01 11.53 11.54 23.2 0.785 0.854 1.682 0.161 0.287 0.199 268 279 266
2.02 22.95 22.97 46.4 1.192 1.016 1.918 0.568 0.449 0.435 266 278 265
2.03 34.26 34.29 69.6 1.329 1.192 2.169 0.705 0.625 0.686 265 278 265
2.04 45.45 45.49 92.8 1.643 1.340 2.425 1.019 0.773 0.942 265 272 264
2.05 56.34 56.59 116.0 1.954 1.539 2.652 1.330 0.972 1.169 265 272 264
2.06 67.51 67.58 139.2 2.313 1.696 2.890 1.689 1.129 1.417 265 271 264
2.07 78.39 78.45 2.613 1.903 1.989 1.336 265 271
2.08 89.15 89.23 2.864 2.082 2.240 1.515 264 271
2.09 99.90 2.272 1.705 271
2.10 110.48 2.450 1.883 270
2.12 131.32 2.613 2.046 270
2.13 141.59 2.591 2.024 270
2.14 - 151.78 - - 2.895 - - 2.328 - - 270 -
Data from table 14 are 
Graph 5 (3-O-ether-BSA)
represented in curves graph 4 (11-0-ether-BSA), 
, and graph 6 (11-O-ether-Thyroglobulin).
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Chapter 3
Production Purification and direct ELISA  
assay of Polyclonal antibodies.
6 6
Rules governing protein conjugate nomenclature used In this 
thesis.
In an attempt to standardise and simplify the text, an outline of the 
protein oyolopenta[a]phenanthrene nomenclature has been included at the 
beginning of chapter 3, with a loose leaf copy available for direct reference 
whilst reading the text.
1. The protein is labelled as the first three to four letters of its 
name(i.e. bovine serum albumin is BSA, Thyrogiobuiin is Thy, Chicken 
ovalbumin is Oval preceded with a single initial i.e. B for bovine or P for 
porcine to identify its species.
2. In all cases conjugate, antigen, serum, affinity column, the 
protein name is followed by the numerical site of linkage to the 
cyclopenta[a]phenanthrene followed by the atom of attachment.
3. Protein conjugate
Is the cyclopenta[a]phenanthrene modified protein 
and the word conjugate is used when the chemistry or physical 
characteristics of this product is discussed.
4. Protein antigen
Where a protein conjugate has been applied to an 
assay, and its roll is that of the target antigen; then the label applied to this 
conjugate is changed from conjugate to antigen.
4. Serum or antigen derived from a conjugate.
Where a serum is derived from an antigen (Protein
conjugate) and for the purposes of discussion the protein carrier is not an 
essential part of the discussion. The serum or antigen are labelled by the 
cyclopenta[a]phenanthrene numerical position of attachment and the atom to 
which the protein is ultimately linked
Examples:-
BSA-17-N-conj = Bovine serum albumin -17- oxime {anti-15,16- 
dihydro-cyclopenta[a]phenanthren-17-one carboxymethyloxime) linked 
conjugate.
BSA-17-N-ant = Bovine serum albumin-17-oxime(anf/ -15,16-dihydro- 
cyclopenta[a]phenanthren-17-one carboxymethyloxime) linked antigen
17-N-linked = Indicates that discussion of the conjugate, antigen or 
serum is being carried out, where the roll of the carrier is not an 
essential feature of the discussion.
Other conjugates of BSA include:-
BSA-16-0- Protein is attached to the 16-position via a hemisuccinate 
ester( 15,16-dihydro-16-hydroxycyclopenta[a]phenanthren-17-one -16.- 
hemisuccinate)
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BSA-15-S- Protein is attached to the 15-position via a thioether 
linkage(15-(3-carboxyethylthio)-15,16-dihydrocyclopenta[a]- 
phenanthren -17-one).
BSA-11-0- Protein is attached to the 11-position via an ether 
linkage(11 -(3-carboxypropoxy)-15,16-dihydrocyclopenta[a]- 
phenanthren-17-one).
BSA-3-0- Protein is attached to the 3-position via an ether 
linkage(3-(3-carboxypropoxy)-15,16-dihydrocyclopenta[a]phenanthren-
17-one).
6 8
The initial requirement of an immunoassay is to generate antibodies 
with high specificity toward the required target antigens, and produce sufficient 
quantities of these antibodies to use in a routine assay.
Steroids were considered a good model system for our purposes 
because of the similarity in size, shape, and some chemical properties with 
cyclopenta[a]phenanthrenes. The carrier protein of choice for the presentation 
of these synthetic haptens was bovine serum albumin (BSA), since much of 
the work on the production of polyclonal antibodies to steroid antigens 
involved this protein and resulted in a number of successful, specific steroid 
directed radioimmunoassays^^.
The rabbit is the most commonly used laboratory animal for the 
production of polyclonal sera, as demonstrated by the communication of 
Nieschlag ef a / 134 where a comparison of animals used for serum production 
revealed the rabbit as the most practical. It is easy to handle and is well 
suited to laboratory animal house facilities, has a blood volume of up to SOOmL 
per animal and the prominent blood vessels in the ears make serum collection 
both easy and relatively painless. Larger animals are used for the commercial 
production of polyclonal sera; these include sheep, cattle, goats, donkeys etc.
Antigen delivery.
Antigen delivery is dependent upon the physical characteristics and 
availability of the respective antigen; each mode of inoculation has its own 
particular associated problems and advantages, and a large number of 
immunisation routes are available"! 35,136,137 jh e  volume of useful antigen 
cannot be quantitated since significant losses are incurred due to catabolism; 
therefore the volumes of antigen required for successful inoculation are 
established by experiment or as the result of handler experience.
Insoluble antigens are more efficient at generating an immune 
response than soluble antigens which are efficiently catabolised. In the case 
of our soluble synthetic antigens it was necessary to form a suspension in a 
suitable adjuvant prior to administering the inoculum.
Adjuvants are non-specific stimulants of the immune system and their 
action, although dependent upon the actual composition, can be divided into 
two effects:-
a. To deposit the antigen at the site of injection in such a manner as 
to prevent rapid catabolism occurring prior to stimulation of the immune 
system.
b. The second function is to stimulate the production of growth 
factors such as lymphocynes which generate the antigen processing cells. An
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unwanted result of this immuno-aotivity is to cause local inflammation at the 
site of the injection.
This effect is largely dependent on the inclusion of activators in the adjuvant. 
The adjuvants used in this study were Freunds complete and incomplete 
adjuvants.
Complete Freunds a d j u v a n t " ! 3 8 ,  1 3 9
The antigen was mixed with heat killed Mycobacterium tuberculosis 
and emulsified with non-metabolisable oils prior to injection into a rabbit. The 
bacterium was responsible for stimulating the production of growth factors and 
activating the immune system. Injections of large amounts of this adjuvant 
cause painful localised aggressive granuloma formation. This toxic effect can 
be reduced by using smaller injection volumes at multiple sites. Boost 
inoculations were necessary, and were carried out at regular intervals. The 
antigen adjuvant mixture used for these boost injections was incomplete 
Freunds adjuvant which excluded the heat killed bacteria, thus reducing the 
localised discomfort generated by the primary inoculation, whilst maintaining 
the required hyper-immune state.
Route of Injection.
The route of administration of the inoculum is dependent upon a variety 
of factors:-
1. The availability of the antigen;
2. Buffer and adjuvants used to stimulate the immune system;
3. The speed at which the immunogen is expected to generate a
titre and the period of hyperimmunisation.
Availability of the synthetic antigens did not pose a problem therefore a 
hyperimmunisation schedule including boost injections was a practical 
proposition. The localised toxic effects caused by inoculation of Freunds 
(complete) adjuvant, which has been discussed, required that a multisite (m/s) 
injection regime be used.
In order to produce sera over a period of about six months or longer, 
boost inoculations were needed to maintain the hyperimmunisation state of 
the rabbit. The sera were collected from the marginal ear vein, obtaining 
between 20-30mL per (test-) bleed.
The method of choice was subcutaneous injection (s.c), involving 
inoculation into the space between the dermis(skin) and muscle. The 
inoculum quickly drains into the local lymphatic system where it concentrates 
in the lymph nodes nearest to the site of injection.
Details of the immunisation schedules used and treatment of the final 
sera are included in methods section Table 1. of this chapter.
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Direct E.L.I.S.A (Enzyme linked immunosorbent assay).
This methodology was developed independently in the early seventies 
by Engval and P e r l m a n n ' ! 4 0 ,  and Van Weeman and Schuurs 1 4 1 ,  Prior to 
discussion of the detailed protocols and principles of the direct assay it is 
necessary to define some of the terms used.
In solution the reaction between an antibody (Ab) and a monovalent 
antigen (Ag, simplest ideal antigen ) is an equilibrium state obeying the law of 
mass action:-
Figure 1
[Ab] + [Ag] [ Ab:Ag ]
^2
Square brackets indicate the concentration of each component, ki is 
the association constant, kg is the dissociation constant and the ratio ki/kg= K 
where K is the intrinsic affinity constant and is a measure of the formation of a 
stable complex. Because of the heterogeneity of the antigen and antibody 
binding sites i.e. antibody will not necessarily contain a single independent 
binding site and the antigen is not monovalent, then an average intrinsic 
affinity constant kg is used ko=1/c where c is the concentration of the defined 
antigen required for occupancy of half the binding sites and this is generally 
referred to as the affinity( definition taken f r o m  142 ) and is largely concerned 
with the antigen binding site.
The antibody binding site also behaves differently from that described in 
the above model i.e. IgG class antibodies have been shown to be bivalent in 
many cases^07,108,143,144 Antibody affinity varies between different 
regions of the antigen also making it necessary to define the overall tendency 
of antibodies to combine with antigens; this is referred to as the 
avidity 137,108,143,145,146
The term antibody is used singularly, but in the case of polyclonal sera it 
actually represents a population of molecules capable of binding to a specific 
antigen, indicating that antibody avidity for this population is a collective term.
In order to assess the reaction quantitatively (1) it is necessary to 
monitor either the loss of starting antigen or antibody, or measure the 
formation of complex. The direct Elisa assay achieves this by adsorbing the 
protein conjugate containing the hapten onto the surface of a solid support 
and all other reagents are in solution. Solution phase antibodies react with 
bound antigen following the reaction scheme, see figure 1 and un reacted
7 1
antibodies are washed off the support. The bound antibody complex is 
quantitatively measured using anti-rabbit antibody enzyme conjugate 
prepared by a variety of m e t h o d s " * 47,148,96,97_ This conjugate antibody 
binds to the rabbit antibody portion of the bound complex, and after removal of 
excess conjugate the bound enzyme can be used to generate a coloured 
chromophore capable of measurement with a spectrophotometer"* 40, The 
chromophore concentration is measured and is proportional to the enzyme 
concentration, and therefore proportional to the bound antibody concentration, 
[Chromophore] a  [Enzyme] a  [Ab:Ag].
Direct assay considerations.
Figure 2
1. Binding antigen to the surface of plate.
- a
Protein-cpp antigen 
conjugate.
In our study the adsorbent surfaces were the walls of a standard 96-well flat 
bottomed plates, which were compatible with an Elisa titre plate reader.
The antigen of choice needed to be the target hapten attached to a 
second protein, to ensure that the antibodies raised against the carrier protein 
did not cross react with the assay carrier protein.
Figure 3
2. Blocking exposed adsorption surface sites.
Polypep Blocking 
protein.
When the antigen had been adsorbed onto the surface of each plate 
well, a second blocking step was necessary to ensure that no surface sites 
were available for non-specific protein-to-surface adsorption, otherwise non­
specific adsorption of either the probe antibodies or the anti-rabbit enzyme
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conjugate would occur later in the assay and result in enhanced, meaningless 
optical density readings.
The blocking agent used for this purpose is usually a protein which shows no 
activity towards any of the assay proteins used. A standard blocking protein 
for this purpose is gelatine and was initially used in our study with success. 
Gelatine solutions were not easy to prepare because of poor solubility 
characteristics, and the solutions prepared were rapidly degraded (within a 
day the solutions started to smell), requiring a fresh preparation for each assay 
. This was clearly not satisfactory therefore two approaches were considered 
to deal with the problem these were:-
a. Use of an alternative more stable blocking protein.
b. Use of an anti-bacterial agent to prevent degradation.
Using an excess of antigen to coat the surface of the wells will leave exposed 
sites of arguably smaller surface area than occupied by the antigen (assuming 
a homogeneous solution of antigen). These sites are capable of anchoring 
small exposed regions (i.e. loops and turns) of larger molecules such as 
described earlier which would cause enhanced positives, therefore efficient 
blocking is necessary. The blocking protein should be smaller than the 
antigen molecule to achieve good blocking, it should not interact with the 
antibody or the subsequent development proteins, and it should have good 
handling properties with regard to solubility and storage. The small size of a 
blocking molecule suggested a peptide or range of peptides. A suitable 
candidate for the purpose was a protein hydrolysate Polypep, this was 
developed and used by cytochemists for the preparation of s l i d e s ' * 49 and is a 
protein digest that is commercially available. Polypep is sold in two forms as a 
high molecular weight fraction and a low molecular weight fraction, as 
determined by viscosity measurements. The low molecular weight fraction 
was considered ideal for the purpose since it contains a range of molecular 
weight species capable of filling any size adsorption space available. This is 
especially important in the latter part of this study when a competition assay is 
to be implemented. The good solubility and storage properties of polypep 
and the repeatable data observed when it was used, confirmed this to be a 
good choice. The possibility of polypep containing a hydralase enzyme which 
may cause protein hydrolysis under assay conditions was considered but this 
did not pose a problem as good repeatability of assays were observed; 
presumably these enzymes were retained in the high molecular weight 
fraction or efficiently removed.
Sodium azide was initially used as a preservative but this caused 
problems with the horseradish peroxidase enzyme used to develop the
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substrate colour reaction. Thimerosal (sodium ethylmercurithiosalicylate) was 
a preservative which was compatible with the horseradish peroxidase 
e n z y m e " *  30 system and this was adopted.
Figure 4
3 . R eaction between bound antigen and 
rabbit antibodies derived B S A -cpp  
conjugates.
i - 0 H >
R abbit anti-cpp  
antibody.
The rabbit antibody targeted at the respective cyclopenta[a]phenanthrene 
analogues described in chapter 2 was incubated at room temperature with the 
bound antigen at varying concentrations (either altering the antigen or 
antibody concentrations depending on the experiment) and after incubation 
the excess antibody washed off.
The enzyme conjugate antibody used in this study was initially derived 
from the goat (source, Sigma) and the later from a donkey (source, Guildhay 
sera). The enzyme of choice for both species of antibodies was the 
horseradish peroxidase.
Figure 5
4. Bound rabbit antibody complex witb the 
anti-rabbit horseradish peroxidase conjugate.
o
anti-rabbit
antibody
Horseradish 
peroxidase enzyme.
After incubation with anti-rabbit horseradish peroxidase conjugate at fixed 
concentration i.e. in excess of bound antigen complex; excess reagent was 
removed by a wash cycle. The bound complex as illustrated in 5. was finally 
treated with substrate buffer containing ortho-phenylenediamine in the 
presence of hydrogen peroxide at pH 5.2. When the reaction colour had 
achieved an optical density of between 1-2, it was stopped by the addition of
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2.5M sulphuric acid and the colour immediately read off using a titretech multi­
well plate reader at fixed wavelength of 492nm.
Results.
Some preliminary experiments comparing serum dilution for direct 
ELISA assay were carried out to establish the working range of the antigen 
and antibody concentrations. Serum 21b(15-S-linked) was tested at an initial 
serum dilution of 1part serum to 250 parts blocking buffer(dil 0.004) followed 
by a serial dilution of 1 in 5 per well, diluting the serum in the direction of wells 
A to H. An antigen concentration of 0.1 mg/mL protein was employed, a 
concentration which represented potential saturation of the plate surface with 
antigen. Both the BSA-15-S- and porcine thy-15-S-linked antigens were 
compared in duplicate with the respective carrier proteins. In addition 
duplicates with no antigen and with a second cyclopenta[a]phenanthrene 
conjugate derived from the BSA-17-N-antigen were investigated.
The plate arrangement was identical to the table 5. presentation (a feature 
common to all assay table presentations in this thesis), see methods section. 
A plot of mean optical density (y-axis) versus Serum dilution (logio x-axis) is 
shown in Graph 1.
Graph 1
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The plot clearly indicates that the serum recognises the hapten -15-8- 
cpp-17-one, since both the BSA and the porcine thyrogiobuiin conjugates 
gave strong comparative titre, showing a titration range from 10“3 to 10"® in 
both cases and exhibiting similar slopes over the linear range, whereas the 
thyrogiobuiin and the BSA show only a weak titres. The selectivity of the
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serum was indicated by the inclusion of a BSA-17-N-antigen. It is evident that 
although cross reaction does occur with this antigen it only represents 
approximately 50% of the titration range observed for the 15-S-derived 
antigen.
Graph 2 shows the titration profile where the antigen concentration is 
varied whilst maintaining a fixed serum concentration of 1part serum to 
25parts blocking buffer. At these high concentrations of antigen and serum 
both BSA hapten conjugate and the BSA carrier protein showed a higher titre 
than was observed for the porcine thyrogiobuiin hapten conjugate. 
Thyrogiobuiin carrier protein showed no observed titre; additionally a mixture 
of cpp-17-one and porcine thyrogiobuiin showed no reaction with the serum. 
This could be due to either the cpp-17-one being removed in the wash cycle or 
that the antibodies do not recognise cpp-17-one as a small molecule. We later 
demonstrate with the competition assay that the former is the case in this 
experiment. These results confirm the production of antibodies to the protein 
carrier BSA and indicate the need to affinity-purify the sera if mammalian 
blood is to be assayed.
Graph 2
Variation of antigen concentration at fixed serum concentration of 
1/25(buffer). Serum derived from BSA-15-S-antigen.
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Taken from raw data table 3, using mean data from table 4.
Mammalian serum albumins share a high level of amino acid sequence 
homology with each other (i.e. human serum albumins share an 84% amino
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acid sequence homology with BSA) and this will cause significant cross 
reaction with the non-purified polyclonal sera used as an assay probe. It is 
interesting to note that as serum dilution occurs see graph 1, BSA interactions 
become smaller indicating the antibodies to this target are of low avidity.
Having established the conditions necessary to achieve a direct ELISA 
assay and having shown that a useful serum was obtained for the BSA-15-S- 
antigen, using the described immunisation schedule it was necessary to 
address the following questions:-
a. How successful have the other synthetic antigens been in 
producing useful polyclonal antibodies to the target hapten?
b. How does the serum titre compare between different animals, 
where more than one animal has been used to raise polyclonal antibodies?
c. How does the antibody titre compare within a single animal for 
different boost inoculations?
In order to answer these questions a number of plates were arranged 
such that each measured the antibody titre in duplicate, following a serial 
dilution in the direction of A to H. The following plate arrangement was used to 
compare two test-bleeds from like sera raised independently in two animals. 
Where a single animal was used for sera production the same plate 
arrangement was used increasing the number of test-bleeds per plate to four:-
Figure 6
General plate arrangement for comparison of titre between sera.
Pre-bleed Pre-bleed
animal a Rax(B) Rax(Bn) Rbx(B) Rbx( Bn) animal b
r h  r h
1 2 3 4 5 6 7 8 9 10 11 12
A O O O O O O O O O o o O
O O O O O O O O o o o O
R represents the experiment number and defines the serum under test.
(a) and (b) are the code letters representing each of the two animals used for 
antibody production.
X. is the number of weeks after the primary injection that the bleed was
collected.
(B and Bn), represents the number of boost inoculations received by the 
animal.
Pre-bleed sera were included in all plates and used as an indicator of 
individual plate variance.
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For example:-
21a.9(2) represents serum 21 (BSA-15-S-antigen, derived) animal a. 
which was subjected to a primary injection followed by two(2) boost 
injections and a test bleed collected 9 weeks from the time the primary 
inoculation was administered.
Before discussing the results of this study it should be noted that the low mean 
optical density readings observed in graphs 3,7, and 9 (from 0 to 0.3) 
compared with graphs 4,5,6, and 8 (from 0 to 2.0), are due to a change in the 
direct assay procedure, this included the following modifications:-
1. The introduction of 0.1%polypep blocking buffer containing 
Tween 80, to replace 0.1% gelatine used in these earlier experiments.
2. Replacement of the goat anti-rabbit horseradish peroxidase 
enzyme conjugate (Sigma) to donkey anti-rabbit horseradish peroxidase 
enzyme conjugate (Guildhay sera) which was shown to be more sensitive and 
reliable.
3. Replacement of 0.01% sodium azide as blocking buffer 
preservative which in our hands gave reduced colour reaction, a result later 
confirmed by a literature s u r v e y ‘d 50; where it was established that sodium 
azide inhibits the horseradish peroxidase enzyme reaction. This preservative 
was replaced by the horseradish peroxidase compatible Thimerosal (0.01%). 
The change in preservative was the major influencing factor for improvement 
of the colour reactions later routinely observed.
Graphs 3 and 4 show a representative sample of the individual direct 
ELISA titrations observed for each of the animals studied, to show the relative 
titration between sera. The titres were compared at a fixed time after the 
primary inoculation i.e. week 25, boost inoculum 6. The full titration data 
recorded for all of the test- and pre-bleeds collected for each of the animals 
and serum studied are presented in tables 6,7,8,9,10. which includes data 
used for graphs 3 and 4.
From graph 3 which represent sera assays derived from the early assay 
protocols it is clear that for the BSA-15-S-antigen inoculated animals, animal
(b) shows an enhanced relative titre over animal (a) and the titre observed for 
the BSA-16 -0 -antigen was in comparison further reduced. Animals used for 
the generation of 3-0- and 11-O-linked sera, in graph 4 used the modified 
assay protocol. The difference between the two animals used for raising the 3- 
Olinked sera followed the same trend as observed for the inoculation of BSA- 
15-S-antigen, where animal (a) showed an enhanced titre over animal (b) 
The BSA-1 l-O-antigen on the other hand showed no essential difference in 
titration levels between the two rabbits immunised with this inoculant.
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Graph 3
A comparison of titre between serum21 (BSA-15-S-ant) rabbit (a), serum 21 (BSA-15-S-ant) 
rabbit (b), and serum 4 (BSA-16-0-ant) taken at week 25 boost inoculation (6) for all animals.
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A comparison of the titre between serum 9(BSA-17-N-ant),serum 22a/b (BSA-3-O-ant) 
and serum 23a/b (BSA-11-O-ant) taken at week 25 boost inoculation number 6.
 «   BSA-11-0-ant.23b.25(6)
-  “A “ ' BSA-11 -0-ant.23a.25(6)
2  ^ g j  — □ —  BSA-3-O-ant 22a.25(6)
§   ^ g J —0 “" BSA-3-0-ant.22b.25(6)
BSA-17-N -ant.9.25(6)(0
.è-
ITJ
I
C
s
I m i l l — I I I I I  n il— I I i i i i i i i I I I I I I  I  I I I I I I I I
10  "  10  10 
Sera dilution
The 17-N-antigen derived serum also gave a good titration range similar but 
slightly reduced over the 11- and 3-O-linked sera.
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The important linear regions of the titration curves for both protocols 
used vary in slope between individual animals and antigen type, but the 
titration range seems to be remarkably similar i.e. from approximately 10'2 to 
approximately 10"5. It is clear from this limited data that good antibody 
production has been achieved for each of the respective antigens.
In order to establish more accurately the useful available sera obtained 
from the immunisation schedules so far undertaken, it is necessary to compare 
and contrast the sera properties both between animals and individual bleeds. 
To achieve this an immunisation test bleed profile was plotted for each serum 
raised. This consisted of a plot of optical density as the measure of individual 
titre at a fixed serum dilution, against the time of serum collection ranging from 
pre-bleed through to final exsanguination.
11-O-linked sera Immunisation test bleed profile.
The serum dilution titrations of sera 23a and 23b illustrated in graph 4 
showed an identical profile for two test bleeds shown, indicating that the two 
animals involved in this immunisation schedule gave an almost identical 
response to the immunogen. A result which was largely borne out by the 
immunisation test bleed profile, see figure 5 .
Graph 5
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The relative similarity in the titre between both rabbits subjected to a parallel 
hyperimmunisation schedule, utilising the same antigen solutions, gave an 
almost identical response throughout the programme, with minor variations in 
relative titre observed in the early stages of the schedule. An increased 
titration from week zero to week 13 (3)was observed, after this period the titre 
of antibody reaches a maximum which remains at a constant level, whilst
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boost inoculation of antigen is maintained up to 25(6). These data indicate 
that the sera within test-bleed collection times 13(3) to 25(6) for both rabbits 
would be expected to behave similarly under assay conditions; as by this time 
in the schedule the animals antibody titre would be expected to have achieved 
a stable state equilibrium. The reduced titre activity observed for week 52 was 
due to the fact that these animals did not receive any boost inoculations 
beyond inoculum (6). The high level of activity observed for these rabbits after 
25 weeks was surprising, both animals gave antibody yields equivalent to 
week 5(1), suggesting that good retention of sera activity was expressed by 
the direct aromatic ring linked antigen.
Because of the possible carcinogenic activity of 11-O-linked cpp 
a n a l o g u e s ' ^ 2 4  and the repeated inoculations of this antigen within the 
immunisation schedule, it was necessary to establish whether tumours had 
been induced in these rabbits. Both animals were subjected to an autopsy by 
the ICRF veterinary surgeon and no tumours were observed, a result that was 
not necessarily predictable. Metabolic cleavage of the ether or degradation of 
the protein conjugate to generate the weakly carcinogenic 11-hydroxy-15,16- 
dihydrocyclopenta[a]phenanthren-17-one[41] may well have been a possible 
mechanism for tumour formation.
3-O-linked and 15-S-linked sera.
Graph 6 illustrates the immunisation profile of the BSA-3-0-antigen 
derived sera. As with the previously discussed BSA-11-O-antigen derived 
sera an increased antibody titration was observed from time 0 to week 13 after 
which time the level of antibody became relatively constant holding the 
maximum titration for the period of hyperimmunisation being maintained (i.e. 
repeated inoculation with antigen) a profile shared by the BSA-15-S-antigen 
derived sera illustrated by graph 7. In the later case maximum titration was 
achieved after week 5 indicating a more stringent response to the antigen 
inoculum; possibly enhanced by a possibly more immunogenic thioether 
linkage, or an effect of substituent presentation. The individual test-bleeds 
from 13(3) to 37(10) were essentially the same and usable for routine assay 
purposes. Test-bleeds 5a(1), 9a/b(2) showed significantly enhanced titres 
compared with the test-bleeds 13(3) and later samples and it was therefore 
considered that these sera should not be included in the general routine assay 
with out further characterisation.
The rabbits inoculated with BSA-3-O-antigen were left from week 25 to 
week 52 with out further antigen boost inoculations; the relative antibody titre
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for both rabbits after week 52 was high, especially in the case of rabbit (a) 
which maintained a titration level equivalent to the maximum titre observed for 
rabbit (b), and the rabbit (b) titration level was only reduced by half over this 
period. Presumably antigen was reversibiy adsorbed onto cellular tissues 
which may have been slowly releasing it into the blood stream, maintaining a 
reduced hyperimmune state long after active inoculation of antigen had 
ceased, an effect observed for the two independent antigens BSA-11-O- 
antigen, BSA-3-O-antigen both linked directly through the aromatic ring 
system.
The titre between animals from both the 3-O-linked and the 15-S-linked 
sera follow the same trend throughout the schedule but each animal exhibited 
significantly different titres per-bleed unlike the 11-O-linked sera which have 
been described. In the case of the 3-O-linked sera a high pre-bleed titre was 
observed when bovine thy-3-O-cpp-17-one bound antigen was used in the 
assay. This titre was specific for animal (a), as rabbit (b) showed normal 
background levels. Graph 6 does not show this effect since the plate exhibiting 
the lowest background pre-bleed was chosen as the start point. Additionally 
for both groups of sera these differences may also be a function of variations in 
the rate of catabolism of the primary inoculum and possibly the initial boost 
injection since all other boost inoculations show an almost parallel 
relationship.
17-N-linked sera.
Only a single rabbit was used for production of sera to this antigen and 
the general trend in serum titration levels has been followed by this antigen 
generating what appears to be reliable sera from 17(4) to bleed out. An 
enhanced titre was observed at 9(2) and small reduction in titre was observed 
until 25(6) after which (with the exception of 29(7) which shows an increased 
titre) the titres remain fairly constant.
The sera so far studied have followed the general trend; an increased 
titration occurs up to the third boost inoculation after which the antibody titre 
remains fairly constant.
There is one exception to this trend, the profile observed for serum 
4(16-0-linked); the first three inocula failed to produce a significant titre, but 
the fourth inoculum generated a major response which gradually improved 
throughout the schedule. A possible explanation for this behaviour may be 
due to the cycIopenta[a]phenanthrene linkage to the carrier protein BSA used 
for antibody production. This linkage was a hemisuccinate ester, which may 
be prone to enzymatic hydrolysis under physiological conditions by
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esterases'! 51. After repeated injection the level of esterases may be reduced 
by effectively saturating the lymphatic system with BSA-cpp conjugate 
allowing sufficient antigen to remain for the production and maintenance of 
antibodies.
All cyclopenta[a]phenanthrene-BSA conjugates used for the production 
of sera proved to be successful. This result is in part due to the delivery of 
good quality antigens to well-established animal facilities, available at the 
ICRF animal unit, but also to the important contribution made by the animal 
technicians involved in sera production.
The direct Elisa assay has identified the useful sera for potential 
competition assay system under development and a list of these are included 
in table 1, below:-
Table 1
Code conjugate derived from Test-bleed range
4 BSA-16-O-cpp-17-one 17(4) to 37(10)
9 BSA-17-oxime-cpp 17(4) to 37(10)
21a BSA-15-S-cpp-17-one 13(3) to 37(10)
21b BSA-15-S-cpp-l 7-one 13(3) to 37(10)
22a BSA-3-O-ether-cpp-l 7-one 13(3) to 25(6)
22b BSA-3-Oether-cpp-17-one 13(3) to 25(6)
23a BSA-11-Oethercpp-17-one 13(3) to 25(6)
23b BSA-11 -O-ethercpp-17-one 13(3) to 25(6)
These sera lie on the flat portion of the test-bleed time profile, exhibiting similar 
antibody titres and it may be assumed they would show similar behaviour in 
any assay protocol. But each serum would be independently tested prior to 
use in any assay differing from that described in this chapter. The Elisa assay
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has also highlighted other important aspects such as the need to affinity-purify 
the sera in order to remove interfering cross reactions caused by 
immunoglobulins targeted at the BSA carrier protein.
Affinity purification.
Affinity purification of sera was considered a necessary step to remove 
interfering cross reactions caused by the presence of rabbit immunoglobulins 
not targeted at the hapten site of the synthetic antigen, and also other non­
specific interactions previously described.
Two approaches were considered:-
a. Using as the affinity column substrate a protein conjugate containing 
the required hapten, but derived from an alternative protein carrier.
b. Using as the affinity substrate BSA, the protein carrier used in the 
production of sera in rabbits.
Method (a) involves selectively removing the antibodies defined by the 
cyclopenta[a]phenanthrene hapten region used in antibody production, 
whereas method (b) selectively takes out the antibodies targeted at the protein 
carrier. The advantage of method (b) over (a) is that a single column is 
required to purify all of the sera and because the useful antibodies are not 
bound to the column support; problems encountered by both denaturing the 
antibodies to regenerate them and loss of tightly bound antigen-antibody 
complexes are obviated. The disadvantages of the latter approach are that the 
unwanted material is eluted with the required target antibodies. This may 
include rabbit antibodies which cross react with similar species antigens in 
other mammals causing false positives. Also when a hapten protein conjugate 
is prepared the modification procedure and the hapten itself causes localised 
areas of dénaturation within the carrier protein, exposing antigenic sites not 
present in the native protein. Approach (b) may therefore result in partial 
removal of the interfering rabbit immunoglobulins only. Both methods were 
investigated, but it was decided that method (a) was the most reliable under 
assay conditions necessary for probing biofluids in mammals.
All of the sera were subjected to affinity chromatography following 
method (a) except the 16-0-hemisuccinate serum which was considered to be 
acid labile i.e. readily undergoes acid hydrolysis. As the affinity column 
procedure required separation of the antibody from the bound antigen after 
complex formation using an acid dénaturation step it was not considered this 
procedure was practical for the hemisuccinate linkage.
The affinity purification method of choice involved using glutaraldehyde 
activated controlled-pore glass as the support matrix. The antigen was 
covalently bound to this support by suspending the activated glass matrix in a
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buffered solution containing the protein conjugate; uptake by the solid support 
of the protein conjugate was measured by U.V.spectroscopic scanning of the 
solution (see figure 9, page 105). When it was judged that the reaction had 
gone to completion the modified conjugate was filtered off and blocked with
0.1% polypep following this same procedure. The columns were washed with 
phosphate buffer, serum applied, and the non-bound material eluted with 
phosphate buffer, monitoring progress by passage through a U.V.flow 
cell(filter 254nm). When all unbound protein had been removed the column 
was washed with 0.1 M aqueous propionic acid and the denatured antibodies 
eluted off the column. Their pH was adjusted immediately to 9.0 with saturated 
sodium bicarbonate and the affinity-purified antigen was dialysed into the 
storage buffer. Figure 7, shows a typical affinity separation profile.
0.1 M CH3CH2COOH
1.0 M CH3CH2COOH
Figure 7
Typical affinity column elution profile,
Elution profile of serum 9(17-N) through the affinity column F1 ,F2  non bound fractions, F3 
eluted with 0.1 M propionic acid, F4,F5 eluted with 1M propionic acid.
The sera were analysed using the direct ELISA procedure, to establish 
which fractions contained the target antigen IgG activity. A typical antibody 
titration profile is presented for the affinity-purified serum 9 (17-N-linked) in 
graph 10 and compares the titre for each serum fraction with the non-purified 
serum. For experimental details see tables 11 and 12, methods section.
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The non-specific binding observed for concentrations between 1.0 to 
5x 10"3 in the non-purified serum were reduced in the affinity purification 
fractions 3, 4 and 5 which contain the antibody activity. ELISA assay of the 
dialysate, F3 (eluted with 0.1M propionic acid), gave the highest antibody titre 
but comparison of this with the non-purified serum shows a marked reduction 
in activity. This reduction in antibody activity may have been caused by either 
irreversible immunoglobulin dénaturation under acid wash, or the high affinity 
antibody complexes bound to the column surface may not have been removed 
by the acid treatment. This latter effect has been observed for some steroid 
antibody complexes. Fractions 4 and 5 were eluted with 1M propionic acid 
and were later combined; these showed antibody activity but significantly 
lower than fraction 3.
Both the BSA-11-Oantigen derived antibodies and the BSA-15-S- 
antigen derived antibodies were subjected to the same affinity purification 
procedure as described for the 17-N-Iinked affinity-purified serum. Column 
elution profiles and ELISA data for the respective fractions are included :-
1. BSA-15-S-serum elution profile figure 8 page 103, ELISA data 
table 14 page 103 and graph 11 page 104
2. BSA-11-Oserum elution profile figure 10 page 105, Elisa data 
table 16 page 107, graph 12 page 107.
Both curves essentially follow the profile discussed for the serum 9 (17-N- 
linked serum).
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The BSA-11-Oserum fractions F2 eluted with 0.1M propionic acid and F3 
eluted with 1.0M propionic acid were analysed further by running a full scan 
U.V. spectrum. Fraction (F2) gave the expected spectrum of 284nm (see figure 
11) of a protein, whereas fraction F3 yeilded a Xmax of 265nm (see figure 12 ) 
typical for a cyclopenta[a]phenanthrene; suggesting this fraction was a mixture 
of antibody as implied by the high titre, including possibly antibody complex, 
protein conjugate. This mixture of products resulting from the strong acid 
treatment are unacceptable as they may cause false positives, and require 
further purification if they are to be used for assay studies.
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Methods
The animal studies were carried out at the I.C.R.F. animal unit in South 
Mimms under the supervision of a veterinary surgeon; the animal maintenance
i.e. injections, bleedings, and exsanguination were carried out by qualified 
animal technicians under our instruction.
A. Preparation of Complete Freunds Adjuvant.(CFA)
The protein conjugate in saline phosphate buffer was mixed with 
heat killed Mycobacterium tuberculosis by vortexing for emulsion preparation. 
Two syringes were half filled, syringe (a) with the above antigen bacteria 
solution and syringe ( b) with Freunds mineral oil mixture(Sigma). The two 
were connected to each other via a luer fitting and the syringe containing the 
antigen was depressed until the water oil mixture were contained in a single 
syringe (b). The oily liquid was transferred back to syringe a by compression 
of the plunger and the process of repeated, mixing in this way until significant 
resistance was observed due to the high viscosity of the emulsion formed. The 
efficacy of the emulsion was tested by removing a drop and adding it to a 
saline phosphate solution; if the oil does not disperse immediately, but 
remains intact it is ready for injection into the rabbit. The rabbit was inoculated 
with a glass syringe using a 19-gauge needle.
B. Preparation of Incomplete Freunds adjuvant.(IFA).
Prepared and delivered in the same way as the above excluding the 
Mycobacterium tuberculosis. This was used for all boost inoculations. 
Subcutaneous injection.
The docile behaviour of the Sandy half-lop rabbit made it unnecessary 
to sedate the animal. It was held firmly by one technician and, starting on one 
side of the back of the neck, skin was pinched between the thumb, forefinger 
and pulled gently away from the body. A needle(19 gauge) was inserted into 
the dermus and waggled from side to side to ensure that the needle was not 
inserted into the muscle. When the needle was arranged correctly the syringe 
plunger was compressed until the correct volume of antigen had been 
delivered (lOOpL per site). The needle was withdrawn and the area gently 
massaged with the gloved forefinger to prevent the inoculum from escaping. 
This process was repeated over 10 different sites on the dorsal region. 
Primary injection delivered a total of Img of antigen dissolved in Im L of 
complete Freunds adjuvant. The boost inoculations delivered 0.5mg of 
antigen in ImL of incomplete Freunds adjuvant.
Collection of bleeds from the marginal ear vein.
The rabbit was placed on a rough surface (smooth surfaces cause the 
rabbit to panic) and its movements were restricted by wrapping with a towel
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and holding firmly but gently. The marginal ear vein was located on the inner 
edge of the ear ( a light shining through the ear aids location if the vein was 
not prominent). A 19-gauge needle was inserted into the vein taking care not 
to hurt the rabbit unnecessarily; blood was collected, 20-30mLs per bleed, 
after which the needle was removed and the ear compressed with a sterile 
gauze held between the forefinger and thumb to stop the flow.
The blood was allowed to clot at 37°C  for 1 hour, a sterile Pasteur 
pipette was inserted into the clotted mixture and rapidly rotated around the 
edge of the tube to separate the clot from the tube walls. The mixture was 
cooled at 4°C  overnight and the serum collected by centrifugation at 10,000g 
for 10 minutes at the same temperature. The serum was stored at -2Q0C 
indefinitely.
Table 2. Immunisation Schedule[1].
Represents an example of the immunisation schedule using the production of serum 4(16-0-linked) and
Week Procedure employed Animals defined by 
serum.
1 Pre-bleed 20mL collected serum 4(16-0-)
Pre-bleed 20mL collected serum 9(17-N-)
Primary iniection in CFA.SC m/s serum 4
Primary iniection in CFA.SC m/s serum 9
1 mg/ml conjugate used for both sera ImL 
iniection volume
4 Boost injection 0.5mL (0.5mg antigen) in 
IFA.SCm/s all other boost inoculations are a 
repeat procedure.
serum 4 and 9
5 test-bleed 30mL collected serum 4 and 9
8, 12, 16, 20,24, 28 Boost iniection serum 4 and 9
9, 13, 17, 21,25, 29 test-bleed 30mL collected serum 4 and 9
32 Boost iniection serum 4 and 9
33 test-bleed serum 4 and 9
34 Boosted with 10% normal antigen dose serum 4 and 9
35 Boosted with 50% normal antigen dose serum 4 and 9
36 Boosted with normal antigen dose serum 4 and 9
37 The rabbits were terminally anaesthetised and exsanguinated 
(bleed out)
From weeks 34 to 36 a boost inoculation was carried out at weekly intervals 
gradually increasing the antigen from 10,50,100% normal antigen levels 1
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week prior to exsanguination. The aim of this procedure was to maximise the 
antibody levels in the blood at the time of the final blood collection. 
Immunisation schedule [2]
Two rabbits were used to raise serum against the BSA-15-S-antigen. 
The schedule was identical to that described for the 16-0-linked and 17-N- 
linked program, with the exception that the weekly boost inoculations for 
weeks 34,35,36 prior to exsanguination were not included.
Immunisation schedule [3]
Two sera were included in this programme; two rabbits were used for 
each serum. These were BSA-3-O-antigen coded 22a/b and BSA-11-0- 
antigen coded 23a/b. Schedule 3 followed the same regime as schedule 1 
except that after 25 weeks boost (6) treatment was suspended and the animals 
were exanguinated at week 52 with out further boost inoculations.
Comment on the immunisation schedules.
The relative titres per animal of the bleed out sera, compared with sera 
at the hight of the hyperimmunisation steady state were high for both 
schedules 1 and 2. These titres (see graphs 7,8 and 9) were sufficiently 
similar to suggest that the weekly boost inoculations prior to exsanguination 
(employed in schedule[2]) and discomfort to the animal they caused were 
unnecessary. As expected schedule 3 yielded a reduced titre as already 
discussed.
Direct Elisa assay.
Plates were Nunclon Delta 96 well plates with a lid, flat bottomed for 
accurate optical density readings.
Buffers and solutions.
1. Saline Phosphate.
Sodium chloride(8g), potassium chloride(0.2g), potassium dihydrogen 
o/t/7O-phosphate(0.2g), disodium hydrogen orf/?o-phosphate(2.9g) made up to 
1 litre with water.
2. Gelatine blocking buffer (requires fresh preparations for each assay).
Gelatine (O.lg), Tween 20 (polyoxyethylene-sorbitan monolaurate O.lg) 
[Sigma]; both were dissolved in saline phosphate( [buffer 1] lOOmL) with 
warming.
3. Polypep (blocking buffer) a ten times stock solution was prepared:-
Polypep(1%,low viscosity grade from Sigma) and Tween 80(1%),
0.1%Thimerasol (mercury-[(0-carboxyphenyl)-thio]ethyl sodium salt;Sigma ). 
The mixture was dissolved in saline phosphate with rapid stirring over a water 
bath at 50°C, the homogeneous solution was allowed to cool and made up to
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final volume with water. This buffer was diluted ten times with saline 
phosphate( buffer 1 ) for use in the assay.
4. Horseradish peroxidase substrate buffer.
Disodium hydrogen orf/70-phosphate(anhydrous,7.1g), citric acid 
(5.22g), diluted to 1 litre with water giving a final pH S.2-5.3.
5. Substrate.
A fresh preparation of the substrate was used for each assay. Ortho- 
phenylenediamine hydrochloride (10mg, care this compound is carcinogenic) 
was dissolved in 25mL of citrate buffer (4) and 25mL of hydrogen 
peroxide(60%, 10Ov/v) was added immediately before adding to the plate. 
This recipe represents sufficient substrate for a single plate at 200pL per well 
with 96-wells.
6. Stop reaction reagent.
Concentrated sulphuric acid (33mL) was dissolved cautiously in 
96.7mL of distilled water.
Antigen binding to the walls of the Elisa plate.
Antigen was dissolved in saline phosphate(l) at concentrations ranging 
from 1-10 ng protein per mL. Aliquots (250|iL) were added to each well using 
a multichannel micropipette(12-channel Titertek 50-250|liL volume range) and 
the plates were covered and left at room temperature for Ihour or overnight at 
400.
Wash cycle.
Using a Titretek plate washer each plate was subjected to the following 
wash procedure:-
The wells are sucked dry, saline phosphate 300pL per well was 
delivered under a pressure stream and this was again sucked dry. The 
process was repeated three times, the plate was removed from the plate 
washer tipped upside down and shaken with a rapid wrist movement to 
remove any residual buffer.
Blocking step.
Blocking buffer(250|iL,[2] or [3] ) was added to each well, coated with 
antigen and the plate covered and stored in a humidity box for a minimum of 1 
hour, after which time the plate was subjected to a repeat wash cycle.
Rabbit antibody incubation.
A fixed volume of serum was diluted with blocking buffer [3] to the 
required dilution. This solution can be either added to the plate wells at fixed 
dilution or subjected to a serial dilution procedure.
Serial Dilution.
As an example;
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1 part in Sparts dilution per well is described.
To all wells A(1 to12) was added reagent (serum, analyte in the 
competition assay etc.) 250pLper well. To all wells B( 1to 12) to H(1to12) was 
added 200|iL of blocking buffer (solution[3]). Aliquots of SOpL of samples from 
all wells A(1 to 12) were removed via a 12 channel pipette and added to all 
wells B(1 to 12) and thoroughly mixed by repeated withdrawal and pumping 
action of the pipette within the wells. After mixing a further aliquot of (50p,L) 
sample from wells B(1 to 12) was removed and added to wells C(1 to 12) and 
the process repeated until wells H (1 to 12) when after mixing a SOpL aliquot 
was removed and disposed of to maintain constant volume through out the 
wells.
The required antibody dilutions were left for Ihour at room temperature and 
excess un reacted serum removed by a standard wash cycle.
Species anti-rabbit horseradish peroxidase enzyme conjugate.
a. Goat anti-rabbit conjugate(Sigma) suggested dilution 1:1000, 
actual dilution used 1: 500.
b. Donkey anti-rabbit conjugate(Guildhay sera) suggested dilution 
1:30,000, actual dilution used 1: 10,000.
The antibody conjugate of choice was dissolved in blocking buffer solution [3] 
at the required dilution and 200pL added to all wells in the Elisa plate and left 
for Ihour at room temperature and washed off in the usual way.
Developing the colour.
Freshly prepared substrate buffer (5, 200pL) per well was added and a 
yellow colour immediately developed. When this colour gave an approximate 
optical density of 1.0,O.D unit as judged by eye 5 0 |liL  of stop solution [6] was 
added after which an immediate optical density reading was measured using 
a Titertek plate reader with a filter at 492nm.
As the ortho- phenylenediamine is considered to be carcinogenic all of 
the disposables used were subjected to oxidation. They were immersed in 
10% sodium hypochlorite containing a trace of indicator potassium 
permanganate oxidising agent (when the solution turns from red to brown the 
oxidising properties are exhausted) overnight and washed with water prior to 
disposal via the usual channels.
Presentation of data.
Using as an example the experimental data presented in graph 2 where 
a plot of mean optical density versus protein conjugate dilution in pg per mL. 
The optical density readings were printed out in the format of the plate 
arrangement (see raw data Table 3 page 93 ). As the data represents 
individual readings and they are grouped as duplicate runs of the same
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sample, the mean optical density was calculated for each dilution within the 
group and this mean data was presented in the same format as the plate 
arrangement and includes in this case the protein serial dilution 
concentrations, see table 4
Table 3 , Raw data from a titretek plate reader used in graph 2.
Data represents variation of antigen concentration at fixed serum concentration of 1/25(buffer). 
Serum derived from BSA-15-S-antigen [21(5)]
W = well number
w 1 2 3 4 5 6 7 8 9 10 11 12
A 0.359 0.367 0.405 0.397 0.619 0.607 0.457 0.428 0.645 0.630 0.646 0.657
B 0.361 0.348 0.346 0.356 0.593 0.600 0.368 0.372 0.629 0.633 0.637 0.675
C 0.346 0.322 0.356 0.356 0.565 0.536 0.377 0.375 0.542 0.576 0.624 0.670
D 0.361 0.364 0.374 0.374 0.479 0.459 0.367 0.386 0.553 0.558 0.626 0.650
E 0.387 0.384 0.392 0.404 0.444 0.425 0.429 0.407 0.405 0.410 0.531 0.510
F 0.376 0.372 0.376 0.387 0.422 0.415 0.399 0.376 0.380 0.394 0.462 0.474
G 0.372 0.372 0.394 0.373 0.382 0.386 0.411 0.364 0.378 0.395 0.406 0.411
H 0.669 0.370 0.728 0.380 0.372 0.544 0.376 0.367 0.372 0.376 0.384 0.395
Wells 1,2 no antigen., Wells3,4 Thyroglobulin(Porcine)., Wells 5,6 Thy-15-S-antigen., Wells 7,8 
Thyroglobulin + cpp-17-one non covalently bound mixture only.. Wells 9,10 BSA., Wells 11,12 BSA-15-S- 
antigen.
Table 4 used in graph 2.
No
antigen
Thyroglobulin Thy-15-S-ant Thy +Cpp BSA BSA-15-S-ant Protein dil in 
mg/mL
0.363 0.401 0.613 0.443 0.638 0.652 0.1
0.354 0.351 0.597 0.370 0.631 0.656 2x10-2
0.334 0.356 0.550 0.376 0.559 0.647 4x10-3
0.363 0.374 0.469 0.376 0.555 0.638 8x10-4
0.386 0.398 0.435 0.418 0.408 0.520 1.6x10-4
0.374 0.382 0.419 0.388 0.387 0.468 3.2x10-5
0.372 0.384 0.384 0.388 0.387 0.409 6x10-6
0.520 0.554 0.458 0.372 0.374 0.390 1x10-6
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The presentation of the statistically modified data in the format of a table, with 
the plate arrangement used in the experiment, is the standard method of 
presentation through out this thesis for all Elisa data.
Table 5 mean data used for graph 1 
BSA-15-S-antigen derived serum titration showing serial dilution of serum with fixed antigen 
concentration of 0.1mg/mL(plate well saturation).
No
antigen
Thyroglobulin BSA-15-S- 
antigen
BSA-17-N- 
antigen
Thy-15-S- 
antigen
BSA Sera21b.21(5)
dilution
0.068 0.392 0.823 0.430 0.844 0.271 4x10-3
0.047 0.147 0.745 0.305 0.790 0.116 8x10-3
0.072 0.086 0.667 0.198 0.718 0.072 1.6x10-4
0.045 0.077 0.449 0.089 0.516 0.048 3.2x10-5
0.067 0.072 0.194 0.054 0.228 0.045 6.4x10-6
0.049 0.070 0.100 0.048 0.114 0.038 1.28x10-6
0.046 0.063 0.085 0.044 0.092 0.038 2.56x10-7
0.044 0.064 0.076 0.048 0.079 0.045 5.0x10-8
The next group of tables represent the total titrations observed for all of 
the sera generated and were obtained following the procedure outlined in the 
discussion.
Pre-bleed Pre-bleed
animal a 
1
Rax(B) Rax(Bn) Rbx(B) Rbx( Bn) animal b 1
11
1
2
1 1
3 4
1
5
1
6
1
7
' 1
8
1
9
' 1 
10 11
1
12
A O O O  O O O O O O O O O
O O O  O O O O O O o O O
Plate arrangement discussed in textQ, which is illustrated by the table format. 
The emboldened data within each table represents the fixed titration values 
used to plot the immunisation profiles illustrated in graphs 5-9.
11-O-linked sera (derived from the BSA-11-O-antigen)
Two rabbits were used in this study, antigen used at fixed concentration 
of lOpg /  mL and was the porcine thy-11-O-antigen. Polypep blocking buffer 
and donkey anti rabbit enzyme conjugate. The emboldened data was used to 
plot the immunisation profile titled “Immunisation test bleed profile of sera 
23a/b (11-O-linked) at fixed sera dilution of 8x10-5." i.e. graph 5. The rest of 
table 6 represents the titrations observed for each rabbit a. and b. at the 
respective immunisation time point (complete set of bleeds obtained from the
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immunisation schedules) and graph 4 uses the time points 23a.25(6), 
23b.25(6) as the representation.
Table 6
Plate 1
Pre-bleed a. 23a.5(1) 23a.9(2) 23b.9(2) 23b.5(1) Pre-bleed b.
0.224 0.735 1.402 1.322 1.077 0.320
0.221 0.410 1.152 1.034 0.815 0.266
0 . 1 0 5 0 . 1 6 7 0 . 7 5 2 0 . 6 1 5 0 . 4 2 5 0 . 1 1 1
0.068 0.083 0.323 0.260 0.155 0.068
0.058 0.063 0.126 0.107 0.078 0.059
0.057 0.058 0.074 0.068 0.060 0.057
0.055 0.058 0.061 0.072 0.054 0.055
0.061 0.057 0.058 0.078 0.051 0.053
Plate 2
Pre-bleed a. 23a.13(3) 23a17(4) 23b. 17(4) 23b.13(3) Pre-bleed b.
0.238 1.565 1.567 1.491 1.419 0.312
0.225 1.384 1.417 1.426 1.358 0.255
0.110 1 . 0 2 4 0 . 9 6 8 1.061 1 . 0 6 4 0.109
0.068 0.514 0.472 0.556 0.525 0.070
0.061 0.193 0.161 0.201 0.207 0.062
0.059 0.090 0.082 0.094 0.093 0.057
0.057 0.061 0.060 0.064 0.062 0.054
0.059 0.057 0.057 0.058 0.054 0.055
Plate 3
Pre-bleed a. 23a.21(5) 23a.25(6) 23b.25(6) 23b.21(5) Pre-bleed b.
0.254 1.708 1.746 1.757 1.757 0.345
0.237 1.563 1.478 1.511 1.650 0.270
0.102 1.121 1.001 1 . 0 1 7 1 . 2 8 7 0.109
0.067 0.547 0.456 0.457 0.681 0.068
0.061 0.198 0.165 0.159 0.257 0.058
0.059 0.092 0.089 0.077 0.104 0.054
0.054 0.064 0.061 0.059 0.062 0.051
0.059 0.058 0.058 0.054 0.053 0.051
Plate 4
Pre-bleed a. 23a.52(6) 23b.52(6) Pre-bleed b. sera dilution
0.236 1.351 1.397 0.306 2x10-3
0.203 0.881 1.007 0.255 4x10-4
0.099 0 . 3 8 8 0 . 4 9 0 0.107 8x 1 0 - 5
0.067 0.144 0.193 0.070 1.6x10-5
0.061 0.077 0.089 0.060 3.2x10-5
0.057 0.064 0.062 0.058 6.4x10-7
0.059 0.062 0.058 0.054 1.28x10-7
0.060 0.060 0.054 0.056 2.6x10-3
utilising the optical density measurements represented in this table.
3-O-linked sera (derived from BSA-3-O-antlgen).
Two rabbits were used in this study, the antigen was bovine thy-3-Oantigen at 
fixed concentration of lO^g /  mL, Polypep blocking buffer with donkey anti­
rabbit enzyme conjugate (1/20,000) was applied. The sera studied was the
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complete set of bleeds derived from BSA-3-Oantigen each with a starting 
1/500 (20|iL in lOmL buffer), 250|iL aliquot added to all wells A, 1 in 5 serial 
dilution from A to H.
Table 7
Plate 1
Pre-bleed
22a.
22a.5(1) 22a.13(3) 22b.13(3) 22b.5(1) Pre-
bleed22.b
Serial
dilution
0.616 1.286 1.684 1.520 1.415 0.302 2x10-3
0.466 1.219 1.688 1.269 1.171 0.402 4x10-4
0 . 1 8 8 0 . 7 4 0 1 . 3 7 2 0 . 7 4 0 0 . 6 8 7 0 . 1 7 6 8 x1 0 - 5
0.090 0.301 0.772 0.309 0.274 0.085 1.6x10-5
0.067 0.122 0.287 0.136 0.114 0.063 3.2x10-5
0.067 0.080 0.121 0.081 0.069 0.059 6.4x10-7
0.062 0.063 0.074 0.066 0.056 0.054 1.28x10-7
0.069 0.059 0.067 0.058 0.054 0.052 2.56x10-8
Plate 2
22a. 17(4) 22a.21(5) 22b.21(5) 22b.17(4)
1.427 1.705 1.711 1.655 1.683 0.411 2x10-3
0.882 1.751 1.702 1.446 1.407 0.318 4x10-4
0.382 1 .381 1.222 0 . 9 0 5 0 . 8 1 3 0.151 8x10-5
0.168 0.811 0.065 0.447 0.346 0.089 1.6x10-5
0.101 0.341 0.278 0.176 0.145 0.071 3.2x10-5
0.076 0.143 0.145 0.102 0.087 0.071 6.4x10-7
0.083 0.091 0.088 0.074 0.070 0.066 1.28x10-7
0.085 0.086 0.074 0.073 0.065 0.066 2.56x10-3
Plate 3
22a.25(6) 22a.52(6) 
Bleed out
22b.52(6) 
Bleed out
22b.25(6) Time In 
weeks
1.466 1.714 1.584 1.407 1.610 0.461 0
1.082 1.685 1.438 1.012 1.472 0.355 5
0.443 1 . 3 0 8 0 . 9 0 4 0 . 4 9 4 1.022 0.158 1 3
0.165 0.689 0.343 0.186 0.457 0.084 1 7
0.092 0.277 0.143 0.095 0.175 0.065 2 1
0.079 0.122 0.084 0.071 0.090 0.062 2 5
0.076 0.085 0.070 0.067 0.065 0.058 5 2
0.077 0.079 0.070 0.061 0.058 0.066
Dilution range in plate 3 is the same as platel and 2, this data was replaced by the time in weeks used in 
the plot for graph 6.
The emboldened data represent the data used to derive the immunisation test 
bleed profile of all sera 22a/b at fixed sera dilution Of 8x10"^ versus time in 
weeks , see graph 6.
15-S-linked sera ( derived from BSA-15-S-antigen)
Table 8
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Plate 1
Pre-bleed a a5(1) a9(2) b5(1) b9(2) _ Pre-bleed Sera Dilution
0.079 0.182 0.228 0.196 0.171 0.075 1.0
0.062 0.232 0.273 0.224 0.244 0.062 2x10-1
0.058 0.258 0.345 0.294 0.300 0.060 4x10-2
0.056 0.189 0.281 0.297 0.276 0.054 8x10-3
0 .053 0 .108 0 .213 0 .248 0 .247 0 .056 1.6x10-3
0.052 0.072 0.124 0.171 0.161 0.052 3.2x10-4
0.050 0.054 0.067 0.093 0.114 0.052 6.4x10-5
0.049 0.051 0.052 0.062 0.085 0.054 1.2x10-5
Plate 2
Pre-bleed a a13(3) a17(4) b13(3) b17(4) Pre-bleed b Timefweeks)
0.060 0.100 0.124 0.099 0.151 0.062 1
0.058 0.174 0.183 0.160 0.152 0.055 5
0.051 0.209 0.207 0.201 0.228 0.052 9
0.054 0.189 0.178 0.215 0.216 0.051 1 3
0.054 0 .129 0 .132 0.201 0 .184 0.050 1 7
0.051 0.093 0.104 0.145 0.134 0.050 21
0.049 0.057 0.066 0.107 0.077 0.050 25
0.050 0.052 0.057 0.081 0.064 0.051 29
Plate 3 33
Pre-bleed a a21(5) a25(6) b21(5) b25(6) Pre-bleed b
0.072 0.128 0.154 0.164 0.172 0.069
0.066 0.203 0.223 0.203 0.188 0.063
0.061 0.250 0.234 0.260 0.254 0.058
0.054 0.183 0.198 0.242 0.250 0.055
0.053 0 .144 0 .142 0.221 0 .219 0.056
0.053 0.107 0.103 0.180 0.150 0.054
0.048 0.068 0.081 0.126 0.105 0.055
0.053 0.060 0.068 0.087 0.079 0.053
Plate 4
Pre-bleed a a29(7) a33(10) b29(7) b33(10) Pre-bleed b
0.068 0.199 0.133 0.180 0.185 0.066
0.065 0.203 0.215 0.204 0.221 0.061
0.057 0.211 0.217 0.230 0.233 0.054
0.054 0.185 0.191 0.247 0.237 0.053
0.051 0 .138 0 .128 0 .203 0 .172 0.051
0.055 0.094 0.089 0.138 0.108 0.053
0.051 0.070 0.062 0.096 0.063 0.049
0.049 0.057 0.054 0.070 0.055 0.049
Serial dilution constant for all plates
Two animals were used in this study the antigen was porcine thy-15-S-antigen 
at a fixed concentration of lOpg /  mL was the blocking buffer and goat anti­
rabbit enzyme conjugate was used to develop the colour reaction. The 
emboldened data represent the data used to derive the immunisation test 
bleed profile of all sera 21a/b at fixed sera dilution Of 1.6x10-3 versus time in 
weeks, see graph?.
9 8
16-0-linked sera(derived from BSA-16-0-antigen).
Only a single animal was used in this study, the antigen used was 
chicken ovalbumin-16-O-conjugate at a fixed concentration of lO p g /m L , 
gelatine blocking buffer was used with goat anti-rabbit enzyme conjugate. The 
emboldened data represents the immunisation test-bleed profile of sera 4 at 
fixed sera dilution of 8x1 with time presented in graph 9. Data used for 
graph 3 are the titres for week 25( boost 6).
Table 9
Platel
Pre-bleed a a5(1) 89(2) a13(3) a17(4) a21(5) serial
dilution
0.064 0.176 0.172 0.143 0.160 0.127 1
0.054 0.153 0.148 0.151 0.149 0.136 0.2
0.049 0.087 0.109 0.099 0.157 0.150 4x10-2
0 . 0 4 8 0 . 0 5 7 0 . 0 6 7 0 . 0 5 0 0 . 1 2 5 0 . 1 3 9 8 x1 0 - 3
0.048 0.048 0.053 0.047 0.094 0.108 1.6x10-3
0.047 0.048 0.048 0.047 0.059 0.076 3.2x10-4
0.049 0.048 0.048 0.047 0.049 0.057 6.4x10-3
0.049 0.049 0.049 0.047 0.049 0.053 1.28x10-3
Plate 2
Pre-bleed a a21(5) a25(6) 827(7) a29(8) Bleed out a Time in 
w eeks
0.076 0.199 0.206 0.213 0.190 0.197 0
0.060 0.168 0.200 0.233 0.203 0.205 5
0.054 0.152 0.191 0.181 0.179 0.189 9
0.049 0 . 1 3 8 0 . 1 5 3 0 . 1 3 3 0 . 1 5 3 0 . 1 6 3 1 3
0.049 0.112 0.116 0.091 0.108 0.147 1 7
0.050 0.076 0.090 0.065 0.068 0.108 21
0.049 0.059 0.061 0.057 0.058 0.082 2 5
0.049 0.050 0.057 0.050 0.051 0.062 2 7
2 9
3 7
Serial dilution is the same in all plates
17-N-linked sera( BSA-17-N-antigen).
Antigen used for this assay was bovine thy-17-N-antigen at a 
concentration of lOpg /  mL. Polypep blocking buffer was used and donkey 
anti-rabbit (1:10,000 [blocking buffer]) was the enzyme antibody conjugate.
The table shows the comparative titrations (serum dilution at fixed antigen 
dilution) of all test-bleeds obtained through out the immunisation schedule 
used. The emboldened data represents the immunisation test-bleed profile of 
sera 9 at fixed sera dilution of 8x10"^ with time.
Table 10
9 9
Plate 1
Pre-bleed 9. 5(1) 9. 9(2) 9. 17(4) 9. 21(5) Sera dilution
0.367 1.416 1.587 1.671 1.650 2x10-3
0.329 0.951 1.470 1.347 1.290 4x10-4
0 . 1 4 9 0 . 4 3 8 1 . 0 5 3 0 . 8 3 9 0 . 7 4 0 8x10-5
0.081 0.164 0.501 0.339 0.287 1.6x10-3
0.071 0.087 0.182 0.134 0.122 3.2x10-3
0.068 0.069 0.090 0.077 0.074 6.4x10-7
0.064 0.064 0.066 0.064 0.062 1.28x10-7
0.064 0.064 0.064 0.062 0.062 2.6x10-3
Plate 2
Pre-bleed 9. 25(6) 9. 29(7) 9. 33(8) Bleed out Time in 
weeks
0.365 1.649 1.701 1.666 1.651 0
0.355 1.227 1.441 1.231 1.184 5
0.152 0 . 651 0 . 9 0 4 0 . 6 4 3 0 . 6 4 9 9
0.089 0.247 0.394 0.253 0.246 1 7
0.078 0.118 0.159 0.112 0.113 21
0.074 0.085 0.092 0.081 0.080 2 5
0.076 0.080 0.077 0.074 0.072 2 9
0.070 0.071 0.070 0.072 0.067 33
3 8
Sera dilution is the same between plates
Affinity Chromatography.
Preparation of giutaraldehyde activated controlled pore glass.
Amino modified control pore glass (16g, 1000 angstrom pore size lOOp. 
particle size) was suspended in phosphate buffer pH 7.2 containing 25%VA/ 
giutaraldehyde and the suspension was agitated using a rotary evaporator 
with slow rotation ( the evaporator was connected to the mains power via a 
rheostat to reduce the input power and slow the rotation rate to a minimum ( to 
ensure limited mechanical damage to the control pore glass) over the week 
end. The control pore glass turned pink when activated and was filtered, 
washed with water, followed by methanol, and dried in a desiccator under 
vacuum.
Preparation of 17-N- affinity column using controlled pore glass
Giutaraldehyde activated control pore glass (2.5g) was added to 0.1M 
phosphate buffer pH7.2 (52mL) containing thy-17-N-conjugate (4mL at a 
protein concentration of lOOpg/mL) and the mixture was agitated via the rotary 
evaporator.
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The reaction between the glass and the protein conjugate was monitored 
by U.V. spectroscopy, i.e. measuring the loss of cyclopenta[a]phenanthrene at 
269nm from solution by removing aliquots of the solution at regular intervals; 
the reaction was complete within 2hr at room temperature. The protein 
conjugate solution was removed by filtration and the glass suspended in 0.1% 
polypep dissolved in 0.1M phosphate buffer pH7.2 and the suspension 
procedure repeated for a further 2hrs. This blocked any unreacted 
giutaraldehyde sites on the controlled pore glass surface; the glass was 
subjected to filtration and washed thoroughly with 0.1M phosphate buffer 
pH7.2.
Affinity chromatography of serum bleed-out
Serum 9 bleed-out (2mL, 17-N-linked) was mixed with 0.1M phosphate 
buffer pH7.2 (50mL) and passed down a column of controlled pore glass 
modified with the above antigen (2.5g) at a flow rate of 0.4mUmin; and the 
eluant was monitored by passage through a U.V. cell of a fixed wavelength 
detector at 254nm. When all the sample had been loaded the column was 
washed with saline phosphate until all U.V. absorbing material had been 
eluted. The column was washed with 0.1 M propionic acid (30mL), followed by 
1M propionic acid (30mL), Fig 7.,(see results and discussion) shows the 
elution profile obtained. Spectra of individual fractions were checked, 
combined to give fraction F3 , eluted with 0.1M propionic acid. Similarly 
fractions eluted with 1M propionic acid were pooled to give fraction F4. Both 
F3 and F4 were immediately and independently subjected to dialysis against 1 
litre of saturated sodium bicarbonate diluted with 4 litres of distilled water to 
remove the acid. All acid washes were dripped into 2mL of saturated sodium 
bicarbonate to neutralise the acid.
Dialysis
Various lengths of dialysis tubing (Visking size 2-18/32") were soaked in 
distilled water for 2hr at room temperature and each tube was sealed at one 
end with three tight knots to form a bag. The sample was poured into the 
respective bag via a glass funnel and the air removed by compressing the 
area above the liquid with the fingers and sealing this end of the tubing in an 
identical manner; each bag contained a separate fraction. The ends of each 
bag were attached to a suitable weight, immersed in a beaker containing 5 
litres of saturated sodium bicarbonate and left stirring overnight at room 
temperature. The bags were removed from the dialysate and immersed in a 
second solution, this time containing the storage medium (saline phosphate 
pH 7.0, 5 litres ) and dialysed at 4^0 for 48hr (no stirring was used in this 
dialysis). Each bag was removed, washed with distilled water, one end cut
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open and the contents transferred to a measuring cylinder where the volume 
was recorded, and transferred to the respective storage vessel.
Table 11
Fraction number Volume in mL
FI non bound 50
F2 non bound 52.5
F3 bound 50
F4 bound 73
F5 bound 78
The concentration of affinity-purified serum applied to wells A was calculated 
by dividing the initial volume of the original serum(2mL) applied to the affinity 
column, by the total volume of each fraction collected see table 11. The 
calculated dilutions of these samples are included in table 13. An ELISA on 
these fractions yielded data from table 12. A plot of the relative fraction
O.D.measurement against the relative serial dilution from table 13 gave the 
comparative plot graph 10 see discussion.
Analysis of purified sera
Table 12
Oriq. serum FI F2 F3 F4 F5
0.461 0.376 0.654 1.541 1.370 1.031
1.208 0.046 0.224 1.329 0.943 0.152
1.568 0.043 0.109 0.848 0.358 0.064
1.705 0.045 0.061 0.356 0.121 0.047
1.247 0.044 0.049 0.126 0.060 0.043
0.981 0.046 0.055 0.074 0.052 0.042
0.355 0.045 0.045 0.059 0.043 0.042
0.119 0.044 0.046 0.052 0.045 0.051
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Table 13
represents the calculated serial dilution for each fraction
Oriq. serum FI F2 F3 F4 F5
1.0 4.0x10-2 3.8x10-2 4.0x10-2 2.7x10-2 2.5x10-2
0.2 8.0x10-3 7.6x10-3 8.0x10-3 5,4x10-3 5.0x10-3
4.0x10-2 1.6x10-3 1.5x10-3 1.6x10-3 1.1x10-3 1.0x10-3
8.0x10-3 3.0x10-4 3.0x10-4 3.0x10-4 2.2x10-4 2.0x10-4
1.6x10-3 6.0x10-3 6.0x10-3 6.0x10-3 4.0x10-3 4.0x10-3
3.2x10-4 1.3x10-3 1.2x10-3 1.3x10-3 9.0x10-3 8.0x10-3
6.0x10-3 2.6x10-3 2.0x10-3 2.6x10-3 1.7x10-3 1.6x10-3
1.3x10-3 5.0x10-7 5.0x10-7 5.0x10-7 3.0x10-7 3.0x10-7
Preparation of bovine thy-15-S-linked conjugate derived control 
pore glass.
Bovine thy-15-S-conjugate (25mL containing lOOpg/mL protein 
concentration) was diluted(2xdilution) sufficiently to allow full scale deflection 
of the major peak at 258nm. Using this peak as a means of monitoring the 
reaction, 2g of controlled pore glass was modified as described for the 17- 
oxime column and the reaction was complete within 24hrs. Using the optical 
density difference at the start of the reaction and when the reaction was 
complete, an estimate of bound protein conjugate per gram of glass was 
established i.e.
50mL of protein solution at 50pgprotein /  mL gave a total protein content 
of 2500|Lig, this solution gave an optical density of 1.56 O.D /  mL. After reaction 
the optical density was reduced to 0.63 O.D /mL, therefore the concentration 
of protein left in solution after reaction was:-
0.63 X  2500pg = 1009.6pg
1.56
therefore bound protein content is 2500-1009.6 = 1490p.g total contained in 
2g of glass =745pg protein /g  of controlled pore glass.
2mL of 21B bleed out sera was loaded onto the affinity column and washed as 
described for the 17-N-affinity column, the separation profile presented 
below:-
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-A .
Non - bound
Figure 8
Affinity separation profile of bleed out serum 21B 
The fractions eluted from the column were basified with sodium bicarbonate 
and dialysed into saline phosphate pH 7.0 as described. The sera were 
analysed by repetition of the 17-oxime direct assay protocol and the data is 
presented in tables 14, below:-
Table 14.
Plate 1 .mean optical density Plate 2, mean opi ical density
Non­
bound
fl
Non­
bound
f2
Non­
bound
f3
Bound
f4
Serum
dilution
Bound
U
Bound
f5
Bound
f6
Bound
f7
0.344 0.375 0.161 2.691* 4x10-2 2.903* 2.884* 2.835* 2.189*
0.376 0.384 0.113 2.217* 8x10-3 1.986* 2.136* 1.504 0.835
0.362 0.212 0.100 1.137 1.6x10-3 1.045 1.016 0.618 0.318
0.180 0.130 0.093 0.413 3.2x10-4 0.297 0.305 0.219 0.192
0.117 0.115 0.089 0.185 6.4x10-3 0.296 0.170 0.144 0.201
0.104 0.086 0.083 0.105 1.28x10-3 0.228 0.203 0.055 0.234
0.113 0.109 0.091 0.104 2.56x10-3 0.209 0.212 0.066 0.140
0.166 0.132 0.117 - 5.12x10-7 0.050 0.066 0.066 0.084
* indicates that the optical density reading 
titretech reader.
guarantee accuracy within the range of the
104
Fractions f i - f3 (non-bound) were washed off with phosphate buffer and 
rejected when it was established that they contained no antibody activity(see 
graph11). Column bound serum fractions f4 , fs.were eluted with 0.1M 
propionic acid and were later combined and renamed Fi ; when their antibody 
titre was shown to follow the same profile(see graph 11). The more strongly 
bound fractions fe, f? eluted with 1M propionic acid were combined to 
generate fraction F2 ; after establishing that these fractions generated a 
reduced but similar titration profile to F i. The fractions F i and Fg were 
independently dialysed and made up to a total volume of 50mL.
Graph 11:
Direct titre of affinity purified fractions from 
Cpp-S-15-derived serum (21B bleed out)
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Serum dilution
Preparation of Thy-11-0-conjugate derived controlled pore glass 
affinity column.
Giutaraldehyde activated controlled pore glass (2.143g) was 
suspended in O.IM phosphate buffer containing the title protein conjugate 
(concentration approximately 50mg /  mL) and subjected to the reaction 
procedure described for the 17-oxime derived serum.
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Figure 9
The U.V.spectrum shows the uptake of protein conjugate from the solution phase onto the controlled pore 
glass after a reaction time of 2 hrs at room temperature.
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2mL of the serum 23b was dissolved in 50mL of saline phosphate and 
passaged through the column as described
Figure .10
Affinity column separation profile.
F2
Sample loaded in 50mL and eluted 
with ISOmL of phosphate buffer pH 7.4
1.0 M CH3 CH 2 COOH
Non - bound
1 0 6
The spectrum of bound 
fractions F2
figure 11
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shows typical protein spectrum with no trace of cyclopenta[a]phenanthrene 
spectrum indicating the eluting protein was in fact denatured immunoglobulin 
and not acid cleaved protein conjugate or antibody conjugate complex, a 
check which was applied to all affinity purified acid wash fractions. The F3 
fractions eluted withI.OM propionic acid;-
Figure 1
?65nm
0.6
0.2
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reveal that the maximum absorption is at 265nm too low to be protein, 
suggesting that this strong acid treatment may result in the degradation 
products of either the protein conjugate, or the antibody-protein conjugate 
complex, or both. Fractions Fg and F3 were dialysed.
Direct sera assay
Volume of initial serum applied was 2mL. Table 15 , indicates the final 
volume collected for each fraction.
Tab e 15
Fraction Number Final volume of fraction in ml
non bound F1 50
Bound F2 68
Bound F3 50
Table 16
initial
serum
initial serum 
dilution
Fl non­
bound
non-bound
dilution
Bound
F2
Bound F2 
dilution
Bound
Fs
Bound 
F3 dilution
0.365 1 0.307 4x10-2 0.774 2.9x10-2 1.149 4x10-2
0.511 0.2 0.171 8x10-3 0.933 5.9x10-3 0.811 8x10-3
0.730 4x10-2 0.115 1.6x10-3 0.679 1.8x10-3 0.373 1.6x10-3
1.173 8x10-3 0.093 3.2x10-4 0.310 2.4x10-4 0.157 3.2x10-4
0.999 1.6x10-3 0.094 6.4x10-3 0.148 4.7x10-3 0.100 6.4x10-3
0.935 3.2x10-4 0.084 1.28x10-3 0.096 9.4x10-3 0.089 1.28x10-3
0.506 6.4x10-3 0.076 2.6x10-3 0.077 1.9x10-3 0.078 2.6x10-3
0.187 1.28x10-3 0.071 5x10-7 0.163 3.8x10-7 0.072 5x10-7
Table 16 represents the data used to generate graph 12. a comparison of the 
Elisa activity for the affinity purification fractions.
Graph 12
Direct assay of affinity purified serum derived from 
BSA-11 -(4-carboxybutoxy)-cpp-17-oneE
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Chapter 4
Competition Assay Studies
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Competition Assay Studies
The direct Elisa assay procedure, developed and used to characterise the 
sera derived from the immunisation schedules described, is unsuitable for the 
detection of small molecules such as cyclopenta[a]phenanthrenes not associated 
covalently or otherwise with a protein carrier. This assay depends upon 
adsorptive binding of the conjugate or macromolecule onto the surface of the 96- 
well plate; adsorption is efficient for large molecules such as proteins, but is not 
suitable for the immobilisation of small molecules such as cyclopenta[a]phen- 
anthrenes and steroids.
Analysis of the sera using this direct assay has established good titration 
curves for the haptenic portions of the cyclopenta[a]phenanthrene-protein 
conjugates, indicating successful antibody production. These haptenic regions 
recognised by the antiserum may encompass not only the cycopenta- 
[ajphenanthrene moiety, but also the bifunctional linker molecule and localised 
regions of the protein carrier. It is therefore necessary to define more precisely the 
antibody recognition characteristics with regard to antigen complex formation, in 
the absence of a protein carrier. Recognition of carrier free cyclopenta[a]phen- 
anthrene analogues or their metabolites in biological fluids is also the key aim of 
this project, and this can only be achieved by using an alternative assay protocol.
Competition assay.
Figure 1
[Ab] + [An] + [A g}| [Ab.An] + [Ab.Ag]-|
[Ab] = Fixed concentration of antibody.
[An] = Variable concentration of soluble analyte.
[AghE = Fixed concentration of bound antigen.
A fixed limiting concentration of antibody is incubated with bound antigen 
(Ag) in the presence of a second antigen referred to as an analyte ( An) which is 
in solution phase. The two antigens compete for the limited amount of available 
antibody and a measure of either bound antigen complex formation, or in the case 
of a radioimmunoassay, measurement of the loss of radioactive analyte or
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formation of radioactive complex. By fixing the concentration of a second 
component either bound antigen or analyte, the third component can be varied to 
give a titration curve. In our study complex formation is measured in the solid 
phase using a modification of the direct assay procedure already described.
The relative binding between the two antigens is dependant on two 
factors:-
1. Affinity of the antibody toward the analyte (An)
2. Relative concentration of the analyte
The antibody and antigen (Ag) concentrations in this assay are fixed and therefore 
limiting, whereas the analyte (An) concentration is varied.
Bound antigen.
The concentration of the antigen (Ag) is not accurately measured; a fixed 
repeatable concentration of bound antigen per assay, is achieved by adding 
excess conjugate solution to the plate wells, thus saturating their surface as 
described in the direct assay. This assumes that each plate well has a constant 
surface area which is saturated when exposed to an excess of antigen. As with 
the direct assay it is essential to ensure that the adsorption sites on the surface of 
the plate wells are capped to prevent non-specific protein surface interactions. 
Therefore antigen binding is followed by blocking any exposed sites with a non 
interactive protein; Polypep was the blocking agent of choice for reasons 
described in chapter 3, although gelatine was initially used.
In order to achieve good competition using as the measure of reaction the 
concentration of bound antigen complex, or a factor proportional to this value, it is 
necessary to define the relative concentration of active antibody in terms of bound 
antigen. As the concentration of active polyclonal antibodies within each serum 
can not be easily measured, and the actual concentration of bound antigen is not 
known, it is necessary to establish the effective antibody concentration by 
experiment.
Antibody concentration.
In graph 4 chapter 3 (page 78 ), a comparison of sera titrations is depicted, 
where serum dilution was measured at fixed (saturated plate well) antigen 
concentration. A plot of optical density at 492nm, which is the direct measure of 
bound antigen antibody complex versus serum dilution, reveals a linear region on 
the resultant titration curves. This region represents the serum concentration 
range at which measurable complex formation is observed. At the linear region 
maximum the concentration of serum antibodies is equivalent to the concentration 
of available antigen molecules. Therefore choosing a serum concentration 
between the maximum and 50% position of the linear portion of this direct assay
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profile, we obtain a concentration of antibodies which is less than the 
concentration of bound antigen and therefore limiting.
Analyte concentration.
The concentration range of the analyte is determined by:-
a. The concentration of antibody and antigen used in the assay.
b. The expected concentration range of the cyclopenta[a]- 
phenanthrene analogues to be found in biological fluids.
The solubility of cyclopenta[a]phenanthrenes in water determines the starting 
concentration of detection. The analyte range needs to lie both above and below 
this concentration a value that approximates 0.5nmol/mL for the model compound
15,16-dihydrocyclopenta[a]phenanthren-17-one[14]. Additionally the concentration 
of [antibody] to [antigen] should lie close to this value as a large excess of either of 
these two components would result in the suppression of signal observed by the 
competing analyte.
To use the assay to answer question 1 above, which concerns the antibody 
antigen affinity, it is necessary to prepare a series of standard solutions of known 
concentration with a wide range of structurally variant analytes, most of which are 
of a hydrophobic nature. The ideal media for the preparation of standard solutions 
are aqueous, buffered to pH 7.0; unfortunately the solubility of cyclopenta- 
[a]phenanthrenes in water (and buffering would reduce the solubility further due to 
the effect of salt concentration) are at the limiting range for spectroscopic 
measurement and therefore accurate assessment of concentration would not be 
possible for many analogues. As a range of concentrations both above and below 
that expected in biological fluids was required and accurate spectroscopic 
measurement of the initial concentrations were necessary, it was decided to 
prepare the standards in a dioxan/water mixture. 1,4-Dioxan is water miscible 
whilst exhibiting a low dielectric constant ( 2.209 e) compared with for example 
ethanol (24.3e) which is significantly more p o la r52. This reduced polarity 
enhanced the solubility of the hydrophobic hydrocarbons at a minimum 
concentration of the dioxan, therefore reducing the possibility of denaturing the 
immunoglobulins used in the assay.
Initial studies revealed two problems when the analyte 15,16- 
dihydrocyclopenta[a]phenanthren-17-one [14] was dissolved in 13%dioxan/water 
at concentrations ranging from between 1.76 nmole/mL to 1.76x10'^nmole/mL, 
these were:-
1. it was shown that unreliable competition was observed when the 
Tween 80 or Tween 20 was left out of the blocking buffer recipe. This was 
probably due to non-specific analyte protein absorption which resulted in variable
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retention of non-covalently bound analyte antibody complex, giving an enhanced 
colour reaction. The presence of Tween 80 reduced back ground colour and gave 
more reliable competition assays; presumably saturating the hydrophobic surface 
protein absorption sites. This observation led to the use of blocking buffer 
containing both Polypep and Tween 80 for the dilution of serum, ensuring that all 
protein was saturated with the detergent.
2. Using these solutions, initial competition assays gave the expected 
titration curves, but it soon became evident that competition reactions became 
weaker or failed completely if repeated a day or so later. This suggested a loss of 
the analyte possibly as a result of adsorption on the surface of the sample vessel 
walls, due to the low concentrations of analyte in use i.e. 1.75- 1.75x10“4 
nmoles/mL. In order to resolve this problem and ensure reliable standard 
solutions of accurately known concentration, it was clear that freshly prepared 
solutions were required each time an assay was undertaken. As many of the 
compounds to be used were either known to be potent carcinogens or were 
untested and potentially carcinogenic, it was impracticable to weigh, dissolve and 
ascertain using Ü.V. spectroscopy the concentration of these solutions prior to 
each assay.lt was therefore decided to prepare a series of saturated analyte 
solutions in aqueous/dioxan .
When a saturated solution is prepared an equilibrium is set up between the 
soluble and insoluble components; the two states follow the law of mass action 
and are dependent upon temperature. Adsorption of analyte from solution onto 
the surface of the container on storage will result in further solubilisation of the 
insoluble analyte to maintain the state of saturation. Eventually the adsorption 
sites on the surface of the storage vessel become blocked and the concentration 
of the cyclopenta[a]phenanthrene, steroid or hydrocarbon (analyte) reaches a 
stable state. The analyte solution is diluted with blocking buffer and subjected to 
serial dilution on the assay plate knowing its initial concentration. Standard analyte 
solutions following identical preparation and storage protocols (see general 
method) were set up and used.
To establish accurate concentrations of the respective analyte by U.V 
spectroscopy the absorption at a defined wavelength was measured and the 
published molar absorption (extinction coefficient) was used to calculate the 
concentration using Beer Lamberts law (see methods section for detail).
As most of the published molar absorptions were measured in ethanol, it was 
important to compare these values with those derived from spectra in dioxan 
(seeTablel). These differences were considered to be experimentally acceptable 
between dioxan and ethanol, thus the published molar absorptions in ethanol
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could be used. The errors due to variance of the molar absorption in 13%dioxan 
water as compared with the above are expected to be similar to the errors of 
measurement of molar absorption for these dilute solute solutions and were 
therefore considered acceptable for use in this work.
Table 1
Compound structure Molar absorption In dioxan found 
(A,max,nm)(dioxan)
Molar absorption published 
(A.max,nm)(EtOH)
Logio 4.94 (264nm) Logio 4.89 (265nm) ref (114)
Logio 4.84 (260.2nm) Logio 4.77 (258nm)ref (162 )
Logi 0  4.69 (253.4nm) Logio 4.58 (251.8nm)ref(163 )
Logio 4.74 (270nm) Logio 4.72 (269nm)ref (163 )
Competition and treatment of data
Graph 1 illustrates the results of four independent sample analytes run 
separately in duplicate on the same plate using as the antibody probe, affinity 
purified serum derived from the BSA-17-N-linked-antigen [A.3]. The bound 
antigen used in the assay was Oval-17-N-antigen. Analyte solutions were added 
to wells pre-coated with antigen, containing Polypep/ Tween 80 buffer arranged in 
duplicate. A total of five (in this experiment one set of wells was run as a control 
without analyte) independent analytes were run on each plate allowing the two 
end wells 1 and 12 to be left vacant thus reducing the end well effect often 
observed. All other wells contained a fixed volume of Polypep /  Tween 80 buffer. 
A serial dilution (in this example )1 in 5 per well of the analyte solutions from wells 
A to H following the procedure described in the methods section. A fixed volume 
of antibody was added to all wells and the mixture incubated usually overnight at 
room temperature to allow equilibrium between the respective reactants to be 
achieved. The plates were developed as described in the methods section and 
the optical densities read off. As each analyte was run in duplicate the mean 
optical density was calculated and this value (y-axis) plotted against the logio 
[analyte] concentration measured in nmol/mL (x-axis). As the independent 
analytes were subjected to identical procedure and reagents on the same plate, 
their data were directly compared by plotting them on the same scale using an
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overlay programme format (provided by Cricket graph for the Apple M a c in t o s h '•53) 
as illustrated in graph 1.
Graph 1
Sera affinity purified(Fraction F3) BSA-17-N-ant derived antibodies.
£
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The correct name for chrysene-1-one is 1,2,3,4-tetrahydrochrysen-1 -one.
To establish the relative cross-reactivity of the respective analytes a standard 
compound was chosen to act as a reference. In the case of this serum the 
reference of choice was 15,16-dihydrocyclopenta[a]phenanthren-17-one[14]. An 
arbitrary point on the reference curve was identified and used directly to compare 
the other analyte profiles. The site for comparison in this study was referred to as 
the 50% standard analyte titre, this was calculated as follows:-
Maximum - Minimum + Minimum = 50%Standard analyte titre 
2
from graph 1, 1.225-0.76 + 0.76 = 0.995
2
A line was extrapolated through the reference curve maximum to the y-axis and 
the optical density read o ff, a second line was extrapolated through the reference 
curve minimum position to the y-axis, as indicated in graph 1. The two readings 
subtracted and the difference divided by two was added to the minimum reading. 
A line (in the example provided i.e. 0.995 optical density units) was drawn from the 
y-axis at this 50% reference titration position through the complete overlay graph
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as illustrated. At the point of intersection between the 50% standard titration line 
and each of the other analyte titration curves a vertical line was dropped to cut the 
x-axis, where a concentration value was read off. In the case of data presented in 
this graph , the following concentrations were observed;-
Cpp-17-one [14] 0.125 nmole/mL
Cpp-16-one [15] 8.000 nmole/mL
Cpp-15-one [16] N
Chrysen-1-one [22] 0.250 nmole/mL
where N indicates that the respective analyte curve did not cross the 50% 
standard analyte titre position at any position within the scale of the overlay plot 
used, indicating no observed reaction. Note that a slight extrapolation of the 16- 
one curve was necessary to achieve an accurate assignment (great care must be
exercised when undertaking extrapolations of this nature).
These concentration values represent a measure of the relative cross 
reactivity of a number of independent analytes with the antibodies present in the 
probe serum, at a fixed titration defined by the standard analyte, for a single plate 
assay.
In order to extend the range to encompass data between plates, the 
standard analyte which is included in all assays involving a particular serum probe, 
was normalised by assigning it an arbitrary value of 1. The relative concentration 
values obtained for each analyte within a plate were divided into the concentration 
of the standard reference analyte and the result was multiplied by 100 and
expressed as a percentage relative cross reactivity.
Relative cross reactivity = nmoles standard analvte X 100
nmole of sample analyte
therefore using the data obtained from graph 1 a relative cross reactivity for the 
respective analytes measured is presented below:-
Cpp-17-one [14] 100%
Chrysen-1-one [22] 0.125/0.250 X 100 =50%
Cpp-16-one [15] 0.125/8 X 100 =1.6%
Cpp-15-one [16] N. shows no observed cross reaction
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From the analyte curves of 15,16-dihydrocyclopenta[a]phenanthren-17- 
one[14] and chrysen-1-one [22] it is clear that the two compounds show similar 
titration profiles. The analyte relative cross reactivity indicates a 50% difference, a 
value which is seemingly large in relationship to the observed titration curves. 
This difference is a result of using a logarithmic scale for depicting the 
concentration range. As the value assigned to the standard and the choice of 
standard was arbitrary, relative cross reactivity values both above and below the 
reference compound can be expected depending upon the analyte antibody 
affinity.
The panel of antibodies generated were all derived from substituted 
analogues of 15,16-dihydrocyclopenta[a]phenanthren-17-one [14]; it was therefore 
hoped that under competition conditions this compound would be sufficiently well 
recognised by all members of the panel to allow a direct comparison between 
sera derived from different conjugates within the series. This proved not to be the 
case as the BSA-11-O-antigen derived sera failed substantially to recognise this 
analogue. All of the sera derived from conjugates linking the cyclopenta[a]- 
phenanthrene through the D-ring gave sufficiently good recognition of this 
compound for it to used as the reference analyte. Therefore the data from these 
sera were compared and contrasted with each other directly, whereas the 3-0- 
linked and the 11-0 -linked sera were considered independently using alternative 
reference compounds.
Results and discussion.
The 17-keto function is the most polar bond in the 15,16- 
dihydrocyclopenta[a]phenanthren-17-one[14] molecule and would be expected to 
play an important role in antibody recognition. The 17-carbon atom is sp2 
hybridised and is a  to the aromatic C-ring; crystallographic d a t a  ”•54,155,156. has 
demonstrated that it lies in the same plane as the A/B/C aromatic ring system. As 
one would expect with this arrangement it is conjugated to the ring system as is 
demonstrated by the change in chromophore which occurs when the carbonyl is 
reduced to the hydroxyl analogue showing a shift in the UV maximum ‘••^ . The first 
question to be addressed with regard to antibody recognition concerns the effect 
of the carbonyl group.
All tables will include comparative data between purified and non-purified 
sera derived from the same rabbit, the aim being to establish the effect of the 
purification step on the selectivity of the polyclonal sera.
Table 2
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17-N fA .3] 17-NrA.Sl 16-0fB.51 1 5 - S [0.5] 15-S[C.51
Analyte purified Non- purified Non-purified purified Non- purified
1 0 0 1 0 0 10 0 1 0 0 1 0 0
1 1 28 15 4
7 4 25 N 4
N N N 24 3
OH
3 3 4 - 3
N N N N N
6 2 0 7 6 1 0
4 1 12 N 1
cxP^ 6 5 1 - 3
o p ® 2 0 24 13 3 8
Table 2 compares the cross-reactivity of the three D-ring linked sera with a series 
of D-ring modified cyclopenta[a]phenanthrene analogues. Migration of the 
carbonyl group from position 17 (D-ring) to position 16 (D-ring) takes it out of the 
influence of the aromatic C-ring electrons with the result that the carbonyl is no 
longer conjugated. The 17- carbon atom is transformed from a planar sp2 
hybridised state to a tetrahedral sp3 hybridised state. Graph 1, and table 2 ,show 
that this modification results in a loss in antibody binding for both the affinity- 
purified and non-purified sera of the BSA-17-N- antigen [A.3] derived serum of the 
order of 99% in both cases.
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The15-S-linked-serum [C.5] also shows a reduction of activity for both the 
affinity-purified serum (85% loss of activity),and the non-purified serum (96% 
reduction in binding). In this instance the affinity-purified BSA-15-S-antigen [C.5] 
derived serum has demonstrated an improved cross reaction with the analyte [15]. 
The BSA-16-0-antigen [B.5] derived serum showed a reduced cross reactivity of 
72%, even though the cyclopenta[a]phenanthrene was linked to the carrier protein 
via the same position. Linkage of the 16-hydroxycyclopenta[a]phenanthren-17- 
one [21] to the protein (from which this serum was derived) was through a 
tetrahedral sp3 16-carbon atom, whereas the carbonyl functionality results in the 
16-carbon being planar i.e. sp2 again indicating the possible importance of the 
stereochemistry about the site of attachment.
The introduction of a methyl group at the 17-position, to give 17-methyl-16- 
keto-cpp [17] analyte, marginally improved the binding to each of the sera except 
for the purified BSA-15-S-antigen derived serum the activity of which was 
abolished.
Further migration of the carbonyl from 16 (D-ring)[15] position to the 15 (D- 
ring)[16] position results in complete loss of measurable binding for both the 17-N- 
linked [A.3 ]- and the 16-0-linked [B.5] sera whereas the 15-S-linked serum [0.5] 
showed a 3% non-purified binding with an improved 24% purified serum binding, 
again the linkage occupies the same site of attachment but a different 15-carbon 
configuration. This positional change brings the carbonyl back under the influence 
of the aromatic C-ring electrons re-introducing the carbonyl into the conjugation 
system, suggesting that a steric effect rather than the change in conjugation 
properties are playing a more predominant role in antibody binding for these 
modifications. These findings are also substantiated by the sodium borohydride 
reduction of the 17-keto compound [14] to give the 17-hydroxy analogue [65] 
resulting in 3% cross reaction with both the 17-N-[A.3] and 15-S-linked [0.5] sera 
and 4% for the 15 -8  -linked serum.
Removal of the 17- substituent whilst retaining the full ring system i.e. 16,17- 
dihydro f  17±Fcyclopenta[a]phenanthrene [12] resulted in complete loss of cross 
reactivity for all of the D-ring linked sera. The introduction of a double bond into 
the D-ring at positions 15,16 showed a significantly increased cross reactivity for 
the 17-N-linked sera [A.3]; both affinity-purified and non-purified gave 20 fold 
increase compared with the hydrocarbon [10] and a five fold reduction compared 
with the reference compound[14]. Thel 6-O-linked serum [B.5](non-purified) and 
the 15-S-linked serum [C.5] (non-purified) also showed an increased cross 
reaction of 13% and 8% respectively. These data were consistent with the 
introduction of a 17-methylene group, compound[18], which showed similar
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increased cross reactions for each of the respective sera, suggesting that the 
planarity, or the increased electron density distribution, due to and influenced by, 
the degree of conjugation may play a role in the analyte antibody recognition 
characteristics. To test this further a range of compounds were evaluated showing 
variant degrees of conjugation on D-ring sera cross-reactivity Table 3 illustrates 
the results observed.
Removal of the 11,12-double bond to give [30], reduces the effective ring 
conjugation, although the 17-keto group remains conjugated through the 13,14 
double bond and the aromatic B-ring. Both the BSA-17-N-linked [A.3]- and BSA- 
16-O-linked [B.5] derived antibodies showed a reduced cross reaction to 33%, and 
36% compared with the reference Cpp-17-one[14]. Affinity purification of the 17- 
oxime serum reduced this cross reaction further by approximately a third, 
suggesting that some of the antibodies responsible for this activity were either 
removed or irreversibly denatured as a result of the purification procedure. The 15- 
S-linked serum [C.5] showed only a weak interaction with this analogue.
Further reduction of the 13,14 double bond to generate 11,12,13,14,15,16- 
hexahydrocyclopenta[a]phenanthren-17-one [29] resulted in complete loss of 
cross reaction with the 16-O-linked serum [B.5] and only a 1% cross reaction with 
the15-S-linked serum [0.5]. The 17-N-linked serum [A.3] showed a higher than 
expected interaction with a 16% cross reaction with the non-purified serum, but 
this activity was destroyed in the affinity purification step to give only 1% cross 
reactivity.
Equilenin[7], which shares the conjugation characteristics of
11,12,13,14,15,16-hexahydrocyclopenta[a]phenanthren-17-one [29] which was 
weakly detected by the non-purified 17-N-linked [A.3] serum, was not detected by 
any of the D-ring linked sera, a result influenced by the presence of the 3-hydroxy 
and the 18-methyl substituents. Using the 17-N-linked serum [A.3] oestradiol[9], 
oestrone [8] and 3-deoxyoestrone[69] were probed and in all cases no reaction 
was observed; removal of the 3-substituent appeared not to have any influence 
upon the antibody recognition characteristics for these single aryl ring containing 
oestrogens. Additionally the saturated B and C ring characteristics and the axial
18-methyl group make them unlikely candidates for binding to these antibodies. 
This is a useful result within the context of this study, as all mammals carry the 
single aryl ring derived oestrogens and mares have been shown to carry the 
napthalenic oestrogens, such as equilenin and 3-deoxy-equilenin, as part of their 
normal hormonal make up (see chapter 1).
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Table 3
17-N 17- N 1 6 - 0 1 5 - S 1 5 - S
Analvte purified Non - purified Non - purified purified Non - purified
1 0 0 1 0 0 1 0 0 1 0 0 1 0 0
(x 9 ^ 1 2 33 36 - 4
o # - 150 - - 130
1 16 N - 1
equilenin
N N N N N
IS]
35 40 6 - 3
N N - N N
Reduction of the 13,14-double bond in 15,16-dihydrocyolopenta- 
[a]phenanthren-17-one [14] results in two isomeric products c/s- and trans-
13,14,15,16-tetrahydrocyclopenta[a]phenanthren-17-one. Both of which show 
reduced conjugation of the C-ring and complete isolation of the 17-keto group from 
the aromatic ring system. The two isomers show quite different structures, the 
trans analogue being largely planar following a similar shape to compound [14], 
whereas the c/s isomer is markedly distorted out of plane at the 13,14- ring
junction (see figure 2). ____ ____ _____
Compound [38] was synthesised in 1966 by C o o m b s !  114 as a precursor to 
cbmpdund [14], and was the original analytical sample used for the referenced
paper j This was purified and subjected to the competition assay; it
was found that both the 17-N-linked serum [A.3] and the 15-S-linked serum [C.5]
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gave cross reactions of 150 % and 130 % respectively, a surprisingly high cross- 
reactivity by both sera.
It is unlikely that this compound is to be found naturally occurring other 
than in a rapidly transitional process, because of its vulnerability to air oxidation in 
acidic medium; but the enhanced activity it exhibits requires further investigation.
As already suggested it was synthesised as a precursor intermediate which 
was to undergo oxidation to give the model compound [14]. Its Isomeric form was 
not established, as both Isomers undergo this aromatisation reaction. The clear 
differences In planarity of these Isomers make It necessary to resolve the 
configuration of compound [38], In order to establish what the antibodies are 
recognising.
cis-13,14,15,16-tetrahydro- 
cyclopent[a]phenanthren-17-one
trans-13,14,15,16-tetrahydro- 
cyclopenta[a[phenanthren-17-one
Figure 2
Both a UV spectrum and thin layer chromatography revealed compound 
[38] to be a mixture of two components; one of which was Identified as the 
oxidation product [14], which was removed prior to further analysis.
1hnMR established the H(12)— H(13) dihedral angle was approximately 
1040 (calculated from the coupling constant J 12,13=1-8Hz using the Karplus 
equation). This was consistent with the trans -Isomer, dihedral angle of lOBO 
compared with the cis -isomer having a dihedral angle of 530. The dihedral 
angles of both Isomers were predicted by the Chem draw 3-D computer modelling
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package"l57_ This evidence combined with the antibody binding studies (it is 
unlikely that the cis - isomer would be recognised because of its C(13)--C(14) out 
of plane deformation) does support the view that compound [38] is the trans 
isomer. The enhanced antibody binding may be due to the targeting of a different 
population of antibodies to that recognising the cyclopenta[a]phenanthrene 
analogues. Although it is likely that localised in-situ oxidation had occurred to 
generate compound [14] this would account for 100% binding but not the 
enhanced activity.
Increasing the conjugation by introducing a six membered ring linked to 
12,13 and 17 positions (i.e. the b face of the phenanthrene system) in the form of 
3-methylcholanthrene[5] resulted in significant cross reaction with the BSA-17-N- 
antigen derived serum[A.3] i.e. (see graph 2) non-purified 40% and a small loss of 
activity for the affinity-purified serum to give 35%, the other D-ring linked sera only 
exhibited marginal recognition of this compound.
Graph 2
Competition of 3-methyIcholanthrene and 11-methylcyolopenta[a]- 
phenanthrene probing with affinity purified 17-linked[A.3] serum.
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Presumably the recognition of this analogue may be a result of antigen 
presentation. It has been demonstrated by X-ray crystallography (chapter 2) using
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the model compound [A.4 b] that the isomeric form of the oxime used in the BSA 
conjugate preparation was the trans compound [A.3]. A comparison of the 3- 
methylcholanthrene structure and the trans -17-oxime-15,16-dihydrocyclopent- 
[ajphenanthrene reveal close similarities with regard to the spatial arrangement 
about the 17,18 C=C-CH3 of the former and the oxime C=N-0 of the latter which 
are highlighted in figure 3.
Figure3
^OCHgCOOX
3-methyl cholanthrene 17-oxime-cpp linker molecule
X = amide linked to protein.
The detection of 3-methylcholanthrene[5] is a particularly important result because 
of its value as a tool for studying the mode of action of carcinogens "158,159 a  
35% relative cross reactivity using the 17-N-linked serum [A.3] , is sufficient to 
achieve good detection of this compound, as demonstrated by the standard 
solution where down to 0.2 nmoles of 3-methylcholanthrene[5] was observed. The 
selectivity differences between the 17-, 16- and 15-linked sera make it relatively 
easy to differentiate the 3-methylcholanthrene[5] from the cyclopenta[a]- 
phenanthrene reference compound, simply by probing the sample with two or all 
three of these sera. It is interesting to note that 3-methylcholanthrene was 
recognised whereas 12-methyl-15,16-dihydrocyclopenta[a]phenanthren-17-one 
[61 ] was not detected by any of the sera. Both analogues are substituted at the 
12- and 17-positions with an sp2 carbon at C-17, suggesting that the substituent 
in this case a methyl group in the latter, as opposed to the aromatic six membered 
ring in the former, is sufficient to influence antibody recognition.
Effect of substitution.
Table 4 illustrates the results for a range of monomethyl and dimethyl 
homologues of 15,16-dihydrocyclopenta[a]phenanthren-17-one [14] being 
independently probed under competition assay conditions using the three D-ring 
linked sera. None of the monomethyl analogues (2-,3-,4-,6- or 12-) cross reacted 
with any of the D-ring linked sera.
Table 4
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Analyte 17-N-serum 17-N-serum 16-0-serum 15-S-serum 15-S-serum
Methyl position Purified Non-purified Non-purified purified Non-purified
1 not run 30 1
2 N N N N N
3 N N N N N
4 2 N 0 .2 N N
6 N N N N N
7 25 56 N 19 8
11 150 116 2 2 18
1 2 N N N N N
1 1 ,1 2 -dimethyl - 0.5 N - 0.5
E
w
c0)O
.1
5
Graph 3
Competition between non-purified serum 9(BSA-17-N-ant) 
derived antibodies and mono-methyl-cpp-17-one substituents
3-methyl-11,12-dihydro-cpp-17one 
♦ —  2-methyl-cpp-17-one 
3-methyl-cpp-17-one 
7-methyl-cpp-17-one 
cpp-17-one
10  ^  1 0 '  10  
Concentration in nmoles/ml
The 7-methyl [ 5 9 ]  compound was detected by both the 17-N-linked [A.3]and 
15-S-linked [ C . 5 ]  sera, whereas the 16-O-linked serum [ B . 5 ]  showed no observed 
response. This moderately c a r c i n o g e n i c ^ GO, compound [ 5 9 ]  has a methyl 
substituent situated in the K-region of the molecule, a region which is noted for its 
chemical reactivity 161,162 50,51 and a position of historical importance, already 
discussed in chapter 1. But the position itself is hindered by the close proximity of
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the two 15-methylene D-ring protons, because they lie at either side of the plane 
of the methyl group, preventing it from twisting out of plane, the molecule is in a 
permanent state of s t r a i n  154,155,, The result of this substitution is the generation 
of a completely planar s t r u c t u r e  154,155,. Unlike other methyl substituents the 7- 
methyl group is not positioned at right angles to the ring system, but occupies the 
region between the C and D rings which may effectively shield this group from 
blocking the antibody recognition sites.
Benzo[a]pyrene (see table 8 ) also cross reacted with the 17-N-linked [A.3] 
and 15-S-linked [C.5] sera, but was not detected beyond 1% by the 16-0-linked 
serum[B.5]. Structurally benzo[a]pyrene is not dissimilar to the 7-methyl -15,16- 
dihydro-cyclopenta[a]phenanthrene-17-one [59] as illustrated in figure 4.
Figure 4
7-methyl-cpp-17-one Benzo[a]pyrene
Benzo[a]pyrene may be considered to be a chrysene analogue with a six 
membered aromatic ring replacing the 5-membered C-ring of the 
cyclopenta[a]phenanthrene; in addition it contains a second six membered 
aromatic ring fused to the [m,n cyclopenta[a]phenanthrene,nomenclature] position 
equivalent to the cyclopenta[a]phenanthrene K-region. This shows a similar 
substitution pattern to that exhibited by the 7-methyl analogue[59], and again 
adopts a completely planar structure. The 15-S-linked serum [0.5] does not 
appear to distinguish between these molecules (benzo[a]pyrene cross reactivity of 
22% and 7-methyl cross reactivity of 19%), although the 17-N-linked serum [A.3] 
appears to be more discriminating [benzo[a]pyrene 16%, 7-methyl 25%(affinity- 
purified), 56% (non-purified). The differences in binding for the non-purified serum 
and purified 17-N-linked serum [A.3] indicates significant loss of this activity 
suggesting that affinity purification using either the 7-methyl or benzo[a]pyrene as 
the immobilised antigen may improve the detection properties of these analogues. 
The 11-methyl compound [60] cross reacted very efficiently with the 17-N-linked 
serum [A.3], giving values of 116%, 150% for the non-purified and affinity- purified 
sera (see graph 2 for affinity-purified titre). Significant binding to the BSA-15-8-
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Graph 4
Benzo[a]pyrene probed with 17-linked [A.3] affinity purified serum.
Cpp-17-one [14] 
Benzo[a]pyrene [67]
E
I 0.9
■(3 0.8
!TJ
75
0.7
■5. 0.6
0.4 THf
Concentration in nmoles/ml
antigen [C.5] derived serum was also observed i.e. 22% purified and 18% non- 
purified. Like the K-region which includes the 7-position , the area occupied by 
the 11-methyl group is the bay region which is also a very hindered site. Unlike 
the 7-methyl analogue the presence of a methyl in this position causes 
considerable deformation or twist giving an A/C angle of 12.5° 154,155 156 du© to 
its steric interaction with the carbon-1 proton. Clearly this distortion had no 
observed blocking effect on the antibody binding sites. This serum appears to 
recognise to varying extents the 11-,7- and 1-monomethyl analogues, which all 
share the common feature that they are substituents occupying areas close to the 
angular fused ring junctions; regions where the methyl substituents may to some 
extent be shielded by the ring configuration. To further clarify this effect it was 
decided to investigate a number of other 11-substituted analytes see table 5.
Increasing the size of the 11- substituent from a methyl to an ethyl group 
irradicated all cross reaction with the complete panel of D-ring sera studied. It 
must also be noted that the ethyl compound shows a marked reduction in 
carcinogenicity when compared with the methyl equivalent. X-ray crystallographic 
d a ta " ! 56 for the 11-ethyl derivative indicated the presence of two polymorphic 
forms of this analogue:-
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a.
b.
Both carbon atoms of the ethyl group lie approximately in the plane 
of the ring system.
In the second polymorph the second carbon atom is out of plane of 
the ring system.
In solution free rotation of the ethyl group within the restricted boundaries of the 
bay region would occur ensuring that both configurations are present with other 
conformers. Because the second carbon atom the ethyl group exceeds the bay 
region; it becomes visible to the antibodies and inhibits binding. Further bulky 
substituents such as methoxy[43] and higher alkoxy analogues[44],[45],phosphate 
triester compound [48] see table 5, hydroxymethyl [42] also showed no cross­
reactivity with any of the D-ring linked sera.
Table 5
17-N-serum 17-N-serum 16-0-serum 15-S-serum 15-S-serum
R group Purified Non- purified Non -purified purified Non -purified
methyl 150 116 2 2 18
ethyl N N N N 1
1 ,1 1 -methane N N N N 1
hydroxymethyl N N N
hydroxy N N N N
1 0(CH 2bCONHC gHi 1 [D.5] N
’ (Et0)20P0 [48] N N N
Methoxy N N N
ethoxy N N N
propoxy - - N - N
The 11-[3-(cyclohexylcarboxyamido)propyl] ether [D.5], prepared originally as a 
model for the reaction of the active N-hydroxysuccinimide esters with primary 
amine, also showed no cross-reactivity.
A second series of methyl analogues were investigated derived from the 
11,12 - reduced compound, 11,12,15,16-tetrahydrocyclopenta[a]phenanthren-17- 
one [30] (see leading structure table 6)
The unsubstituted compound gave significant cross-reaction for both the BSA-17- 
N-antigen[A.3] and the BSA-16-0-antigen[B.5] derived sera. The 3-[33] and 4-[34] 
monomethyl analogues and the 11,12 - dimethyl analogue [37] showed no marked 
binding with any of the D-ring linked sera as was the case in the former series. 
Weak recognition of the bay region 1-methyl [31], and 11-methyl [36] analogues
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was observed for both of these sera although this was reduced compared to 
activity obtained from the first series of compounds.
Table 6 
o
cæ :
Analyte 17-N[A.31 17-NIA.31 16-OrB.51 15-S[C.51
Methyl position Purified Non-purified Non-purified Non-purified
unsubstituted 1 2 33 36 4
1 15 11 4
2 50 1 6
3 N N N N
4 N 1 N 2
6 N N 16 13
11 7 15 4
1 1 ,1 2 -dimethyl - N N N
Recognition of the bay region 11 -methyl compound was unexpected as unlike the 
former series of compounds the bay region was less hindered because of the 
tetrahedral nature of the 11-carbon atom, where the proton and the methyl group 
lie either side of the plane of the ring therefore not interacting with the 1-proton to 
generate strain in the molecule. Méthylation of this position would result in the 
methyl group being situated either above or below the plane of the rings which 
would be expected to inhibit antibody binding on steric grounds. The BSA-17-N- 
ant [A.3]derived sera showed a further deviation from the first series of 
compounds in that the 2-monomethyl [32] analyte showed a 50% cross reactivity 
with it. This serum did not cross react with the 6-monomethyl [35] derivative but 
both the 16-0[B.5]and the 15-S [C.5] linked sera showed a 15% and 13% cross 
reaction respectively with this compound. It is important to note the relative 
activities of purified and non- purified serum for the 17-linked series where the 
unsubstituted analogue binding was reduced by one third for the 1-methyl and 2 - 
methyl derivative antibody binding was completely abolished for the purified- 
serum; establishing at least for this serum that the antibodies involved in the 
binding of this group of analogues may not be the same as those binding to the 
fully aromatic homologues.
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Polarity of the substituent.
A most dramatic effect in change of polarity is the modification of a ketone to
a hydroxyl, as seen in the chemical reduction of the 17-ketone [14] to 17-alcohol
[65] where binding with the 17-N-linked sera [A.3] was reduced from 100 to 3%.
The size of the two functional groups are similar; the hydroxyl group like many
other inactive 17-substituents is situated on a tetrahedral C-17 carbon atom,
where as the ketone generates an sp2 carbon. Evidence for the inhibition of
binding in this instance points not to the polarity, but to the spatial arrangement of
the modification. To address the problem of polarity a number of hydroxyl and
alkoxy analogues have been looked at and these are presented in table 7.
Table 7
Analyte 17-N[A.3] 17-N[/L3] 16-G[B.S] 15-S[C.5]
substituent purified Non purified non-purified non-purified
2 -hydroxy N N N N
3- hydroxy N 0.5 N N
11 -hydroxy N N N N
16-hydroxy - N 1 0 0 1
11 -methyl-16-hydroxy - N 6 0.1
2 -methoxy - N N N
3-methoxy - N N N
6 -methoxy N N N 3
1 1 -methoxy - N N N
15-methoxy N N 8 44
The 2-[39],3-[40], and 11-[41] mono-substituted hydroxy and the 2-[51],3-[52],6- 
[50] (weak interaction with the 15-S-linked non-purified serum), and 11-[43] 
methoxy analogues failed to cross-react with any of the D-linked sera which was 
consistent with binding found with the methyl substituents. The 11-methoxy [43] 
and 11-hydroxy [41] analogues both failed to generate a response and in the 
earlier discussion it was implied that this was a function of bulk, an alternative 
explanation may be as follows.
Forming a methano bridge between the 1 and 11-position has the effect of 
forcing the molecule back into the plane of the ring s y s t e m ‘•54,155. \\ has been 
suggested from X-ray crystallographic d a t a ‘•56 that the 11-methoxy[43] compound 
in the crystalline state is locked into a cis conformation with the 12-proton, the 
molecule adopting a planar arrangement. This suggests that the oxygen interacts 
with the 1-proton, indicating possible hydrogen bonding as illustrated in figure 5, to 
form a bridge similar to that present in the 1,11-methano analogue [47]. If this 
hydrogen bonding is maintained in solution, the bay region bridge may account for 
the failure of this molecule to cross-react with the D-ring linked sera, a result 
paralleled by the 1,11-methano analogue which also showed no observed cross­
reaction with any of the D-sera. The 11-hydroxy compound could also adopt this 
structure. It is not clear why the hydroxyl and the methano analogues fail to 
interact, it seems probable that the antibody epitope passes through or interacts
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with the bay region and this linking of the 11- and 1- substituent together by 
covalent [47] or a strong hydrogen bond [41,43] blocks access.
Figure 5
CHs H
11 -methoxy-cpp-17-one
As already discussed in chapter 2 the 15-hydroxy- and 16-hydroxy-cpp-17- 
one[21] analogues are primary metabolites in the metabolism of cpp-17-one[14] 
derived compounds. The 15-S-linked serum [C.5] and the 16-Olinked serum [B.5] 
were designed specifically to recognise them respectively. As the 15-hydroxy 
compound was not available the 15-methoxy derivative [20] was used as a model 
for recognition and gave a cross reaction of 44% with the 15-S-linked serum [0.5] 
(see graph 5) and the 16-hydroxy analyte [21] gave high cross reaction of 100% 
with the BSA-16-G-ant [B.5] derived serum (see graph 6). The 11-methyl-16- 
hydroxy-cpp-17-one [53] a primary metabolite of the 11-methyl-15,16- 
dihydrocyclopenta[a]phenanthren-17-one [60] was also weakly detected to the 
extent of 6% by the 16-O-linked serum[B.5].These results confirmed our choice of 
antigen presentation used to generate these sera.
These hydroxy-substituents have shown similar behaviour to their non-polar 
counterparts i.e. methyl groups and methoxy groups suggesting that steric effects 
of substituent position are more important than the polarity of the substituent.
The only true indication that polarity may contribute to the cross reactivity so 
far observed in this study is the increased binding exhibited by the reference 
ketone[14] over the 17-methylene[18] compound (data presented in table 2), 
where a cross reactivity (for non-purified sera) from 100% for the carbonyl is 
reduced to 20%, 17-N-linked serum [A.3], 7% for the 16-0-linked serum [B.5] 
and 10% BSA-15-S-ant [C.5] derived serum, all showing a significant reduction in 
binding, whilst both compounds share similar structural features such as positional 
arrangement, bulk and conjugation properties.
131
Graph 5
Non-purified 15-S-derived serum[C.5] used 
to probe 15-methoxycpp-17-one[20]
0.6
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I Cpp-17-one [14] 
15-methoxycpp-17-one [2 0 ]
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Graph 6
Non-purified 16-0-linked serum [B.5] used to probe
Q g hyrdoxyl and methoxy modified analytes.
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Cpp-17-one [14]
11 -hydroxymethyl-cpp-17-one[42] 
2-methoxy-cpp-17-one [51]
16-hydroxy-cpp-17-one [2 1 ]
11 -hydroxy-cpp-17-one [41]
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Effect of the D-ring.
An interesting feature of this study is the effect of the D-ring on recognition, 
both in terms of position, presence, and size.
Table 8
Analyte 17-N[A.31
N
16-0[B.5]
N
15-S[C.51
N
N - -
, OH
N N N
N N -
, NON
N N N
N N N
16 1 2 2
N N 0 .2
Evidence for the need of a D-ring situated on the [a] face is indicated by the 
failure of all sera to recognise benzanthracene [68] which has an extra 6- 
membered ring fused to the [b] face, whereas 3-methylcholanthrene [5] which 
shares a similar configuration but has a five membered D-ring fused to the [a] face 
of the phenanthrene, shows significant binding. It was also shown that the 11- 
methyl-cpp-17-one[60] gave a strong cross reactivity with each of the D-ring sera, 
whereas the 4-methyl phenanthrene[27] which shares the phenanthrene ring 
structure excluding the D-ring, does not cross react with any of these sera.
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Expansion of the D-ring from a 5-membered ring to a 6-membered ring (see 
graph 1 ) whilst maintaining the integrity of the carbonyl adjacent to the aromatic 
C-ring, as seen for the 1,2,3,4-tetrahydrochrysen-1 -one [22] results in the cross 
reactivity with all of the D-linked sera. The 16-Olinked serum[B.5] gave 100% 
binding, the 17-N-linked serum [A.3] and 15-S-linked serum[C.5] binding activity 
was reduced by half and 78% respectively.
Table 9 
Chrysene analogues
Chrysene derived 
analytes
17-N-linked 
serum [A.3] 
non-purified.
17-N-linked 
serum [A.3] 
purified
16-0-linked 
serum [B.5] 
non-purified.
15-S-linked 
serum [C.5]
N - - -
- 50 1 0 0 2 2
- N N 1 2
- N N N
- N N N
■ - N N -
- N N N
Unexpectedly introduction of a bay region methyl group in this chrysenone to give 
[28] abolishes binding to both the 17-N-linked [A.3] and 16-Olinked [B.5] sera 
and reduces the activity by half for the BSA-15-S-ant [0 .5 ] derived serum 
indicating that the six membered D-ring has influenced the level of detection for 
substitituted analogues. Chrysene [1] did not cross react with the 17-N-linked 
serum[A.3], and the other chrysenes included in table 9, exhibiting methyl 
substituents at the 11- and 17-positions with varying degrees of saturation of the 
D-ring also failed to elicit any cross reaction with any of the sera .
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3-Linked and 11-linked sera.
Both the 3-0-linked[E.6] and 11-O-linked [D.6] sera were derived from 
antigens attached to the cyclopenta[a]phenanthrene and the carrier protein 
through a carboxypropoxy cross linking agent directly attached via an -Oether to 
the aromatic rings in the molecule. Many problems were encountered concerning 
assignment of cross reactivity, due to the failure of these sera to reliably cross 
react with the analyte 15,16-dihydrocyclopenta[a]phenanthren-17-one [14] initially 
used as the reference analyte. Thyroglobulin carrier protein used in the assay as 
the bound antigen source amplified non-specific binding effects and possibly 
variations in the plate architecture when these sera were used as probes, but 
chicken ovalbumin carrier improved the quality of the Elisa data. It became 
evident as the studies progressed that these sera showed different properties to 
that exhibited by the D-ring linked sera.
3-Olinked serum [E.6].
This serum did recognise 15,16-dihydrocyclopenta[a]phenanthren-17-one 
[14] to a variable extent an average value of 24% (mean of 14 assays) was 
calculated. The reproducibility of the cross reaction varied from zero to 50% 
making its use as a reference compound impossible.
The 3-hydroxy-cpp-17-one [40] turned out to be the target antigen and as 
its cross-reactivity was completely reproducible, it was therefore used as the 
internal reference analyte. This result was particularly important because it 
confirmed the reasoning for antigen design to be correct(see chapter 2). Also the 
3-hydroxy analogue[40] represents a potential product of aberrant metabolism for 
some oestrogens, following the hypothesis of Marrian discussed in chapter 1, 
making it a useful probe for testing this potential metabolic route.
Other compounds showing weak cross reactivity include the D-ring 
substituent containing 17-methylene-cpp[ 18], 17-methyl-cpp-15,16-ene[19], 
and Diels hydrocarbon [2] suggesting that substitution at this position is important 
for recognition and both sp2 and sp3 carbons are allowed. The 2-methyl-cpp-17- 
one [55] (12.5%), 4-methyl-cpp-17-one [56] (15%) compounds were weakly 
detected, but the 2-hydroxy analogue [39](N) is not picked up. The 3-methoxy- 
cpp-17-one [52] was not detected whereas the 3-methyl-cpp-17-one [56] was 
found to cross react to the extent of 14%, a weak interaction compared with the 3- 
hydroxy-cpp-17-one [40]. The bulk of the methyl group and the hydroxyl are
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similar whereas methoxy would be approximately twice their size. This would 
suggest that whereas steric blocking may play a role in the failure of the antibodies 
to detect the methoxy analogue, the most likely reason for the limited interaction 
with the 3-methyl compound lies in its reduced polarity, probably requiring 
hydrogen bonding with the antibody binding site to achieve maximum interaction. 
Graph 7 illustrates the antibody interaction with the 3-hydroxy and 3-methoxy 
analogues.
Graph 7
Example of 3-linked sera[E.6] non-purified.
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Table 10 shows the results of antigen binding to non-purified 3-Olinked serum 
[E.6] using cyclopenta[a]phenanthrene analogues, and includes other steroid and 
polycyclic aromatic hydrocarbons sharing structural similarities to the target 
antigen.
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Table 10
Standard Analyte non-purified 3-Olinked serum [E.6 ]
3-hydroxv-cpp-17-one [401 1 0 0  (reference analyte)
cpp-17-one [14]
24 (mean of 14 assays)
cpp-16-one[1S]
N
cpp-15-one [16]
N
cpp-15-16-ene[12] N?
cpp-17-methvl-16,17-ene[19] 6.7
cpp-17-methvlene [18] 7.1
cpp-16,17-dihydro-15 -H [1 0] N
Diels hydrocarbon [2] 8.7
1-methyl-cpp-17-one [54]
2-methyl-cpp-17-one [55] 12.5
3-methyl-cpp-17-one [56] 14
4-methyl-cpp-17-one [57] 15
6-methyl-cpp-17-one [58] N
7-methyl-cpp-17-one [59] N
12-methyl-cpp-17-one [611 N
11 -methyi-cpp-17-one [60] N
11-ethyl-cpp-17-one [46] N
1 -11 -methano-cpp-17-one [47] N
2-methoxy-cpp-17-one [51] N
3-methoxy-cpp-17-one [52] N
6-methoxy-cpp-17-one [50] N
11-methoxy-cpp-17-one [43] N
15-methoxy-cpp-17-one [2 0 ] N
2-hydroxy-cpp-17-one [39 ] N
11-hydroxy-cpp-17-one [41] N
11-hydroxymethyl-cpp-17-one [42] N
16-hydroxy-cpp-17-one [2 1 ] N
11-methyl, 16-hydroxy-cpp-17-one [53] N
(11,12 reduced) 3-methyl-cpp-17-one [33] 1.4%
(11,12 reduced) 4-methyl-cpp-17-one[34] N
3-methylcholanthrene [5] N
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11-0-linked [D.6]serum.
As already discussed the 11-O-linked serum [D.6] has no cross reaction 
with the cpp-17-one [14]. The target antigen for this serum was the 11-methyl- 
cpp-17-one [60], and was used as the reference analyte. As with the 3-O-linked 
serum [E.6] this also confirmed the antigen design strategy (discussed in 
chapter2) used for antibody production to be correct.
Other 11-substituted analogues were investigated and the results 
presented in table 11.
Table 11
standard analyte Cross reaction with affinity-purified fD.51
11 -methyi-cpp-l 7-one[60] 100 (reference analyte)
11 -ethyl-cpp-17-one f 46] N
1-11-methano-cpp-17-one |471 N
1 l-methoxy-cpp-17-one 1431 0.3
11-ethoxy-cpp-17-one |441 60
11-propoxy-cpp-17-one [451 40
11 -hydroxy-cpp-l 7-one 1411 N
ll-hydroxymethyl-cpp-l 7-one 1421 N
(11,12 reduced) cpp-17-one [301 N
Graph 8
competition assay using 11-0-linked affinity-purified serum.
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Increasing the carbon chain from methyl to ethyl [46] abolished activity completely; 
the methano compound [47] also showed no observed binding. Both direct 
hydroxylation of the ring to give [41] and hydroxylation of the 11-methyl group to 
give the 11-hydroxymethyl -cpp-17-one [42] failed to elicit antibody recognition. 
Alkoxy formation of the 11-hydroxy compound [41] increased the cross reaction in 
the case of the methoxy[43] to the just measurable (0.3%). Further increase in the 
alkoxy chain to ethoxy resulted in significant antibody recognition (60% cross 
reaction), and the propoxy compound [45] gave a 40% cross-reaction. This data 
shows the importance of the alkyl ether bond in the antibody recognition, 
indicating that the propyl-O-ether portion of the cross linking group (carboxy- 
propoxy) is being recognised by the antibodies. These antibodies were not 
removed in the affinity purification step because the antigen used for the 
preparation of the affinity-column shared the same linking molecule as used for 
serum production see methods section chapter 3.
The only other analogues so far tested to give a reaction was the 1-methyl 
[54] which cross reacted to the extent of 30% and Diels hydrocarbon 1%. None of 
the steroids or hydrocarbons tested have given any cross-reaction. The high 
specificity of this serum towards the 11-methyl and its ethyloxy/propyloxy 
analogues makes it a valuable antibody for confirming the presence of the 11- 
methyl [60] (carcinogen) as opposed to the non-carcinogenic unsubstituted 
compound [14] or other positives identified when probing with the less specific D- 
ring linked sera is important and underlines the value of a panel of antibodies such 
as produced in this programme.
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Table 12
Standard Analyte 11-0-linked[D.61
11 -methyl-cpp-17-one[60] 1 0 0  (reference analyte)
cpp-17-one [14]
0.3
cpp-16,17-ene[ 191 1
Deils hydrocarbon [21 1
1-methyl-cpp-17-one [541 30
2-methyl-cpp-17-one [551 N
3-methyl-cpp-17-one [561 N
4-methyl-cpp-17-one [571 N
6-methyl-cpp-17-one [581 N
7-methy l-cpp-17-one [59] N
12-methyl-cpp-17-one [61] N
15-methoxy-cpp-17-one [201 N
2-hydroxy-cpp-17-one [39 1 N
3-hydroxy-cpp-17-one [401 N
16-hydroxy-cpp-17-one [211 N
Napthalenic cpp-17-one [291 N
3-methylcholanthrene [51 N
Oestrone [81 N
Oestradlol [91 N
Equilenin [71 N
Androstenedione [641 N
Benzo[alpyrene [671 N
Benzanthracene [681 N
General conclusions
The extensive programme of antigen design, synthesis, purification and 
characterisation has proved to be justified. All sera showed antibody activity 
toward the intended analyte antigen, showing differing degrees of selectivity 
toward structurally similar analytes.
Linker molecule effects.
The sera derived from carboxypropoxyl-Olinkage directly attached to the aromatic 
A or B rings of the cyclopenta[a[phenanthrenes proved to be very selective toward 
their target antigen. The 11-O-linked serum [D.6] demonstrated that significant 
recognition of the propoxy linker molecule was observed. This cross reactivity may 
be eliminated by further purification steps as described. This procedure should
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also be applied to the 3-O-linked serum [E.6] which could not be tested for this 
activity because the respective standard analytes were not available.
Other evidence for linker molecule directing effects was the detection of 3- 
methylcholanthrene [5] by the 17-linked serum [A.3], and the preferential detection 
of 17- sp2 carbon containing cyclopenta[a]phenanthrene analogues compared 
with their sp3 counterparts(i.e. hydroxyl), due largely to the sp2 nature of the linker 
molecule. The relatively low binding activity of the 16-keto-cpp [15](28% as 
opposed to 100% for the 17-keto-cpp) by 16-Olinked serum [B.5] and 15-keto-cpp 
[16] (24% as opposed to 100% for the 17-keto-cpp) by the 15-S-linked serum [C.5] 
in both cases the hapten was linked through an sp3 carbon targeting an analyte 
with an sp2 configuration at the linker position.
Linker molecule design is normally limited to generating an invisible spacing 
group which is physiologically stable and enhances visibility of the antigen to the 
immune system. Arguably where a linker molecule does not achieve the 
requirement of invisibility, the antibodies targeted to this bifunctional reagent can 
be removed by selective affinity column chromatography (using an alternative 
linker molecule to bind the antigen to an affinity column). Using this criteria for 
the removal of linker molecule effects, it should be possible to design linker 
molecules which are not invisible, but add defined structural features to the 
generated polyclonal serum. Features which can be removed or included by 
selective affinity purification of the resultant sera, using the same or a different 
bifunctional linker molecule to attach the primary antigen to the affinity column. For 
example if the antibodies recognising the compound 3-methyIcholanthrene[5] are 
different to the antibodies targeting the 15,16-dihydrocyclopenta[a]phenanthren- 
17-one[14] in the 17-N-linked serum; then with careful selection of the affinity 
linker molecule it should be possible to separate the respective antibodies to the 
former compound [5[ from the latter compound [14]. This has not been tested but 
in principle it should be possible. Such a scheme may result in better use of 
antigen presentation to generate more flexible sera. The use of computer aided 
chemistry may have predicted some of the activities observed and made such a 
design strategy possible.
General assay requirements.
Two criteria were essential requirements of the assay procedure:-
a.The assay should be practical for probing large numbers of samples.
b. That the assay should detect the biologically important members of the
cyclopenta[a]phenanthrene analogues described.
The panel of antibodies have met both criteria; the D-ring linked antibodies have 
shown good but flexible specificity toward a number of analogues including some
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other polyoyolio aromatic hydrocarbons of interest, whilst the direct ether aromatic 
ring linked sera have shown high selectivity toward the target antigens. It follows 
from this observation that to test large numbers of samples a single D-ring derived 
polyclonal serum (used because of their flexible response), such as the 17-N- 
linked serum could be used as the initial probe. Samples generating a positive 
response to this serum would be further probed with the rest of the panel to home 
in on the activity. Having identified a positive sample and selectively eliminated 
possible activities and suggested a structure, the sample should be subjected to 
chemical analysis such as mass spectroscopy to confirm the source of activity.
The data so far accrued has been obtained under ideal conditions and the 
conclusions so far presented have given an insight into the mechanics and 
potential of the assay. The critical outstanding question is how will this panel of 
antibodies and the proposed procedure behave in biological fluids such as blood 
or urine. Preliminary studies pertaining to this question are addressed in chapter 
5.
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Methods
Safety procedures for handling of carcinogens.
The substrate orthophenylenediamine and some of the hydrocarbons used 
in this study were proven carcinogens, whilst others remain untested, but have 
many of the characteristics of potential carcinogens. It was considered necessary 
to treat many of them as carcinogenic and take the relevant safety measures 
accordingly.
Disposable equipment used in the assays was soaked for three days in 
oxidising media (5% sodium hypochlorite) to destroy any carcinogenic activity prior 
to disposal. Reusable equipment was subjected to the same oxidation procedure, 
followed by soaking in the basic detergent Decon-90 for 3 days with daily changes 
of detergent, followed by an acetone and water wash.
Manipulation of carcinogenic substances and potentially contaminated 
equipment was carried out in a fume hood using absorbent paper lined trays to 
contain the hazardous material, disposable gloves were used in addition to the 
usual laboratory safety clothing. All gloves were changed each time an operation 
required handling items outside the tray to ensure that no carcinogen was 
transmitted to the laboratory by accident. Disposable items such as gloves tissues 
etc, were transferred to plastic bags and disposed of via the carcinogen waste 
system usually by incineration.
Preparation of saturated aqueous dioxan solutions of the polycyclic 
aromatic hydrocarbons and steroid compounds under investigation.
Between 10 and 20mg (or weight depending upon availability of the 
synthetic compound) were accurately weighed into a glass vial and dissolved in 
redistilled dioxan (lOmL). This solution was added dropwise to a rapidly stirred 
5%dioxan water (lOOmL)solution warmed to SO^c in a water bath and the stirred 
suspension maintained at this temperature for 1 hour. The suspension was left for 
a minimum of 1 week (often longer) to settle; centrifugation on this scale was 
considered too risky because of the potential carcinogenic activity of some of the 
compounds. Aliquots of each solution were monitored by UV spectroscopy to 
establish the equilibrium concentration, published or experimental molar 
absorptivity values were used to calculate the concentration of the respective 
compound. Table 13 show the final concentrations, and includes Molar absorption 
data and their references, and where molar absorbence values have been 
determined by experiment these are indicated.
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Calculation of Molar Absorbtivity (Extinction Coefficient).
Using Beer - Lambert law which relates the transmittance (Iq/I) of light 
through a sample of defined thickness and fixed concentration:-
Logio Oo/I) = kcb = A
lo= is the intensity of the radiation energy (light) striking the sample 
I = is the intensity of the radiation energy (light) emerging from the sample 
k = a constant characteristic of the solute 
c = concentration of solute 
b = path length through sample 
A = Absorbence or optical density 
when c is expressed in moles per litre A = Scb 
where S is known as the molar absorbtivity or extinction coefficient.
In these experiments quartz cells were used with a path length of 1cm therefore:-
A = Sc where b = 1 
8 is expressed as LogioS (Àmax).
Since cyclopenta[a]phenanthrenes show complex spectra containing many 
signals, the signal used for measurement of (A,max) is identified by brackets 
adjacent to the molar absorbtivity value. Some of the estimated concentrations 
were higher than expected; these compounds may have formed stable emulsions 
in dioxan water mixture, therefore showing deviations of optical density 
measurement from that expected if Beer Lamberts law was obeyed.
Table 13
Data used to calculate analyte concentrations
Structure Molar Absortivity used to 
calculate concentration 
(X,max in nm)(Solvent)
Opticai Density 
measurement (OD) 
(Xmax) (solvent)MW [ ]
Concentration in 
13% dioxan/water 
in nmole/mL
14
Log1 0  4.89(265)
(EtOH) (ref 114) 
Logic 4.94(264)
(Dioxan) ( by exp)
0.591 at
(265.9) in Dioxan 
MW [232]
7.61
15
Log10  4.77(258)
EtOH (ref 162) 
Logic 4.84(260.2)
Dioxan ( by exp)
1.16 at (259.5) 
MW [232] 16.6
16
Logic 4.58(251)
EtOH (ref 163) 
Logic 4.695(253.4)
Dioxan ( by exp)
0.52(252) 
MW [232] 10.5
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Logio 4.72(269)
EtOH (ref 163) 
Logic 4.737(270)
Dioxan ( bv exp)
2.304shoulder (270) 
h/IW[216] 42.2
oS® . .
Logic 4.77(259)
EtOH (ref 163) 0.190(258) 
MW [218]
3.22
Logic 4.80(259)
EtOH (ref 163) 2.842 
( 259.3) 
MW 232
45.04
06^ ° „
Logic4.736(260.9) 
Dioxan ( by exp) 2.808x2(dil) 
MW [246]
103
Logic 3.28(367)
EtOH (ref 163) 0.238(373.5) 
MW [230]
53.2
Logic 4.34(299)
EtOH (ref 163) 
Logic 4.18(294)
Dioxan (by exp)
2.161(291.2) 
MW [230]
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OCp^H.
Logic 5.022(267nm) 
EtOH (by exp) 2.340(270.3) 
MW [262]
22.3
a$^ °" .
Logic 4.95(265)
EtOH (ref 116) 1.759 x3(dil) 
(266.7)
MW [248]
59.2
ex?* ^
Logic 4.839(264.3) 
Dioxan (by exp) 1.097 (265.2) 
MW [246]
15.9
ox  ^ .
Logic 4.30 (229)
Log 1C 4.80 (256.5) 
both EtOH (ref 164)
0.63 (240) 
MW [260]
31.6
a .
Logic 4.13 (308)
EtOH (ref 164) 0.166 (306.3) 
MW [258]
12.3
c5*^  . , Logic5.319EtOH (ref 164) 0 .1 2MW [246] 0.574
0 $^ „
Log 1C 4.43 
(225),4.96(272),
(ref 164)
0.573 (231.8) 
MW [256]
7.6
(S'
Logic 4.137(296)
EtOH ( by exp) 1.133(298) 
MW [192]
82.6
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Logio 5.32 (267)
EtOH (ref 115) 0.45 (268) 
MW [260]
2.15
Logio 3.301(250)
EtOH (ref 165) 1.0(280) 
MW [272]
50
Logic 3.301 (250)
EtOH (ref 165a) 0.078(280) 
MW [270]
39
»
Logi 0  3.873(257)
(EtOH)
(ref 114)
0.68(260) 
MW [235]
91
Equilenin 7
Log 1 0  3.755 (281.7)
( by exp)
0.275(281.1) 
MW [264]
48.3
Logic 4.70(282)
EtOH (ref 115) 0.775(283) 
MW [234]
15.4
Logi 0 4 .5 5 (2 7 6 )
EtOH (ref 166) 2.344(277.7) 
MW [248]
32
Log 10  4.56(272), 
4.68(283), 3.29(327)
(ref 115)
1.119(275.5) 
MW [248]
15.0
x ï S ^  „
Logio4.7(283)
EtOH
(ref 115)
0.255(285) 
MW [248]
5.45
O
' 34
Logic 4.5 (276)
EtOH (ref 115) 0.714(277.8) 
MW [248]
10 .21
O
* 35
Log 10  4.5(276), 4.65 
(287) (ref 115) 0.708 (277.1) 
MW [248]
10.1
^  „
Log 1 0 4 .6 8  (282)EtOH 
(ref 115) 2.082(283.5)
MW[248]
25.0
„
Log io4.89(270)(ref115)
0.481 (273) 
MW[261]
6 .2
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a #  .
Logic 3.88(303)
EtOH (ref 114) 0.504(301.8)
MW[234]
53.4
Logio 4.74(274.5)
EtOH (ref 167) 0.126(274) 
MW [248]
2.3
Logi 0  4.807(278)
EtOH ( by exp) 0.82 X 5(278.60 
MW [248]
63.9
Logi 0 4.98(261)
EtOH (ref 124) 0.385(261) 
MW [248]
4.0
o x "  «
Logi 0 4.85(265)
EtOH (ref 167) 1.77(265)
MW[262]
25
„
Logi 0  4.86 (261)
EtOH (ref 163) 0.5 (262) 
MW [262]
6.9
CH 3  CH2  0
44
Logi 0  4.91 (261)
EtOH (ref 124) 0.909 
MW [276]
1 1 .2
C H 3(C H 2)20
0 3 T »
Logio 4.92 (262.5)
EtOH (ref 124) 0.772(264) 
MW [290]
9.28
^  «
Logio 4.91(264.5)
EtOH ( ref 30) 0.635 (265) 
MW [260]
7.81
1^  „
Log 10  4.76 (277)
EtOH (ref 166) 0.345 (280) 
MW [244]
8.74
Logio 4.83(262)
EtOH (ref 168) 2.63 (264) 
MW [384]
38.8
OAc 4 9
Logio 4.87 (263)
EtOH (ref116) 0.341 (266.1) 
MW [304]
3.6
0 ^
OCH 3  5 0
Logi 0  4.98(270)
EtOH (ref 115) 0.518 (272.5) 
MW [262]
5.4
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O Logio 4.81 (271)
EtOH (ref 167) 0.5 (262) 
MW [262]
6.9
0^.0^  .
Logic 4.78(269)
EtOH (ref 163) 0.145 (265) 
MW[262]
2.19
Logi 0  4.88(264)
EtOH (ref 116) 1.315 x3(dil) 
MW [262]
52
Logic 4.84(266),EtOH 
(ref 166) 0.523(264.5) 
MW [246]
5.6
X ( 9 ^  „
Log 1C 5.05 (267)
EtOH (ref 115) 0.174 (270.4) 
MW [246]
1.55
^  s.
Logic 5.02 (267)
EtOH (ref 115) 0.21 (267) 
MW [246]
2 .0
o
' 57
Log 1C 3.22 (352)
EtOH (ref 115) 0.09 (348.5) 
MW [246]
54.2
O
* 58
Log 1C 5.06 (266)
EtOH (ref 115) 0.4 (268.4) 
MW [246]
3.1
oS  ^ »
Log 1C 4.79 (268)
EtOH (ref 168) 0.52 (268) 
MW [246]
8.4
o 5 ^  „
Log 1C 4.83 (264)
EtOH (ref 115) 0.205 (265) 
MW [246]
3.03
Log 1C 4.85 (268)
EtOH (ref 163) 0.08 (266) 
MW [246]
1.13
„
Log 1C 4.76 (275)
EtOH (ref 166) 0.152 (270.6) 
MW[272]
2.64
„
Log 1C 4.88 (264)
EtOH (ref 114)
0.59 (272) 
MW [260]
7.7
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Androstenedione 64
Log 10 4.20(244)(ref 165b) 2.331 (246.9) 
MW [284]
146*
solution was 
prepared in 2 0 % 
dioxan/water.
OH Quantitative reduction of 
[14] with NaBH4  
Logi 0 4 .7 7 (2 5 9 ) EtOH.
2.179(257.6)
MW[233]
24.6
[D.5] 6 6
see page 19 and the loose 
structures sheet.
Log 1 0 5 .0 1 7 8 (2 6 3 ) 
EtOH (by exp)
0.114(263) 
MW [415]
1.094
o S ®  ,
chrysene
Log 1 0  5.25(275.4)
(ref 169)
1.78(275.4) 
MW 228
4.5
Benzo[a]pyrene
Log E 4.76(296) MeOH. 
(ref 170) 0.842(296.4)
MW[252]
14.6
Benz[a]anthracene 6 8
Log 10  4.682 (287.3) 
EtOH ( by exp) 0.155(287) 
MW [228]
3.22
See reference 177 MW[254]
3- methyicholanthrene
Log 1 0 3 .6 3 (3 2 7 ) 
Benzene (ref 9) 0.21 (322) 
MW[268]
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General Assay procedure for comparing potential antigens.
The plates were coated with antigen (200pL) dissolved in saline phosphate 
at a protein concentration of lOpg/mL, and left at room temperature for a minimum 
of Ihour. The excess antigen was removed using a titretech plate washer 
following a standard wash programme.
0.1%Polypep,0.1%tween 80 in saline phosphate (250pL) was added to 
each well and the solution was left at room temperature for Ihour (an excess of 
50pl of blocking agent was used over bound antigen solution, this was to ensure 
that capillary action up the sides of the plates does not cause non specific binding 
of antibody or antibody conjugate later in the procedure). After incubation with 
blocking buffer the wells were subject to a wash cycle.
General wash cycle.
Using a titretech plate washer the programme used for each wash cycle 
involved initial extraction of the solution from the wells by suction, followed by
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spraying the wash buffer saline phosphate (see chapter 3 for recipe) into each 
well. The extraction of wash buffer was repeated and fresh buffer added a 
process that was repeated for each well three times. At the end of each wash 
cycle a small amount of residual liquid was left in the wells; this was removed by 
inverting the plates over a sink and shaking the plates using a sharp wrist action.
After the wash cycle plates were manually shaken dry before sample was 
added. Sample (125pL, in the form of a saturated aqueous/dioxan solutions) was 
added in duplicate to wells A (see plate arrangement) containing 125pL of 
blocking buffer. To all other wells from B to H blocking buffer (200pL) was added; 
serial dilution in this example 1:5 was carried out. An aliquot of 50pL of solution 
from wells A was removed simultaneously by multiple pipette and added to wells B 
in the same order of collection, by withdrawing and pumping the pipette plunger 
three times, the buffer and sample were mixed in wells B.
General Plate arrangement.
Reference Sample 1 Sample 2 Sample 3 Sample 4 
analyte
o o o o o o o o o o o o
End wells left blank
A repeat sample was removed from wells B and added to wells C and the process 
repeated until wells H when the final 50pL collection sample was disposed of to 
maintain constant volume through out the wells. Immediately following the 
addition of sample, 50pL of serum containing the probe antibodies was added to 
each well and mixed.
These serum antibodies were prepared by dilution in blocking buffer 
solution at a dilution determined to give a good competition range for the choice 
internal standard, this concentration was established by experiment.
The reaction was left overnight at room temperature in a humidity box, 
although it has been demonstrated that competition was achieved within 2hours at 
room temperature.
The plates were washed and subjected to a colour development reaction to 
establish the concentration of bound antibody-antigen complex product. Two 
methods of colour development were used including the donkey anti-rabbit 
procedure described in the direct assay page (92) , chapter 3, and Biotin 
streptavidine p ro c e d u re 71 described here.
150
Biotin streptavidin procedure (Amersham International).
Attachment of small molecules such as biotin (MW244) to a primary 
antibody effectively increases the efficiency of the primary antibody to target the 
required antigen,when compared with conjugating the antibody with a large protein 
such as horseradish peroxidase used in the previous chemistries. The 
antigen/primary antibody complex are then treated with the streptavidin conjugate, 
a protein with high affinity toward the b io t in  1 7 2 . 1 7 3 ,  The streptavidin in our study 
is modified with horseradish peroxidase, but alternative or additional 
chromophores such as fluorescent or c h e m i lu m i n e s c e n t 1 7 4 , 1 7 5  probes could also 
be applied. The potential of the biotin streptavidin procedures as detection 
systems lie in the potential amplification of signal. This aspect of the study is not 
included in the thesis because due to a shortage of available time it was not 
investigated. Although it was considered necessary to gain some experience with 
this system as it clearly offered potential improvement in sensitivity. Both whole 
antibody-biotin and Fab-biotin conjugates were evaluated and found to give similar 
colour yields in our system. Whole antibody-biotin was chosen to work with.
20pL of whole antibody-biotin conjugate as supplied by Amersham was 
dissolved in lOOmL of polypep buffer. 200|liL of this solution was added to each 
well and the plate left in a humidity box at room temperature for Ihour, followed by 
the usual wash cycle. A second solution containing 20pL of horseradish 
peroxidase-streptavidin conjugate in lOOmL of polypep buffer was prepared, 
200|iL of this added per well and left in a humidity box at room temperature for 
Ihour, again followed by a standard wash cycle. The plates were treated with the 
usual OPD/H202 /citrate buffer followed by acid stop reaction and Titretech read 
out at 492nm as described in the direct assay methods section chapter 3. From 
the raw optical density data mean values were calculated and subjected to the 
data treatment described in the results section of this chapter.
Characterisation of 13,14,15,16-tetrahydrocyclopenta[a]phenanthren-17-one 
[38].
Figure 6
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Thin layer chromatography (using dichloromethane as the eluent) on the 
white crystalline solid [38] (analytical sample prepared by Coombs and Croft for 
the p a p e r" !  1 4  jn  1 9 6 6 )  revealed two spots, a minor spot at Rf 0 . 2 3  identified from 
the UV spectrum (see emboldened peaks)of the sample as compound [14] the 
expected air oxidation product, and also co-migrated with this spot when co-eluted 
together on the same tic system. The second much larger spot estimated to be 
approximately 9 0 %  plus, gave an Rf of 0 . 4 9  and the sample U.V was consistent 
with compound [38]:-
Sample U.V spectrum in dichloromethane:-
212.1 nm, 238.1 nm,263.5nm, 286.4nm, 301.1nm,316.4nm, 330.9nm,336.2nm 
Published U.V spectrum in EtORU^
239nm, 303nm, 316nm, 330nm, 336nm,
Samples were purified by streaking the sample along the origin line on a 20x20 
analytical plate and chromatographing in dichloromethane. The plate was scraped 
at the region containing the compound [38] spot (as indicated by shining U.V light 
254nm over the plate) and extracted with chloroform. The chloroform was 
evaporated under reduced pressure and the residue weight obtained. The purified 
compound was subjected to either Elisa competition assay or proton NMR.
Proton NMR studies
1 r  NMR using a Brucker ÔH (300MHz, CDCI3):- 
Ô8.15(1H,dH-1), 8.1-7.7 and 7.6-7.4 (5H, multiplets,aryl,H),7.35 (1H,d,H-11), 5.85 
(1 H,dd,H-12), 3.7-3.5 (6H,multiplet, H-13,-14,-15,and -16) ppm from 
tetramethylsilane. Figure 7 shows the proton NMR observed for the compound 
[38].
Analysis of spectrum
From the chemical shifts the Hi can be identified as the 8.15  ppm double doublet 
(coupled approximately 1 0H z at H 2 and approximately 1H z to H 3 ). H i 2 is 
probably the 5.81 ppm double doublet (J 11,12 approximately 10H z  ,J l2 ,1 3  
approximately 1.8Hz).
Irradiation of 8.15 ppm caused NOE at 7.35 ppm therefore confirming that 
7.35 ppm is H11.
Irradiation at 7 .35  ppm removes the 10H z coupling at 5.81 ppm confirming 
that H i2 is at 5.81.
Decoupling at 5.81 Hz results in the collapse of a doublet at 7 .35  confirming 
the 11,12 coupling, additionally a triplet at 3 .4 H z  collapses into a doublet and a
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doublet at approximately 3.9Hz collapses to a singlet with further 
coupling,suggesting that either of these signals could be H13.
Irradiation of 3 .4  ppm removed the 1 .8H z coupling at 5.81 ppm (H 12) 
indicating this to be the region occupied by the H 13 and J i2 ,1 3  =  1-8Hz. This 
evidence is complicated by the additional signals in this region making a more 
qualified assignment difficult to confirm by further NOE or decoupling experiments.
A chem- draw 3-D model of both the cis and trans version of compound 
[38] were drawn and subjected to energy minimisation. This revealed that:- (see 
table 14)
Table 14
Geometry of the bonds Bond anqles Coupling constants
trans H(13)— H(14) 1740 J approximates 9Hz
trans H(12)— Hf13) 108° J approximates 1Hz
cis H(13)— H(14) 70 J approximates 8Hz
cis Hf12)— H(13) 530 J approximates 3Hz
The J values were calculated from the Karplus equation. From The NMR 
spectrum only H(12) has been fully resolved. H(13) lies at either 3 .48  ppm or at 
3.9ppm. The close proximity of the carbonyl at the 17-carbon position and the 
double bond adjacent to the 13 position would suggest the H(13) proton lie in the 
higher field position; but decoupling experiments show that irradiation of the 3 .48  
results in the collapse of the 1.8H z coupling observed at 5.81 (H12). Confirmation 
that the H(12)— H (11) coupling (10H z) by decoupling experiments, implies that 
the H (13) proton is positioned at 3.48 ppm and that the coupling constant of 1 .8H z  
represents H(12)— H(13) coupling. If this reasoning is correct then the H(12)— 
H(13) dihedral angle is approximately 1 0 4 °  (from the Karplus equation) which is 
more closely associated with the trans H(12)-H(13) angle 1 0 8 °  suggesting this 
to be the correct configuration.
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Chapter 5
Preliminary studies using the assay on
biological fluids.
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Chapters 1 -4 dealt with the preparation of synthetic antigens, antibody 
production, followed by sera characterisation. A competition assay was 
defined and each of the sera were studied with regard to their specificity 
toward a large number of structurally similar compounds. The next stage in 
the programme was to investigate the behaviour of these sera in the presence 
of human biological fluids such as blood and urine.
Preliminary studies on human urine
Human urine was the most easily obtained source of biofluid and was 
readily available. A simple investigation was set up using both male and 
female urine supplied by normal and apparently healthy members of the 
chemistry department. Two urine samples one male and the other female 
were probed with non-purified BSA-17-N-antigen derived serum. The 
experiment included a 15,16-dihydrocyclopenta[a]phenanthren-17-one [14] 
spiked urine to act as a positive control in addition to the usual positive control 
compound [14] in dioxan /  water. Graph 1 illustrates the results:-
Graph 1
Probed with non-purified BSA-17-N-antigen derived serum.
0.44 -g
£ 0.42cCJO)TT 0.40
0.38i
S
0.36
"S.o
c
g2
0.34
0.32:
0.30 4
0.28-
Polypep only 
CPP/polypep 
Female urine/polypep 
Female urine+CPP+polypep
Male urine
Serial dilution measured for Cpp[14] in nmoles/mL
The cyclopenta[a]phenanthrene-17-one[14] concentration was 
corrected for volume in both sets of curves, to ensure that the positive control 
in urine and in dioxan water can be compared directly. The presence of male 
or female urine slightly enhanced the observed optical density readings
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compared with the polypep control. Neither the male or female urine showed 
any observable competition, unless spiked with cyclopenta[a]phenanthrene; 
and the profile of the spiked sample followed closely that of the dioxan/water 
standard analyte profile. These data suggested both the absence of this 
analyte and confirmed that urine containing the analyte gives the expected 
binding profile. The absence of binding was good evidence that the anti­
serum antibodies did not interact with other factors in the urine giving so 
called non-specific binding, a result that was a little surprising as non-purified 
serum was used as the probe. This led to the question, was it necessary to 
affinity-purify the anti-serum antibodies prior to their use as a probe.
In order to test this question and develop the program further a reliable 
source of human urine and blood samples were required. Preferentially from 
a larger population, including both genders of varying age groups and state 
of health. A collaboration was set up with Mr John. H. Davies, surgeon in the 
department of Urology at the Royal Surrey County Hospital, Guildford. Mr 
Davies arranged for urine and blood samples to be supplied to our laboratory 
from patients within his and other hospital wards, including out-patients, 
undergoing treatment for a variety of problems at the hospital. The primary 
purpose of these samples were to provide the hospital with important routine 
diagnostic information about each patient. The unused samples left after 
diagnostic tests had been completed were passed onto our laboratory with 
the following information:-
a. Urine:- Patient name, collection date and in some cases ward 
name.
b. Blood:- Patient name, date of collection and hospital number.
In order to retain the anonymity of the patients, a coding system was set up 
for the purpose of data presentation. Each patient was given a specific 
number with the letter M or F to define their gender. A record of the patients 
was held at the hospital and a record of the received samples along with their 
number code retained in the laboratory. Not all patients supplied both blood 
and urine samples, the blood samples received after diagnostic testing was 
usually of low volume sometimes as little as 200pL. This made it impossible 
to run a comparative assay study on blood and urine from the same patient 
using all of the antibody probes as described in chapter 4, our preliminary 
studies were therefore limited to two sera only.
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Choice of Anti-serum antibodies as probes.
It is important to define, preliminary experiments within the context of 
the general strategy envisaged. This proposes three steps:-
1. To assay a large number of human biofluid samples, using a 
single antibody probe which exhibits a more flexible binding response or 
specificity toward the target analogue. This may include some of the 
structurally similar (as far as the polyclonal antibody is concerned) biologically 
important molecules which are present in the samples.
2. To test the positives observed from serum A against the other 
four rabbit polyclonal antibodies raised and tested. To eliminate non-specific 
positives and to define more closely the nature of the observed binding.
3. Sample positives passing through the above strategy will then 
be either subjected to chemical analysis to resolve the origin of the activity. Or 
depending on the definition of the experimental requirements, be used to 
establish activity in defined populations.
With this programme in mind, as a general probe the D-ring linked sera 
were considered to be the preferred choice because of their more flexible 
response to a larger range of structurally similar compounds. Of the D-ring 
sera the most suitable candidate was the BSA-17- N-antigen derived serum. 
This showed an affinity not only to the biologically important 
cyclopenta[a]phenanthrenes i.e. [14],[60],[59] but also other important 
compounds such as benzo[a]pyrene[67] and 3-methylcholanthrene [5]; in 
general some of the important carcinogens were targeted.
The second serum of choice for the purposes of these experiments 
was the more specific 11-0 -ether derived serum which recognises only the 
11-methyl-cpp-17-one[60] and some 11-O-alkoxy-cpp-l 7-one analogues [44 ], 
[45 ]. A positive for both of these sera would imply (providing non-specific 
cross reactivity could confidently be eliminated) an 11-substituted 
cyclopenta[a[phenanthrene (probably 11-methyl-cpp-17-one [60]) and 
carcinogen.
Comparison of non-purified and purified sera.
The first question to be tested concerned the need to use an affinity- 
purified serum as the probe source; clearly the use of non-purified serum 
would be more cost effective if it were found to be reliable. The evidence of 
other studies suggest this possible scenario to be unlikely, but the inclusion 
of non-purified serum within this short study would give invaluable information 
concerning the type of non-specific cross-reactivities expected and indicate 
whether affinity-purification was sufficient to eliminate these effects.
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In all tables presented the failure to cross-react with the probe serum 
antibodies is represented by the letter “ N ” and the values given for a 
positive reaction were calculated using the procedure described in chapter 4 
pages (113-116). The cross-reactivity values are relative to the internal 
standard used; in the case of 17-N-linked serum this was 15,16- 
dihydrocyclopenta[a]phenanthren-17-one[14], and the 11-Olinked serum used 
11-methyl-15,16-dihydrocyclopenta[a]phenanthren-17-one [60]. The data is 
not intended to be a quantitation of cross-reactivity, only an indicator of the 
relative extent of urine/blood interaction with the probe sera.
Table 1 compares and contrasts the effect of probing urine samples 
with non-purified, affinity-purified polyclonal antibodies derived from BSA-17- 
N-antigen, and affinity-purified BSA-11-O-antigen derived antibodies.
Table 1
Human urine samples probed with 11-0-linked affinity-purified serum and a comparison of
Patient code 17-N-linked affinity-purified 
BSA incubated /serum
17-N-linked non-purified 
serum
11-0-linked affinity-purified 
BSA incubated/serum
3F 8 - 0.7
18M N N N
38M N - N
19M N 21 N
39M N - N
16M N - N
33M N N N
5 N - N
6M N - N
40M N - N
11M N - N
7M 2 7 N
36M - N N
1M N 4 N
31F 0.5 - N
9M 2 - -
14 N - -
4M N N -
Baby 10 N - -
12F 2 N -
22F N N -
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8M N 3 -
2M 2 34 -
13F N 7 -
34M 938 - -
37M N N -
30 N - -
15M N - N
17M N N N
2GM N N N
21F N - N
24M N - N
23F N - N
25F N - -
27M 4 - -
35M N - -
29M N - -
32F 9 19 -
28M N - -
42M N - -
41M 12 - -
Pregnancy
urine
N - -
26F N - -
44M N - -
Some urine samples were not labelled with patient name or their sex, these were included in the study 
and were given numbers only.
Data from table 1 Indicates that some cross reaction with urine was 
observed with non-purified serum and that affinity purification combined with 
BSA incubation of the antibody containing serum significantly reduced this 
effect. Up to 40% of the urine samples probed with 17-N-linked non-purified 
serum gave a positive reaction, being reduced to 23% after affinity 
purification. Of the affinity-purified positives only two samples gave activity in 
excess of 10% binding. This cross-reaction for the non-purified serum was 
suggestive of protein-antibody interaction. Protein is normally only found in 
patients suffering from specific disease states such as diabetes, where it is a 
diagnostic marker, or when the patient has suffered relevant physical 
damage. Therefore protein assay is a standard routine diagnostic test carried 
out on all urine received by the hospital; neither of the two patients with
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positive reaction to probe serum were reported to have protein in their urine. 
Graph 2 shows a profile of three patients probed with non-purified BSA-17-N- 
serum.
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Graph 2
Human urine samples probed with non-purified BSA-17-N-antigen 
derived rabbit polyclonal antibodies.
Cpp-17-one (+ve control) 
Patient 3 urine
Patient 4 urine
Patient 2 urine(34%cross reaction) 
No anaiyte(-ve control)
0 .9 -
0.8
Concentration of Cpp-17-one in nmoles / ml
Patients 3 and 4 gave no observed cross-reaction with the 17-N-linked serum, 
but patient 2 showed a significant cross-reactivity compared with the internal 
standard cpp-17-one[14] of 34%. Graph 3 illustrates the reduction of binding 
activity for patient 2 from 34% to 2.25% as a result of affinity purification and 
BSA incubation of the probe antibody serum.
None of the urine samples probed with affinity-purified /BSA incubated, 
11-0-linked serum were found to be positive. This indicates that the low 
background activities of the equivalent 17-N-linked serum may have some 
significance. One of the urine samples patient 34M gave a very high cross 
reaction, this will be discussed later in more detail.
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Graph 3
Human urine probed with affinity-purified BSA-17-N-derived 
serum after incubation with 0.1%BSA
I I I I  I TTT|I I I 11 I I I
■—  Patient 2 (2.25%cross-reaction) 
Cpp-17-one[14] 
Patient 8 
Patient 13
50% standard analyte
10 " 10" 10 ' 10 
Concentration of Cpp-17-one[14] in nmole/mL
Probing human blood samples.
Table 2 shows that probing human blood with non-purified 17-N-linked 
antibodies is not a possibility and indicates that up 90% of the blood sera 
probed, yielded very high cross-reactions compared with the internal analyte 
[14]. Graph 4 shows a typical profile observed when probed with non-purified 
17-N-linked serum.
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Graph 4
Human blood samples probed with non-purified 17-oxime-BSA 
derived rabbit polyclonal antibodies, typical profile.
ve control (no analyte) 
Cpp-17-one internal standard
 # —  Patient 26
Patient 27 
Patient 1
I 11II11
Cone of Cpp-17-one in nmoles/ml
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Affinity purification of the antibodies on a controlled pore glass column 
(as described in the general procedure chapter 3) using Oval-17-N-conjugate 
as the affinity column antigen, resulted in substantial loss of cross reactivity.
Additionally incubation of non-purified probe antibodies with 0.1%BSA 
for between 30 minutes and Ihour prior to assay application also showed a 
substantial reduction in binding activity. It was decided to combine affinity 
purification and incubation with 0.1%BSA in the final assay procedure; graph 
5 shows a typical profile of human blood sera after probing with antibody 
serum treated this way. The final protocol used in these experiments involving 
the incubation of affinity-purified antibodies with 0.1%BSA is presented in the 
methods section.
Both modes of cross-reactivity correction, are indicative of rabbit 
antibodies targeted to the BSA carrier protein epitopes contained in the 
polyclonal sera. Although human sera does not contain bovine serum 
albumin, human serum albumins share an 84% amino acid sequence 
homology with this protein. It is therefore not surprising that some cross 
reaction was observed.
Table 2
Human blood samples probed with 17-N-linked sera showing the effect of affinity purification
Patient 17-N-linked affinity-purified /BSA incubated 17-N-linked non-purified serum
Code serum
36M N 2500
1M N 3103
31F N 1500
33M - 3571
18M - N
19M - 1200
38M - N
39M - N
14 N 1714
13F - 600
34M - 3214
37M - 2500
35M - 2143
41M - 2000
26F - 3103
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Graph 5
Human blood probed with affinity-purified BSA-17-N-antigen 
derived antibodies after incubation with 0.1% BSA solution
Cpp[14] (+ve control) 
Patient 36
1.2 1
£
a
? Patient 11.0
■(5
Patient 31Î0)■D
8
0.9
No analyte (-ve control)0.8
0.7 50% standard analyte line
0.6 “
0 .5 -
0.4 -
0.3
Concentration of cpp[14] in nmole/mL
Affinity purification and BSA incubation is not the complete answer to 
the problem of cross reaction; as a sample of rat plasma probed with
0.1%BSA incubated with non-purified BSA-17-N-antigen derived serum, and 
a second sample probed with affinity-purified polyclonal antibodies gave a 
substantial positive result even though in both experiments a poor positive 
control was observed. This experiment was not repeated (due to the 
shortage of time), and the data was not included in the thesis, this 
inconclusive result suggested that any positives observed should be assigned 
with care; it was decided that interpretation of blood positive data should be 
considered with some caution, bearing in mind the intensity of the non­
specific cross-reactions observed.
In conclusion non-purified sera can not be used to probe human biofluids.
Result of the urine positive samples.
Table 1 outlines the result of assaying a total of 21 urine samples with 
the BSA-11-O-antigen derived serum and 44 samples with the 17-N-linked 
serum. A comparison of non-purified and combined BSA/affinity-purified 
serum shows a significant loss of non-specific cross-reaction but residual 
activity of about 2-3% cross-reactivity was still observed. To allow for this 
background a cut off needed to be imposed, an arbitrary value of 10% cross­
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reactivity was chosen as this would cover the possible reactivities so far 
observed in this study; although a larger population of samples may require a 
more stringent allowance for non-specific effects.
Of the 21 urine samples probed with the 11-Olinked serum only one 
showed cross-reactivity Patient 3 female 0.7%, this particular patient also 
exhibited a limited cross-reactivity with the BSA-17-N-antigen derived serum. 
The relative cross-reactivities for both sera were below the arbitrary cross­
reactivity threshold and was considered to be non-specific in character.
Of the 44 urine samples probed with the BSA-17-N-antigen derived 
serum, 10 samples showed some reaction with the probe; the positives 
included 8 which were below the arbitrary cut off point of 10% cross-reactivity 
and two exceeded this value. Sample 41, a male patient, gave a 12% cross­
reactivity, a marginally positive result using the 10% threshold criteria. Patient 
34 (male) gave an activity of 938% cross-reactivity, which required further 
investigation.
Patient 34 urine samples.
The presence of protein in the urine was not reported for patient 34, 
and he was not a smoker so it is unlikely that any activity would be a result of 
smoke inhalation other than passive contact. If the activity were the function 
of a cyclopenta[a]phenanthrene or other polycyclic aromatic hydrocarbon (or 
their respective metabolites"!), extraction with an organic solvent would result 
in this activity migrating to the organic layer; protein or strongly hydrophilic 
molecules will not be soluble in the right choice of organic solvent.
The urine was extracted with ethyl acetate. Both polycyclic aromatic 
hydrocarbon or cyclopenta[a]phenanthrenes would be expected migrate into 
the ethyl acetate fraction. Extraction resulted in the ethyl acetate extract 
retaining significant activity see graph 6.
This graph shows a deviation from the linear at one point from within 
the linear range of each curve, the data can therefore be treated in two 
ways:-
1. direct-read out of the curves not correcting for the deviation 
from the linear.
2. extrapolate the points around the deviation to give a best fit 
linear curve.
Graph 6 illustrates the data for both methods and both procedures are 
considered.
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Graph 6
Comparison of titre for patient 34M urine before and after EtOAc extraction, 
probed with BSA-17-N-antigen derived serum
1.2-3
E ' - ' I
I :
15 to i
:
1 :
^  0.9 i
2 :
50% standard analyte line
cpp-17-one[14]
original urine 
EtOAc extract
-ve control0 .8 1
0.7
Concentration of Cpp-17-one[14] in nmole/mL
from this graph the original urine gave a cross-reaction of
data treatment method 1 data treatment method 2
original urine 1000% original urine 571%
EtOAc extract 516% EtOAc extract 516%
In an attempt to quantify these cross-reactions in order to understand the 
distribution of activity more clearly the data was corrected for volume. The 
ethyl acetate fraction gives the same value which ever data treatment is used 
because the 50% analyte line cuts through one of the points of the EtOAc 
curve. -
data treatment method 1 
original urine:-
1000. (15mL70.100mL) =150000
data treatment method 2 
original urine:-
571 . (15mL70.100mL) = 85650
EtOAc extract:-
516 . (1mU0.025mL) = 20640
EtOAc extract:-
516 . (1ml70.025mL) = 20640
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The proportion of activity extracted into the ethyl acetate was
data treatment method 1 data treatment method 2
(20640/150000). 100= 13.8% (20640/85650). 100 = 24%
This transfer to the ethyl acetate fraction is indicative of the presence 
of a small molecule (unlikely that a protein would be soluble in ethyl acetate), 
but the relative efficiency of extraction of 14% and 24% for the two data 
treatments 1 and 2 respectively, is lower than would have been expected if 
the antigenic molecule were a polycyclic aromatic hydrocarbon or cyclopenta- 
[ajphenanthrene. Assuming the ethyl acetate extractable antigen is the same 
as the antigen left in the aqueous layer, which may not be the case.
Patient 34 was a permanent resident at a mental hospital in Surrey and 
regularly attended the Royal Surrey hospital department of urology for routine 
unblocking of his urinal tract. The patient was asked to supply urine samples 
over a period of time at his residence. Approximately two litres of urine was 
supplied. This was extracted with ethyl acetate and analysed for activity 
using the ELISA competition assay. Unfortunately only the ethyl acetate 
fraction was analysed for activity. It is therefore only possible to compare the 
ethyl acetate extracts and not the total ELISA activity of the original urine 
sample.
Graph 7
Patient 34M bulk sample EtOAc extract,probed with 
BSA-17-N-antigen derived serum
0.4 n
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No analyte (-ve control) 
Cpp-17-one[14] (+ve control) 
Patient 34M EtoAc extract
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0.2 -
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Concentration of Cpp-17-one[14] in nmole/mL
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A better profile was observed for this sample. As described in the 
methods section the ethyl acetate fraction was evaporated to dryness and 
redissolved in methanol (lOmL) therefore a 0.125mL aliquot of this methanolic 
solution gave an ELISA activity of 25% this represents:-
2 5 .(1 0 /0 .1 2 5 ) = 2000 total ethyl acetate extract activity.
Which compares with value of 20,640 for the previous urine sample 
analysed after correction for volume. This means that the bulk sample activity 
is reduced by
(2000/20640). 100 = 9.7% over the primary urine sample collected.
This preliminary data confirms the presence of one or more substances 
capable of binding to BSA-17-N-antigen derived antibodies and which are 
sufficiently hydrophobic in nature to allow extraction into ethyl acetate. It can 
not be assumed that the activity left in the aqueous layer of the former sample 
is the same as extracted as only the organic soluble fraction has been 
analysed in the bulk sample. It is difficult to compare and contrast the two 
urine samples with confidence, this reduction in antigenic-activity to 
approximately 10% for the bulk sample, collected at his home of residence, 
compared with the antigenic-activity of the single sample collected whilst at 
the Royal Surrey County hospital prior to a urinal tract operation, is 
significant. It may reflect a difference in the care regime i.e. diet, drug regime, 
time of sample collection. It may be a function of the problem causing the 
urinal blockage.
What is clear is that the activity is persistent in this patient; but it is not 
consistent with an aberrant metabolism, as one would expect a continuous 
build up of the analyte causing antigenic activity with urine collections giving 
an accentuated bulk sample activity.
Further work on patient 34 required.
In order to understand the relative activity distribution in both samples 
it is necessary to assay the original bulk urine and the aqueous extract left 
after ethyl acetate extraction.
The ethyl acetate extract should be chromatographed on a preparative 
scale and fractions collected. All fractions including regions between UV 
detectable peaks should be kept and analysed using the competitive Elisa 
assay with all five sera. This will confirm the active fraction and indicate a 
possible range of potential analyte structures responsible ( by comparison of 
the relative activities observed in chapter 4) for the activity.
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The fraction responsible for the biological activity will finally subjected to 
chemical analysis; Mass spectrometry, possible U.V spectra and if sufficient 
material is present Hn m R and F.T.I.R spectroscopy. Unfortunately insufficient 
time was available to carry out this methodical study.
Whilst at the Imperial Cancer Research Fund at Lincoln’s Inn Fields, I 
was able to separate an analytical sample of the methanolic (ethyl 
extract)solution on a Waters 994 analytical H.P.L.C with a diode array 
detector, using a 0-18 microbore analytical column. This was worth 
undertaking because it enabled a UV spectrum to be generated for each 
measurable peak. Inspection of the chromatogram see figure 1 shows that 
peak 12 fraction 29 has a spectrum Im ax 263, 281, 294nm which could be a 
spectrum of a cyclopenta[a]phenanthrene analogue but the quality of the 
spectrum was not good enough to identify it with confidence.
2 0 0
W a v e l e n g t h  2 0  0 ------ 3 6  0 nm
3 0 0
Figure 1
Conclusion.
In conclusion the preliminary aim of this study was to identify 
cyclopenta[a]phenanthrenes with special reference to the biologically active 
molecules showing carcinogenic behaviour in human urine or blood. The 
presence of a carcinogenic cyclopenta[a]phenanthrene or a carcinogenic 
polyaromatic hydrocarbon known to cross react with our antibodies i.e. 11 - 
methyl-15,16-dihydrocyclopenta[a]phenanthren-17-one[60],7-methyl-15,16- 
dihydro-cyclopenta[a]phenanthren-17-one, 3-methylcholanthrene [59] or 
benzo[a]pyrene [67] would imply the potential initiation of a cancerous event. 
Such a finding would require further testing of the subject to establish
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persistence of the carcinogen accompanied with a complete medical check up 
to diagnose the presence of cancer. As a cancer screen this type of assay is 
potentially very practical.
This work has defined the primary requirements of an assay and 
addressed some of the problems encountered when applied to biological 
samples. The activity observed for a specific patient was investigated with 
out conclusion largely due to the shortage of available time.
For the assay to be used routinely for bulk sampling two problems 
need to be addressed these are:-
1. Bulk antisera needs to be generated and purified. This requires 
the inoculation of larger animals such as goats, sheep or cattle for antibody 
production.
2. To remove non-specific cross-reactivities it would be better to 
use a completely different species of carrier protein to present the hapten to 
the host animal immune system, such as limpet haemocyanin. This 
combined with the use of ovalbumin as the carrier for bound antigen and 
other procedures described, may achieve a non-specific cross reaction free 
assay.
3. Definition of the background activity threshold needs to be 
established by investigating a larger number of samples and subjecting the 
data to methodical statistical analysis.
4. The recent development of a computer programme and 
interfacing package between the spectrophotometer which allows a print out 
of data, calculation and graph plot of the results, makes the computation of 
data a great deal more e f f ic ie n t " !^6_ This programme would need to be 
extended further to accommodate the statistics necessary for a multiple assay 
strategy.
5. Total automation of the assay using commercially available 
robotics as a means of achieving large numbers of reproducible data at the 
minimum cost would be an essential requirement and the computer 
programme discussed in item 4 should be designed to meet this requirement.
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Methods
O.D. represents mean optical density and all values inserted into the following 
tables represent the mean optical density of a duplicate sample.
Data for Graph 1
A plate was set up containing male and female urine samples, with the 
following controls;
1. cpp-17-one[14], polypep buffer, ratio 1:1 (+ve control)
2. Female urine,polypep buffer (ratio 1:1)
3. Female urine, polypep buffer and cpp-17-one[14] (ratio of 1:1:1)
4. Polypep buffer only
5. Male urine, polypep buffer, ratio 1:1
The antibody probe used was non-purified 17-N-antigen derived serum
[9.25(6) ] at a dilution of 1/10,000 at 50pL per well, following a 1/5 dilution in
the direction of A to H in the usual way, with each well containing lOpg/mL 
protein Oval-17-N-conjugate as the bound antigen. Graph 1, table 3 illustrates 
the results. Goat anti-rabbit horseradish-peroxidase was used for 
development of colour in this assay
Table 3
No antigen 
Polypep O.D
Cpp[14]
nmole/mL
Cpp[14]
O.D.
Female urine + 
Cppf141 nmole/mL
Female urine + Cpp 
[141 O.D.
Female 
urine O.D
Male urine 
O.D
0.380 0.76000 0.293 0.50700 0.302 0.381 0.425
0.361 0.15200 0.314 0.10140 0.327 0.366 0.398
0.375 0.03000 0.348 0.02028 0.385 0.393 0.395
0.356 0.00600 0.372 0.00406 0.399 0.396 0.387
0.367 0.00120 0.364 0.00081 0.413 0.387 0.393
0.365 0.00024 0.369 0.00016 0.395 0.403 0.394
The urine samples were plotted against the cyclopenta[a]phenanthrene [14] 
spiked urine concentration, and the standard analyte mixture was plotted 
against the well containing its own optical density (column 3) and the well 
containing no antigen(well 1). In this way it was possible to compare the 
response of cpp-17-one [14] in the presence of urine with the standard 
analyte preparation directly.
Final Protocol.
Combined use of :-
1. affinity purification and
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2. incubation of the antibody with 0.1%BSA 
solution in the assay reduced the cross reactivity observed for patient 2 to 
3% only as indicated by graph 5. As both incubation with 0.1% BSA and 
affinity purification were individually successful in reducing cross reactivities 
both in urine and blood, both methods were combined and included within the 
assay protocol. The final protocol is presented below.
1. Loading antigen;
Ovalbumin-Cpp antigen is dissolved in saline 
phosphate buffer at a concentration of lOpg protein /  mL. The solution 250pL 
per well was loaded onto the 96 well plate using multichannel micropipette, 
and left covered in a sandwich box at room temperature for Ihr, and washed.
2. Blocking;
0.1% polypep/tween 80 buffer 300pL /well was added to 
all wells and the plates left at room temperature for Ihour as described and 
washed.
3. Preparation of polyclonal antibody solution;
Affinity rabbit antibody serum was dissolved in 0.1% BSA 
phosphate buffer at the required dilution for at least Ihour prior to plate 
application and left at room temperature.
4. Serum incubation; (using 1:5 dilution per well as the example.)
a. To all wells in the A row were added the duplicate range 
of sample analytes at the initial concentration, including the internal standard, 
each well containing 250pL total volume.
b. To all wells in rows B to H are added 200pL of 
polypep/tween 80 blocking buffer.
c. Using the multichannel micropipettes 50pL aliquots from 
wells A are withdrawn and pumped into to the wells B in the same column 
arrangement from which the initial sample is collected. The added samples 
are thoroughly mixed by a withdrawal and pumping action of the 
micropipette(3 x). After this action was complete a 50 pL aliquot was removed 
from wells B and added to all wells C and the process repeated through to 
wells H. At wells H after the mixing action was complete a 50pL aliquot was 
removed and disposed of to maintain constant volume through out the plate.
d. To all rows of wells from A to H are added a 50pL aliquot 
of the 0.1%BSA affinity-purified antibody described in 3 of this protocol. Each 
multiwell addition is followed by the mixing procedure described in 4c, after 
the addition is complete the plate is covered and incubated at room
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temperature in a humidity chamber(sandwich box) for Ihour. Followed by a 
wash cycle.
5. Development of colour reaction;
a. 20pL of biotinylated donkey IgG (Amersham  
International) was dissolved in lOOmL of 0.1% polypep/tween 80 phosphate 
saline buffer.
b. 200pL of solution (a.) is added to all wells from rows A to 
H. and the plates covered and left at room temperature in an incubator for 
Ihour. Followed by the usual wash cycle.
c. 20mL of streptavidin modified with horseradish 
peroxidase (Amersham International) was dissolved in lOOmL of 
0.1%polypep/tween 80 saline phosphate buffer.
d. 200pL of solution (c.) is added to all wells from rows A to 
H and the plate incubated in the usual way, for Ihour at room temperature; 
followed by the usual wash cycle.
6. Substrate buffer was prepared and used as described in chapter 3 
and the plates read at 492nm using the Titertek as described.
7. All wash cycles were identical and as described in chapter 4.
Data for Graph 2
The antibody probe used was non-purified 17-N-antigen derived serum 
[9.25(6) ] at a dilution of 1/10,000 at 50pL per well, following a 1:3 dilution in 
the direction of A to H in the usual way, using an initial dilution of 1/3 of 
standard analyte in polypep buffer; with each well containing lOpg/mL protein 
Oval-17-N-conjugate as the bound antigen. Graph 2, table 4 illustrates the 
results(end well data omitted).
Table 4
Cpp[14]conc
nmole/mL
Cpp[14]0.D. Patient 3 urine Patient 4 urine Patient 2 urine No Analyte
0.08500 0.868 0.989 1.044 0.835 1.071
0.02833 0.908 1.065 1.038 0.931 1.091
0.00944 0.930 1.061 1.047 1.021 1.071
0.00315 0.999 1.084 1.098 1.061 1.117
0.00105 0.998 1.043 1.067 1.045 1.065
0.00035 1.021 1.081 1.094 1.088 1.070
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Data for graph 3
The final protocol was applied to these samples using a 1 : 3 dilution per well 
starting with 1/3 dilution of standard analyte in polypep a applying a serial 
dilution.
Table 5
Cpp[14]
concentration
Cpp [14] O.D Patient 8M Patient 2M Patient13F
0.761 0.321 0.738 0.484 0.769
0.254 0.318 0.747 0.627 0.730
0.085 0.347 0.749 0.739 0.789
0.028 0.441 0.881 0.787 0.831
0.009 0.549 0.836 0.851 0.918
0.003 0.645 0.878 0.860 0.852
0.001 0.707 0.821 0.789 0.835
Data for graph 4 .
The antibody probe used was non-purified 17-N-antigen derived serum 
[9.25(6) ] at a dilution of 1/10,000 at 50pL per well, following a 1/3 dilution in 
the direction of A to H in the usual way, with each well containing lOpg/mL 
protein Oval-17-N-conjugate as the bound antigen. Using biotin horseradish 
peroxidase detection system described in the general procedure.
Table 6
Cpp[14]conc
nmole/mL
Cpp[14]0.D. Patient 26 Patient 1 Patient 27 No antigen
0.08567 0.718 0.712 0.632 0.613 0.968
0.02822 0.774 0.494 0.527 0.511 0.951
0.00941 0.829 0.497 0.494 0.451 0.956
0.00314 0.880 0.671 0.632 0.684 0.925
0.00105 0.907 0.759 0.743 0.796 0.966
0.00035 0.915 0.806 0.816 0.837 0.971
0.00012 0.935 0.918 0.905 0.882 0.960
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Data for graph 5
The final protocol was applied to these samples using a 1 : 3 dilution per well 
starting with 1/3 dilution of standard analyte in polypep a applying a serial 
dilution.
Ta ble7
Cpp[14l cone CppFHlO.D Patient 36 Patient 1 Patient 31 No analyte
0.084500 0.405 0.793 0.786 0.799 0.907
0.028200 0.518 0.823 0.788 0.811 0.958
0.009390 0.647 0.793 0.794 0.847 1.008
0.003131 0.750 0.901 0.889 0.907 1.015
0.001044 0.894 0.952 0.973 0.962 1.041
0.000348 0.954 1.124 1.068 1.083 1.145
Extraction of first urine sample with ethyl acetate.
Urine (15mL) was extracted with 3 x 20mL of ethyl acetate and the combined 
organic fractions were evaporated to dryness and dissolved in Im L of 
methanol. The initial volume of this methanolic solution used for the assay 
was 25|LiL( lower volume was used to reduce the effect of methanol on the 
antibody activity) made up to 300pL, followed by a 1 in 3 dilution per well, 
where as the initial urine used lOOpL diluted to 300pL followed by 1 in 3 
dilution per well.
Table 8
Cpp[14] cone 
nmole/mL
Cpp[14]O.D. Patient 34M 
original urine
Patient 34M 
EtOAc extract
No analyte
0.084 0.946 0.772 0.838 1.070
0.024 0.997 0.845 0.910 1.075
0.009 1.051 0.952 1.022 1.100
0.003 1.067 0.931 1.026 1.096
0.001 1.103 1.081 1.080 1.079
Extraction and assay of the bulk urine sample
The urine was subjected to ethyl acetate extraction (3 x approximately 500mL 
aliquots) and the combined washings (1600mL) were evaporated to dryness 
and gave a residue weight of 0.45g. This was dissolved in lOmL of methanol 
and an assay was run on this methanolic solution; the results are illustrated 
in graph 7.
175
An initial dilution of 125|llL methanolic urine solution and 125|iL 
polypep/Tween 80 buffer followed by a 1 in 5 serial dilution per well arranged 
from wells A too H on a standard 96well plate. The standard protocol was 
used for this assay.
Table 9
Cpp[14] cone 
nmole/mL
Cpp[14]0.D Patient 34 EtoAc 
extracted urine
No analyte
3.805 0.158 0.156 0.327
0.761000 0.149 0.175 0.295
0.152200 0.180 0.214 0.321
0.030440 0.235 0.274 0.331
0.006088 0.269 0.318 0.368
0.001218 0.304 0.327 0.346
0.000244 0.334 0.313 0.339
0.000049 0.347 0.323 0.357
HPLC analysis of patient 34M bulk sample ethyl acatate extract.
The analytical sample was chromatographed using the following conditions:- 
The methanolic urine(0.1mL diluted to ImL final volume in methanol) 
was injected (50pL) onto a C-18 microbore analytical HPLC column and the 
eluents were detected with a diode array U.V detector which was set to 
measure and produce spectra for any peak showing adsorption at 
220nm(used for protein analysis), this should include many of the simple and 
complex aromatic compounds present. A water to methanol linear gradient 
from 5% methanol to 100% methanol over 80mins,with a column oven 
temperature controlled at 50^0,1 minute fractions were collected throughout 
the chromatography and kept back whether peaks were observed or not. The 
following chromatogram see figure 1, and the respective U.Vspectra were 
obtained.
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Two affinity-purified anti-sera raised against 15,16-dihydrocyclopenta[a]phenanthren-17-one, linked 
through 5 -6  atom-long chains at C-11 or C-17 to bovine serum albumin, were employed in  a competitive 
ELISA assay to search for cyclopenta[a]phenanthrenes in human urine. Having carefully eliminated recog­
nition o f human serum albumin (which shares 84% amino acid homology w ith BSA), one o f these sera gave 
positive results w ith 10 out o f 46 urine samples collected from general hospital patients. The urine that gave 
the strongest response was extracted exhaustively w ith ethyl acetate and positive ELISA activity could be 
demonstrated in the extract. While these preliminary results are interesting and encouraging much needs to 
be done before we can say that cyclopenta[a]phenanthrenes do indeed occur in  humans.
Keywords: cyclopenta[a]phenanthrenes, immunochemical detection, ELISA assay, human urine.
IN T R O D U C T IO N
Cyclopenta[a]phenanthrenes (cpps) are polycyclic aromatic compounds with the 
same carbon ring skeleton as steroids. Diels’ hydrocarbon (1), isolated as a dehydro­
genation product o f cholesterol,* played an important role in the elucidation o f 
the structures o f bile acids and sterols sharing the same ring structure over 50 
years ago. Besides numerous reports o f its occurrence among products o f the 
incomplete combustion o f plant materials it is now known that this and related 
hydrocarbons occur naturally in mineral oils^ and river and lake sediments,^ as 
well as in overheated cooking oils'* where they are probably also derived from plant 
sterols.
Extended studies by us  ^ and earlier pioneering investigations by Butenandt and 
Dannenberg^ have demonstrated that methyl and certain other substituents at C-7 
and especially C-11 endow cpps with varying degrees o f carcinogenicity. Thus o f 
all the methyl homologues o f the parent 17-ketone (2), the 11-methyl-17-ketone (3) 
is more active than benzo[a]pyrene on mouse skin, the 7-methyl isomer is less 
active, but the 7,11-dimethyl homologue is the most carcinogenic cpp studied to 
date.^ The 11-ethyl-17-ketone is also less active than (3) and further extension o f 
the alkyl chain abolishes carcinogenic potential. Both the 11-methoxy- and the 
11-ethoxy-17-ketones are moderately potent carcinogens.
Interest in cpps was renewed with the demonstration o f the presence o f 18- 
hydroxyoestrone (4) in human pregnancy urine,^ because 18-hydroxylation causes the 
angular methyl group to be lost from (4) at slightly acid or alkaline p H  giving 18- 
noroestrone (5). In  equine animals the main oestrogen is equilenin (6); should loss o f 
the methyl group occur from this naphthoic oestrogen, the 18-nor derivative could 
yield the cpp (7) by further dehydrogenation (Figure 1).^ I t  is o f course at present 
unknown whether this or alternative metabolic or biosynthetic routes to cpps can
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FIG U R E  1 Compounds mentioned in the text.
occur in vivo, and especially whether this might be associated with any particular 
disease state. The aim o f the present work is therefore to develop a sensitive assay 
capable o f answering the question “ do cpps exist in animals or man?” .
In  other communications^®’** we describe in detail the production o f five polyclonal 
antibody sera directed against cpps attached to bovine serum albumin via 5 -6  atom- 
long linker arms at various points on their periphery. The reason for this approach is 
the expectation that these sera would recognise various parts o f the cpp structure and 
hence afford a flexible method o f searching for compounds o f this class in the aqueous 
environment o f animal tissues and body fluids. Also detailed is their selectivity for 
some fifty synthetic cpps as well as various chrysenes and other polycyclic aromatic 
hydrocarbons and assorted natural steroids. In  the present communication we 
describe the competitive E L IS A  assay used, and as an illustration o f the scope o f 
this test display a representative sample o f these results. Preliminary findings from  
a pilot study with human urine from a series o f 46 general hospital patients is also 
reported.
MATERIAL AND METHODS
The two anti-sera used in the present work were raised against the 11-ether acid (8) 
and the 17-oxime acid (9) (Figure 2) covalently bound to BSA via amide links.** 
Both were affinity purified by passage down glutaraldehyde activated controlled- 
pore glass columns modified with the respective hapten linked covalently to 
ovalbumin.*® The affinity purified antibodies were eluted with dilute acid which 
was immediately neutralised with saturated sodium hydrogen carbonate solution, 
and then dialysed against saline phosphate buffer (solution A , below). Sera dilutions 
necessary in the E L IS A  assay were established by preliminary trials.
HOgClCHglaO, N.O.CH2CO2H
8 9
FIG U R E  2 Cyclopenta[a]phenanthrene haptens employed in this communication.
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The urine samples were from routine ward testing at the hospital from patients with 
a variety o f conditions. The age, disease status, sex, and smoking history o f these 
patients was also available, but not disclosed until the testing was completed. The 
samples were kept frozen at —20°C until required.
The cyclopenta[a]phenanthrenes employed were available from previous syntheses, 
and the steroids and PAHs were obtained from commercial sources. They were 
dissolved in pure dioxan which was added dropwise to water stirred at 50°C, and 
left to settle at room temperature for several days before the supernatant was 
carefully removed for analysis or use in an E L IS A  assay. The concentrations o f the 
resultant saturated solutions containing 13.4% v/v dioxan were measured by ultra­
violet spectrophotometry*® and solutions were diluted as required for addition to 
the plates.
Competitive ELISA assay
Standard 96-well optically flat-bottomed plates with lids supplied by Nunc were 
employed with the following reagents and protocol.
Saline phosphate buffer (solution A ) contained sodium chloride (8g), potassium 
dihydrogen orthophosphate (0.2 g), and disodium hydrogen orthophosphate (2.9 g) 
dissolved in 11 o f water.
Blocking buffer solution (solution B) was saline phosphate (A ) containing 0.1%  
polypep (low viscosity), 0.1%  Tween 80, and 0.02%  thimerosal, all from Sigma. 
Horseradish peroxidase substrate buffer (solution C) contained citric acid (5.22 g) and 
disodium hydrogen orthophosphate (7.1 g) in 11 o f water, p H  5.2-5 .3 .
Substrate (solution D ), freshly prepared before use, contained ort/zophenylene 
diamine monohydrochloride (10 mg) and 100 volume (60% ) hydrogen peroxide 
(1 0 /il)  in citrate buffer (C, 25 ml); this is sufficient for a single 96-well plate.
Stop solution (E) consisted o f concentrated sulphuric acid (33 ml) made up 11 with 
water.
Antibody incubation solution (solution F ) consisted o f saline phosphate buffer (A ) 
containing 0.1%  BSA and 0.1%  Tween 80.
Bound antigen detection solutions (G ) anti-rabbit Ig, biotinylated species specific 
whole antibody (Amersham International, 2 0 /il) in blocking buffer (B, 100 ml), 
and (H ) streptavin-horseradish peroxidase conjugate (also from Amersham, 20 /il)  
in the blocking buffer (B, 100 ml).
Assay procedure. Serial dilutions were made using a multichannel micropipette 
(Titertech, 12-channel, 5 0 -2 5 0 /il model). The plates were washed automatically 
with saline phosphate buffer (A ) using a Titertech microplate washer (S8/12) on a 
standard wash cycle, and incubated at room temperature in a humidity box. 
Optical densities were measured on a Titertech Multiscan Plus M k  I I  plate reader.
A ll 96 wells in the plate were coated with ovalbumin antigen (200 /il in each well), at 
a protein concentration o f 10 /ig /m l in saline phosphate (A ), for 1 h. The plates were 
then washed, and blocked with the polypep buffer (B, 250 /i l in each well) for an 
additional 1 h. A fter being washed again, all the wells were filled with the antibody 
incubation solution (F, 200 /il/well); this was followed by solutions o f the test 
samples (100 /il/w ell) in the first row o f wells only, all in duplicate. This row then 
contained:- well 1, blank (solution F); wells 2 &  3, positive control; wells 4 &  5, 
sample 1, wells 6 &  7, sample 2; wells 8 &  9, sample 3; wells 10 &  11, negative control
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(solution F ), well 12, blank (solution F). The solutions in these wells were mixed by 
repeated withdrawal and compression with the 12-channel pipette, and 100/il was 
transferred from each well to the corresponding well in the second row. A fter again 
being mixed this was repeated to the third row, and so on to the eighth row  
from which 100/il was discarded from each well to keep the volume constant at 
200 /il/well. Finally the probe anti-serum (in solution F , 50 /il)  was added to all wells 
and the plates were incubated overnight. They were washed and the biotinylated anti­
rabbit antibody solution (G , 200 /il)  was added to each well, incubated for 2 h, and 
submitted to the wash cycle. Each well was next filled with streptavidin horseradish 
peroxidase conjugate solution (H , 200 /il)  for 2h; it was then washed again and 
freshly prepared substrate solution (D , 200 /il)  was added. W ithin  a few minutes an 
orange colour developed; when this had reached a good intensity (>  1.0 optical 
density units) the reaction was terminated with the stop solution (E, 50 /il)  and the 
plate was read at 492 nm without delay. M ean values o f duplicates o f the optical 
density measurements were plotted on the y axis against concentration on the x axis.
Modified assay with human urine
The affinity purified antibody (probe anti-serum) was incubated for 1 h with 0.1 %  
BSA and 0.1%  Tween 80 in saline phosphate buffer prior to addition to the plate. 
Three specimens o f patients urine took the place o f the three samples in the above 
protocol, but the plate arrangement was otherwise unchanged.
Ethyl acetate extraction of urine
Urine (15 ml) was extracted six times in a separating funnel w ith freshly distilled ethyl 
acetate (20 ml). The combined extracts were dried over anhydrous magnesium 
sulphate, evaporated to dryness, and the residue was dissolved in methanol (1 ml) 
for examination by the E L IS A  procedure.
RESULTS
After affinity purification and the BSA incubation step the anti-sera no longer 
detected human serum albumin which shares 84% amino acid homology with the 
carrier protein BSA, and were judged suitable for the pilot study. Table 1 illustrates 
their selectivity with various cpps, steroids and P A H .
The 17-oxime-derived serum was used mainly in the pilot study with human urine 
because it detects a range o f cpp structures.*® The 11-ether-derived serum was also 
used for selected samples.
Samples o f urine from 46 patients have now been screened against the 17-oxime- 
derived serum. Figure 3 illustrates graphs drawn for typical plates, with mean 
duplicate optical density values on the y-axis plotted against concentration o f the 
positive control on the x-axis. Owing to minor variations between plates, the point 
o f intersection for the line drawn parallel to the x-axis (at 50% optical density of 
the positive control) with the positive control curve occurs at 0.03 nmole/ml in the 
left-hand graph, but at 0.04 nmole/ml in the right-hand graph. In  order to be able 
to compare plates, results are therefore calculated as percentages o f the positive 
control value for each plate.
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T A B LE  1
Selectivity* o f the two sera towards some cpps, steroids, and PAHs.
Compound 11-ether 17-oxime
17-ketone (2) 0.3 100
1 -methyl-17-ketone 30 9
2-methyl-17-ketone 0 0
3-methyl-17-ketone 0 0
6-methyl-17-ketone 0 0
7-methyl-17-ketone 0 56
11-methyl-17-ketone (3) 100 116
12-methyl-17-ketone 0 0
3-hydroxy-17-ketone (7) 0 0.5
11 -hydroxy-17-ketone 0 0
11 -ethoxy-17-ketone 60 0
Diels’ hydrocarbon (1) 1 4
Oestrone 0 0
Oestradiol 0 0
Equilenin 0 0
Androstenedione 0 0
Chrysene 0 0
Benz[a]anthracene 0 0
Benzo[a]pyrene 0 12
* Cross-reactions are measured as percentages o f the positive 
control, the 11-methyl-ketone (3) fo r the 11-ether serum, but the 
unsubstituted ketone (2) fo r the 17-oxime serum. For both sera 
the practical lim it o f detection was o f the order o f 1 pmole/ml for 
these ketones.
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Patient 2 
Patient 3 
-ve control
•2i
>>
.0 -in
c0)XJ
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0 .4
0.2
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1.4 - Patient 5 
Patient 6 
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1.0 -
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0 .4
1 01.01 1.001
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F IG U R E  3 Response o f urine from  six individual patients to the 17-oxime serum.
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On this basis the intersection o f the curve for patient 3 occurs at 0.30 nmole/ml, or 
about 10% o f the positive control. A ll o f the other five samples shown in this figure 
are clearly negative, clustering around the negative control above the 50% optical 
density line. O f the 46 samples examined in this way, ten were positive, and nine o f 
these were in the range 1 -1 0 %  o f the positive control. However, the tenth was 
recognised about 10 times better by this serum than was the positive control. 
This urine was extracted with ethyl acetate and extracts were examined by the 
E L IS A  technique. About 10% o f the activity passed into the organic solvent 
suggesting that at least this proportion was due to small molecule(s) recognised 
by the serum. Selected samples were also assayed with the 11-ether serum; all 
were negative including two which were positive to the 17-oxime serum, again con­
firming that these positives are not due to the detection o f protein epitopes in these 
samples o f urine.
DISCUSSION
As can be seen from Table 1, the two anti-sera used as probes in this study showed 
significantly different antigen binding characteristics. The 17-oxime derived anti­
serum detected a range o f cpp analogues including the carcinogenic 11-methyl- and 
7-m ethyl-17-ketones as well as benzo[a]pyrene, whereas the more specific 11-ether 
derived anti-serum recognised only certain 11-substituted-17-ketones, and only a 
few exceptions to this were observed.
Urine from one in five o f the patients in the pilot study showed a positive 
E L IS A  response to the 17-oxime derived serum, equivalent to 1 -10%  o f that 
given by about 30 pmole/ml o f the cpp ketone (2), whilst one patient displayed a 
level some 100-1000 times higher than these. This result was later confirmed by 
a second independent collection o f urine from this hospital-based patient suffering 
from schizophrenia and diabetes. The fact that the E L IS A  activity was partially 
removed from this patient’s urine by solvent extraction points to involvement o f 
a small molecule, and confirms that it was not due to cross reaction with an 
unusual protein in this urine. However there appeared to be no consistent relation­
ship between these positives and the particular disease status, age, sex, or smoking 
habits among these hospital patients. Since the 17-oxime anti-serum detects also 
some biologically important phenanthrene-based P A H  (Table 1, also reference 
10), chemical identification o f the compound(s) responsible for this E L IS A  activity 
will be necessary before a conclusion as to its origin can be made. The selected 
urines probed with the 11-ether anti-serum exhibited no positive reactions; these 
included two urine samples positive to the 17-oxime anti-serum, thus excluding 
for example the carcinogenic 11-methyl-17-ketone from being involved since both 
anti-sera detect this compound.
I t  is clear that screening needs to be extended in several directions. A  much larger 
population o f both hospitalised patients with defined disease status as well as normal 
subjects need to be studied in order to ascertain better the frequency o f positives and 
to detect others with abnormally high responses. The present results are all single time 
points; it w ill be important to follow positives over a protracted period for this might 
provide clues as to the origin o f this activity. A ll five sera raised against these cpp 
antigens and discussed in more detail in reference^® must be employed because they 
each identify different regions o f the molecule, and hence different analogues. They 
also exhibit common recognition sites, allowing cross reference between sera as 
described in this communication.
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W hile these results are interesting and informative, much remains to be done 
before we can answer the question “do cyclopenta[a]phenanthrenes occur in human 
biofluids?” .
REFERENCES
1. O. Diels, W. Gadke and P. Kording, Annalen, 459 (1927) 1-26.
2. B. J. M air and J. L. Martinez-Pico, Proc. Am. Petrol. Inst., 42 (1962) 173-85; B. Ludwig, G. Hassler, 
P. Wehrung and P. Albrecht, Tetrahedron Lett., 22 (1981) 3313-16; A. S. Mackenzie, C. F. Hoffmann 
and R. J. Maxwell, Geochim. Cosmochim. Acta, 45 (1981) 1345-55.
3. S. G. Wakeham, C. Schaffner and W. Giger, Geochim. Cosmochem. Acta, 44 (1980) 415-19; Y. L. Tan 
and M . Heit, Geochim. Cosmochim. Acta, 45 (1981) 2267-79.
4. L. Schmid, Get. Lebensmittelunter Hyg. 53 (1962) 507-10; M . W ilk  and W. Taupp, Z. Naturforsch. 24B 
(1969) 16-23.
5. M . M . Coombs and T. S. Bhatt, “ Cyclopentafajphenanthrenes", Cambridge University Press, 1987.
6. A. Butenandt and H. Dannenberg, Arch. Geschwulstforsch., 6 (1953) 1-7.
7. M . M . Coombs, T. S. Bhatt and S. Young, Brit. J. Cancer, 40 (1979) 914-21.
8. S. Kashino, D. E. Zacharias, R. M . Peck, J. P. Glusker, T. S. Bhatt and M . M . Coombs, Cancer Res. 46 
(1986) 1817-29.
9. K . H. Loke, G. F. M arrian and E. J. D. Watson, Biochem. J., 71 (1959) 43-8.
10. M . B. Jones and M . M . Coombs, Polycyclic Arom. Compounds, 4 (1994) (In  preparation).
11. M . B. Jones and M . M . Coombs. In  Polycyclic Aromatic Compounds; Synthesis, Analytical Measure­
ments, Occurrence and Biological Effects, ed. P. Garrigues and M . Lamotte, pp. 1783-1788, Gordon 
Breach Science Publishers, Amsterdam, 1993.
Antigens prepared from cycIopenta[a]phenanthrenes
MICHAEL B. JONES* and MAURICE M. COOMBS
Imperial Cancer Research Fund Laboratory, Department of Chemistry, University of Sumey, 
Guildford, Surrey, GU2 5XH, Engand.
* Present adress:- Imperial Cancer Research Furtdiaboratories, Lincoln's Inn Reids, London
WC2A 3PX, England.
ABSTRACT _
Five derivatives of 15,16-dihydrocyclopenta{a]phenanthren-17*one were synthesised bearing 5-6 
atom-long linker arms terminating with carboxyl groups. Linkage at C-3 and at C-11 was through O-butyryl 
ethers, at C-15 by way of a S-ether with thiopropionic acid, at C-16 via a hemisuccinate ester, and at C-17 
through a carboxymethyloxime. These hapten acids were allowed to react, as their active N- 
hydroxysuccinimide esters, with the lysyl e-amino groups present on proteins to form antigens suitable
for the production of polyclonal antibodies .
Keywords: cyclopenta[a]phenanthrenes, protein conjugates, antigens
INTRODUCTION
Cyclopentafajphenanthrenes such as Diels' hydrocartwn (1 ) (fig. 1 ) occur in petroleumi and mineral 
oils2 and even in cooking oils which have been overheated^. Plant sterols are thought to act as their 
precursors in these sources. We ourselves have been more interested in the 17-ketones of this series, 
such as the ketone (2) (15,1 B-dihydrocyclopentafajphenanthren-l 7-one) because of the suggestion that 
fully aromatic phenanthrene derivatives of this sort might occur in animals and mari as a result of faulty 
oestrogen metabolism .^ Moreover, certain derivatives of this ketone are carcinogenic: for example the 11- 
methyl-17-ketone (3) is a more potent carcinogen than benzo[a]pyrene on mouse skinS, and this presents 
an additional reason for interest in their possible natural occurrence.
Fig. 1 Diels' hydrocart>on (1 ) , 15,16-dihydrocyclopenta[a]phenanthen-17-one (2), and its carcinogenic 
11-methyl homologue (3).
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Of course at present it is unknown whether compounds of this class occur in animals or man, and we 
are concerned to bridge this gap in our knowledge. To this end we have chosen, for several reasons, to 
adopt an immunochemical approach. The foremost reason is that this approach should be capable of high 
sensitivity similar to that offered by mass spectroscopy, but unlike the latter require little or no prior 
preparation of the sample and be directly applicable to aqueous specimens. Also since we do not know 
the precise structure(s) of the compound(s) sought, it is necessary to devise a flexible yet specific method 
for the identification of cyclopenta[a]phenanthrenes as a class. For this reason we decided to prepare a 
panel of polyclonal antibodies using as the antigens the ketone (2 ) attached to the protein carrier through 
a number of different points on the ketone's periphery, in the expectation that this would lead to antisera 
that would recognise different parts of the cyclopenta[a]phenanthrene structure. A preliminary report 
outlining more fully the background of this project and giving details of the competitive ELISA assay 
devised and its application to human urine samples has already appeared^.
8{CH2)2C00R'
a,R=(CH2)3CN
b,R=(CH2)3COOH 
O*
C,R=(CH2)3C0,
NOCHoCOOR'
b, R'a.R' = H
d,R=(CH2)3CONHC6Hii
Fig. 2 , Haptens and intermediates involved in their synthesis
MATERIALS AND METHODS
Most of the cyclopenta[a]phenanthrene derivatives employed were available from previous syntheses.
16,16-Dihydro-3-hydroxycyclopenta(a]phenanthren-17-one was a generous gift from Professor R. G. 
Harvey. Ultraviolet spectra were recorded with ethanol solutions unless otherwise stated and are 
expressed as Xmax(togio £) where £ is the molar absorbtion coefficient in mole/litre. Infrared spectra were 
measured as Nujol mulls. IH n.m r. spectra were mn with CDCI3  solutions (unless othenvise specified) on a 
Bruker instrument at 300 MHz ; chemical shifts are measured in p.p.m. downfield from tetramethylsilane.
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Preparation of 11-f3-cvanoDrotx>xvM5.16-dihvdrocvc(oDentafa?Dhenanthren-17-one (5a)
15,16-Dihydro-11-hydroxycyclopenta(a]ptienanthren-17-one7 (3.0g) and dry potassium cartwnate 
(2.5g) were heated under reflux with 4-bromobutyronitrile (5.3g) in acetonitrile (250mL) for 44h when 
TLC indicated absence of the phenol. The solution was filtered from the precipitated potassium 
bromide, the latter was washed with a little acetonitrile, and the combined solutions were concentrated 
to about 50mL. The yellow crystals that separated from the cooled solution were collected and dried 
(3.4g). A specimen recrystallised from the same solvent had mp 178° (Found: C, 79.95; H, 5.4; N, 4.95. 
C2 1 H1 7 O2 N requires C, 79.95; H, 5.45; N, 4.50%), Vmax2248 (C=N) and 1694 cm-1(C=0).
Hvdrolvsis to 11-(3-carfaoxvproDoxvl-15.16-dfhvdrocvclQDentafalphehanthren-17-one fSb)
This nitrile (5a) (1.6g) was dissolved in hot glacial acetic acid (100 ml.) giving a golden solution which 
became deep red following the addition of an equal volume of conc. hydrochloric acid. The mixture was 
boiled under reflux for 35 min, cooled, and the yellow crystalline solid filtered off and dried (1.28g). A 
specimen recrystallised from acetic acid had m.p. 222-223°.(Found: C, 75.6; H, 4.95 C2 1 H1 8 O4  requires 
C, 75.45; H, 5.4%), vmax 1730 (acid C=0). 1665 cm'1 (ketone C=0).
3-f3-Cyanopropoxv)- (4a).and 3:(3-cart?QxyprQPoxy)-15.16-dihYdrpcyclopentaIa]phenanthrenJ7Qne.i4b), 
This nitrile (4a) was prepared from the 3-hydroxy-17-ketone as described above. It formed yellow 
needles, m.p. 175° (Found: N, 4.2%), vmax 2250 (C = N) and 1698 (C=0) cm 1.
Acid hydrolysis of the nitrile (0.17g) as before, gave brick red needles of the acid (4b) (0.15g) lacking 
this infrared CN absorption, Vmax 1728 (acid C=0) and 1652 ( ketone C=0) cm-1, Xmax 221 (3.52), 268.3 
(3.94), 278.7 (4.01), 292.7 (3.66), 323.8 (3.44), 348.8 (3.15), 365.6 (2.74) nm, 6 h (de-DMSO) 8.74 (2H, 
t,1- andll-H), 7.97 (1 H, d, J q j  8.95 Hz, 6 - or 7-H), 7.88 (1H, d, J e j  8.95 Hz, 6 - or 7-H), 7.76 (1H, d,
1 .1 2 8 . 6  Hz. 1 2 -H). 7.33 (1H, d. J 2.4 2.4 Hz, 4-H),7.26 (1H, dd, J i , 2  8.9 Hz. J  2.4 2.4 Hz, 2 -H), 3.45 (2H, 
m, 16-H), 2.79 ( 2H, m,15-H), 2.5 2.3 (6 H, multiplets, side chain methylene protons ).
Ereparation of 15-f3-carboxvethvlthioM 5.16-dihvdrocvclopentafalPhenanthren-17-one (6b )
16-Bromo-15,16-dihydrocyclopenta[a]phenanthren-17-one8 (0.24g), dissolved in dry benzene 
(50mL), was treated at room temperature with triethylamine (0.5mL). After 15 min 3-mercaptopropionic acid 
(0.25mL) was added to the deep yellow solution of the 15(16)-en-17-one, Xmax 313 nm; the colour paled, 
and after 2 h its ultraviolet spectrum disclosed complete conversion to product Xmax 270 nm. Water was 
added and the aqueous layer was acidified with dilute hydrochloric acid and re-extracted with 
dichloromethane. The combined organic layers, beginning to deposit brown solid, were evaporated to 
dryness. The resulting solid was dissolved in hot n-butanol which on being cooled gave cream rosettes of 
needles of the thioether acid (6 a) (0.12g). A sample recrystallised twice from n-butanol had mp 206°.
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(Found: C, 71.2; H, 5.0. C2 0 H1 6 O3 S requires C. 71.4; H, 4.8%), v^ax 1738(acid C=0) and 1679 (ketone 
C=0) cm 'l. X m a x  270.4. 299.7. 353.1, 370.7 nm, Sh 12.35 (1H. s, acid-H), 8.95 (1H. d, J 1 1 , 1 2  8.6 Hz, 
11-H), 8.90 (1H. m, 1-H), 8.40 (1H, d. Je,? 8.8 Hz, 7-H), 8.05 (2H, m, aryl-H), 7.82 (1H d. Je.? 8.8 Hz, 6-H), 
7.78 (2H, m, aryl-H), 5.30 (1H, d. J15. I6 6.5 Hz, 15-H), 3.45 (1H, dd. Jis.166.5 Hz, Jie.ie 19.2 Hz, 16-H), 
2.95 (1H, d, J i6 ,l6  19.2 Hz, 16-H) and multiplets at 2.84 (2H) and 2.72 (2H) due to the side chain 
methylene groups.
Preparation of15.16-dihvdrQ-16-hvdroxvcvc(QPentafalDhenanthren-17-one 16-hemisuccinate (7a).
Dry 15,16-dihydro-16-hydroxycyclopenta[a]phenanthren-17-one9 (50mg) was dissolved in 
anhydrous pyridine (ImL) and succinic anhydride added. After four days at room temperature the pyridine 
was removed by repeated co-evaporation with benzene and the resulting solid was dissolved in ethyl 
acetate. Extraction of the latter with sodium bicarbonate solution and acidification gave a solid which was 
again extracted into ethyl acetate. This solution was dried and evaporated to yield the acid (7a) as a white 
solid (65mg). Owing to lack of material this compound was characterised only by spectrocopy, showing the 
expected C = O bands at Vmax 1740 (ester), 1700 (acid), and 1685 (ketone) cm"1, and 5h (de DMSO) 12.3 
(1H. s, acid H), 8.97 (2H, dd, 1- and 11-H), 8.2-7.75 (6H, m, aryl-H), 5.10 (1H, dd, 16-H), 4.10 (1H, dd, 15- 
H), 3.40 (1H, dd, 15-H), 2.65 and 2.52 (2H each, m, side chain methylene protons).
Preparation of 15.16-dihvdrocvclopentafalPhenanthren-l 7-one carboxvmethvlQximeJSa)
15,16-DihydrocyclopentaIa]phenanthren-17-one (0.59g) was dissolved in boiling ethanol (lOOmL). 
A solution of carboxymethoxyamine hydrochloride (0.8g) in 2N potassium hydroxide solution (4mL) was 
added and boiling was continued overnight. The almost colourless solution containing white solid was 
concentrated to about 4mL, water (lOOmL) was added, and the mixture was shaken with ether, leaving 
white solid at the interface. This was collected, washed wqll with water and dried (0.73g). It,recrystallised 
from a large volume of boiling ethyl acetate as small prisms, mp 225°C (decomp) (Found; C, 74.3; H, 4.8; N, 
4.75. C 1 9 H 1 6 O3 N requires C, 74.5; H, 5.25; N, 4.6%), vmax1736 (C=0) and 1634 (C=N) cm-1, Xmax 
270.8(4.71), 283.7sh(4.67), 286.9(4.50), 295(4.37), 300.7(4,40), 308.8(4.21), 332.6(3.14), 348.5 
(3.41). 356.8 (2.90), 366.2 (3.47) nm. 5h (de- DMSO) 12.7 (1H, s, acid H), 8.84 (1H, d, J1 . 2  7.75Hz,1-H). 
8.77(1 H, d, J11.12 8.7HZ.11-H), 8.1-7.95 (2H, m, aryl-H), 7.79 (1H, d, J n . 1 2  8.7Hz,12-H),7.72-7.65 (3H, 
m, aryl H), 4.71 (2H, s, side chain methylene protons), 3.40(2H, m. 16-H), 3.05 (2H, m, 15-H).
This acid was suspended in 3N HCI containing 20% ethanol and stirred at room temperature for 1  
hour. It slowly dissolved and needle-shaped crystals of the ethyl ester separated and were collected, 
m.p.169-1700 (Found; C, 75.65; H,5.7; N,4.3. C2 1 H1 9 NO3  requires 0,75.65; H.5.75; N,4.2%), Vmax 
1754 cm-1 (ester c=0 ), no OH signal, Xmax 269.7(4.86), 295(4.61), 307.9(3.40), 331(3.33), 339.7(3.11), 
347.5(3.57), 355(3.09), 365.2 (3.61) nm.
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Preparation of N-hvdroxvsuccinimide esters
The 17-oxime-acid (8a) (0.3g ) was stirred in dry dioxan (50mL) with N-hydroxysuccinimide (0.9g) and 
dicyclohexylcarbodiimide (0.36g, DCC) at room temperature for 4 days. The white finely divided precipitate 
of dicyclohexylurea was removed by filtration and the mother liquor was evaporated to give a gum. The 
latter was dissolved in the mininum volume of dichloromethane and precipitated by the addition of hexane; 
this procedure was repeated until a drop of the dichloromethane solution, dried as a film on an NaCI plate, 
no longer showed the presence of DCC by its strong infrared absorption at 2120cm-1.The resulting glass 
(0.46g) was crystallised from ice-cold dichloromethane to yield the NHS ester (8b) (0.121 g), m.p. 178- 
1830 with decomposition, vmax1810,1780cm-1, Xmax (measured in dichloromethane) 270.8(4.71), 
283.7(4.67), 286.9(4.50), 300.7(4.40), 332.6(3.14), 348.5(3.41), 356.8(2.90), 266.2(3.47) nm, 5h 8.71 
(1H, d, 1-H), 8.65 (1H, d, 11-H), 8.0-7.6 (6H, m, aryl-H), 5.10 (2H, s, side chain methylene protons), 3.45 
(2H, m, 16-H), 3.02 (2H, m, 15-H), 2.85 (4H, s, succinimide ring protons).
The 16-hemisuccinate (7a) (75 mg), subjected to the same procedure, afforded the NHS ester (7b), 
m.p. 162-1670, vmax1814, 1783, 1736 (ester C=0), and 1726 (ketone C=0) cm-1. Xmax (in 
dichloromethane) 268.3(5.06), 286.7(4.71), 300.1(4.62), 338(3.42), 354.9(3.61), 372.9(3.62) nm, 5h 
8.75 (2H,dd,1- and 11-H), 8.05-7.70 (6H, m. aryl-H), 5.68 (1H, dd, Jis,l67.7and 4.2 Hz, 16-H), 4.15 (1H, 
dd, J 15,1517.1, J 15.16 7.7 Hz, 15-H), 3.38 (1H. dd, J 1 5 . 1 5  17.1, J 1 5 , 1 6  4.2 Hz, 15-H), 3.04 and 2.96 (2H 
each, m, side chain methylene protons), 2.82 (4H, s, succinimde ring protons).
The thioether acid (6a) (0.49g) was treated as described above to yield the NHS ester (6b) which 
was crystallised from ice-cold dichloromethane, vmax1820, 1790, 1740, and 1720 (ketone C=0) cm-1, 
Xmax (in dichloromethane) 273.3(4.80), 301.5(4.43), 353(3.27), 371.6(3.30) nm, 5h 8.82 (1H, d, J 1 1 . 1 2
8.6 Hz, 11-H), 8.73 (1H, dd,1-H), 8.37 (1H, d, J 6.7 9.0 Hz, 7-H), 8.0 (3H, m, aryl-H), 7.7 (2H, m, aryl-H). 
5.12 (1H, dd, J 1 5 , 1 6  1.3 and 6.9 Hz, 15-H), 3.40 (1H, dd, J 1 5 , 1 6  6.9, J i 6 .1 6 19.2 Hz, 16-H), 3.17 (1H, dd, 
J l 5 , 1 6  1.3, J 16.16 19.2 Hz, 16-H), 2.85 (4H s, succinimide ring protons), 3.05-2.80 ( 4H, m, side chain 
methylene protons).
The 3-ether acid (4b) (0.15g) on treatment by this procedure yielded the NHS ester (4c) as a 
yellow resinous solid , Vmax 1811, 1775, 1735, and 1680 cm-1, Xmax ( in dichloromethane) 205.5, 277.0 
and 320.0 nm.
The 11- ether acid (5b) was subjected to these conditions and after removal of the excess of DCC 
the oil had the n.m.r. spectrum expected for the NHS ester, 6h 9,76 (1H, dd, 1-H), 7.95 (3H, m, aryl-H), 
7.73 (2H, m, aryl-H), 7.42 (1H, s, 12-H), 4.45 (2H, t, 16-H), 3.42 (2H, t, 15-H), 3.70, 3.00 and 2.52 (2H 
each, m, side chain methylene protons), 2.85 (4H, s, succinimide ring protons).This oil was was 
chromatographed on a flash column of silica gel (50g) in dichloromethane with increasing amounts (2-20%) 
of ethyl acetate. Two fractions were collected, running on TLC as discrete, but overlapping spots. Both 
fractions had elemental analyses consistent with the expected NHS ester (5c) (Found: fraction 1, C,69.30;
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H.4.8; N.3.2 ; fraction 2, C,69.35; H.4.95; N.3.2. C2 5 H2 1 O6 N requires C.69.6; H,4.9; N,3.25%), Vmax 
1811, 1781,1733,1688 cm-1. A portion of the oil before chromatography was stirred overnight In dioxan 
(10 mL) with cyclohexylamlne (0.3 mL). The reaction mixture was diluted with dicloromethane which was 
washed successively with dilute sulphuric acid , water, saturated aqueous sodium hydrogen caitronate, 
and water, and dried over anhydrous magnesium sulphate. Evaporation left a solid which was recrystallised 
from hot ethanol as pale yellow needles of the cyclohexamide (5d), m.p. 207-2080C (Found; C,78.15; H, 
7.0; N, 3.25. C2 7 H2 8 O3 N requires 0,78.05; H,7.05; N,3.35%), Vmax 3290 (N-H),1690 (ketone 0=0), 
1640(amide 0=0) cm-1, Xmax 263.0 (5.02), 293.6 (4.64), 3.03 (4.49), 346.1 (3.56), 363.6 (4.21), 381.9 
(4.23) nm, 6 h 9.75 (1H. dd, 1-H), 8.0-7.8 (3H, m, aryl-H), 7.70 (2H, m aryl-H), 7.33 (1H, s, 12-H), 5.35 (1H, 
d, NH), 4.30 (2H, t, 16-H), 3.77 (1H, m, methine-H), 3.35 (2H, t, 15-H), and side chain and cyclohexane 
multiplets at 2.82 (2 H), 2.47 (4H), 1.85 (2 H), 1.6 (3H), 1.32 (2H), 1.05 (3H).
Preparation of protein conjugates
To bovine serum albumin (108 mg, 1.66 mmole) dissolved in 0.1 M phosphate buffer (pH7.1) (50 mL) 
containing dioxan (2mL) was added dropwise with stirring the oxime active ester (8 b) (lOmg, 24.9 mmole) 
dissolved in dioxan (4mL), and stirring was continued overnight at ambient temperature. Small molecular 
weight materials were removed by passing the cloudy solution down a G25 exclusion column (44cm x 3cm 
diam.). The protein, eluted first with 0.1 M phosphate buffer (pH7.4), possessed the strong ultraviolet 
absorption characteristics of the oxime (8 a). To establish further that this was due to covalent binding, this 
solution was dialysed overnight against 0.1 M sodium dIhydrogen phosphate buffer (pH 4.8, 500 mL) 
causing the protein to precipitate out In the dialysis sac. Re-dlalysis against 0.1 M phosphate buffer (pH 
7,1, 500 mL) redissolved the protein, and the ultraviolet spectrum of this solution was unchanged after this 
procedure.
Ovalbumin conjugates and the other BSA conjugates were prepared by essentially the same 
method; in each case the final purified protein bore the ultraviolet absorption spectrum of the 
cyclopentajajphenanthrene acid (4b, 5b, 6 a, 7a, or 8 a) used. In certain cases the conjugate solution was 
also extracted several times with ethyl acetate, but this also had no effect on the wavelength or intensity of 
its spectrum. Estimations of the cyclopenta[a]phenanthrene-to-protein molecular ratios were readily 
accomplished by ultraviolet spectroscopy. The strong chromophores of the cyclopenta[a]phenanthrenes 
with maxima In the 265-270 nm range (see above) allowed the construction of good linear standard curves 
by adding carefully measured quantities of these acids to the appropriate protein solutions; the protein 
contents were assayed by the bicinochoninic acid methodic using the assay kit supplied by Pierce 
Chemicals. With BSA these ratios were generally in the expected 15-30 range (table 1), but with ovalbumin 
they were less possibly owing to the lower solubility of this protein at this pH
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BSA conjugate Ratio of cppiBSA
17-oxlme conjuqate la 30
17-oxime conjugate 1 b 34
17-oxime conjugate 1 b after dialysis 28
17-oxime conjugate 2 42
16-hemisuccinate 1 9
16-hemisuccinate 1  after dialysis 13
15-thioether 9
3- ether 17
1 1 -ether 15
Table 1 . Ratios of cpp bound to bovine serum albumin in the various antigens. The 17-oxime 
conjugates la  and 1 b were derived from the same preparation, divided, and subjected to different 
work up procedures. Dialysis included protein dénaturation at pH 4.8 followed by a second dialysis 
step at pH 7.1, as described.
RESULTS AND DISCUSSION
Small molecules such as cyclopenta(a)phenanthrenes are not immunogenic unless they are 
attached to a macromolecule such as a protein. Moreover the site of attachment of the ketone (2) to the 
protein via the bifunctional linker arm determines the visibility of the hapten to the immune system, and 
hence defines the structural selectivity exhibited by the antisemm. It was therefore decided to prepare a 
panel of antigens by attaching the ketone (2) to proteins at several points on its periphery via 5-6 atom-long 
linker arms terminating in cartxjxyl groups as shown In figure 3; it was thought that a chain of this length was 
required to ensure good visiblity of the hapten. The active N-hyroxysuccinimide esters of these acids were 
allowed to react with the lysyl e-amino groups in the protein to fomi covalent amide links in the antigens.
The sites at which to place the linker chains on this ketone were chosen for the following reasons. 
Retention of a sp2 caiton at C-17, necessary for enhancing carcinogenic activity in compounds of the 
cyclopenta[a]phenanthrene series'! i , was Important and linkage through an oxime at this position met this 
requirement. Moreover this route has been successfully employed to produce antisera to 17- 
ketosteroidsi2. The 15- and 16-positions, especially the former, are major points of oxidative metabolism in 
this ketoneiG, and offered useful sites for linker arms. Nearly all natural steroids bear an oxygen atom at C- 
3 and it has been suggested that cyclopenta[a]phenanthrenes may arise from this source :^ therefore, as 
part of the reason for establishing this assay was concerned with this question, a 3-0-llnked hapten was
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required. Finally, a variety of bay-region 11 -substituted analogues of the parent ketone (2 ) possess 
carcinogenic and mutagenic properties^, and the 11-hydroxy-17-ketone which is itself weakly 
carcinogenici4 offered an a convenient phenolic site for attachment at this crucial position.
11-ether
P -^ —  17-oxime
—  16-hemlsucclnate 
^  ^  15-thioether
3-ether
Fig. 3 Points of linker arm attachment to the ketone (2 )
Chemical syntheses of these new cyclopenta[a]phenanthrenes tsearing linker arms was carried out 
as follows. Succinoylation of the 16-hydroxy-17-ketone gave the hemisuccinate (7a) which appeared to 
be reasonably stable to hydrolysis: Niswenderi2 used an analogous intermediate ester to raise antisera 
against 6 a- and 6 p-progesterone. Succinoylation of the phenolic 11-hydroxy-17-ketone failed to occur, 
probably owing to steric hindrance in the bay-region. In contrast the 3-phenol readily reacted, but its 
hemisuccinate was extremely labile being hydrolysed rapidly even with sodium hydrogen carbonate 
solution. Other methods of linking at these positions were therefore examined and the procedure selected 
involved condensation of the phenols with 4-bromobutyonitrile in the presence of potassium cart>onate to 
yield the cyanopropyl ethers (4a and 5a), followed by vigorous acid hydrolysis . In each case the butanoic 
acid ethers (4b,5b) were obtained in good overall yield from these phenols.
Previously we had found that 15(16)en-17-ones could be readily generated from 16-bromo-17- 
ketones under mild conditions with triethylamine, and that nucleophiles added to these enones at C-15 
with facility15. As anticipated, 3-mercaptopropionic acid was no exception and the 15-thioether acid (6 a) 
was secured in this way: the presence of the sulphur atom at 0-15 was confirmed by the -0.4 p.p.m. 
downfield shift of H-7 and -1.8 p.p.m. downfield shift of l-i-15 in the n.m.r. spectrum of this acid and its 
NHS ester (6 b).The unsubstituted 17-ketone (2 ) reacted smoothly with carfx)xymethoxyamine to yield the 
required oxime (8 a), the n.m.r. spectmm of which disclosed a single, sharp 2 -proton singlet assigned to 
the side-chain methylene group. This suggested a single geometrical isomer, confirmed by an X-ray 
crystallographic study of its ethyl ester which provided suitable crystals for this purpose, showing that the 
molecule possessed the anti structure with the side-chain directed away from the phenanthrene ring 
system as depicted in figure 4. We are indebted to Drs.J. Davies and D. Povey of this Department for this 
data which will be described more fully elsewhere. It was important to establish the precise structure of this 
oxime because presentation of the isomeric syn or anti forms to the immune system would result in the 
production of antisera with different specificities.
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C IS C7 C 60 1 6
C M01 CS
C4m C802
C ISC 2 0 C3C IO
CSC I8
'0 3 C I 2 t 2C l I
C 2 I
Fig. 4 X-ray crystal structure of the 17-oxlme ethyl ester (8 , R='Et) showing the anti arrangement of the 
linker chain away from the rings.
These acids were readily converted into their active N-hydroxysuccinimide esters by reaction with 
N-hydroxysuccinimide in the presence of dicyclohexylcartaodiimide; they posessed characteristic caitionyl 
bands in their infrared spectra at 1810-1820 and 1780-1790 cm-1. and prominent singlets at 5 -2.8 p.p.m. 
in their Hi n.m.r. spectra due to the four equivalent succinimide protons. One of these NHS esters, (5c) 
derived from the 1 1 -phenol, behaved chromatographically as a mixture of two compounds, both analysing 
correctly and having identical infrared spectra. However the mixture reacted readily at room temperature 
with cyclohexylamlne to yield a single amide (5d). It is interesting that during an X-ray study of 11-ethyl-
15,16-dihydrocyclopenta(a)phenanthren-17-one two crystalline polymorphs were found, showing 
different conformations of the ethyl group. In one both ethyl cartxms were approximately in the plane of 
the rings, whilst in the other the terminal ethyl cartxjn was out of this plane 16.
The active esters (4c,Sc,6b,7b,8b) were allowed to react in aqueous dioxan solution with bovine 
serum albumin and with ovalbumin overnight. After separation from low molecular weight materials by 
exclusion chromatography, the proteins possessed strong ultraviolet absorption spectra characteristic of 
the cyclopenta[a]phenanthrene acids used and this provided à convenient way of estimating the bound 
ratios. We were concerned to demonstrate that the spectra were due to covalently bound compounds, 
rather than simple adsorption onto the protein. Dénaturation of the proteins at acid pH in dialysis sacs and 
renaturation in neutral buffer did not alter their spectra qualitatively or quantitatively , thereby excluding 
ionic adsorption. Moreover, extraction with ethyl acetate, a good solvent for these polycyclic aromatic 
compounds, also had no effect thus eliminating the possibility of hydrophobic adsorption. The bound 
cyclopenta[a]phenanthrene-to-protein molecular ratios, at least for the BSA conjugates (see Table 1), were 
also roughly in accord with the known number of available lysyl e-amino groups in this protein. Finally, as will
be described in a forthcoming p a p e r i7 .  they acted as efficient immunogens, useful antisera being 
obtained from each of the five antigens described here. The remarkable selectivity of these antisera
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among a wide range of cyclopenta[alpfienanthrenes as well as some steroids and polycyclic hydrocartxins 
will also be presented fully in that communication.
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6 6
Rules governing protein conjugate nomenclature used in this 
thesis.
In an attempt to standardise and simplify the text, an outline of the 
protein cyclopenta[aphenanthrene nomenclature has been included at the 
beginning of chapter 3, with a loose leaf copy available for direct reference 
whilst reading the text.
1. The protein is labelled as the first three to four letters of its 
name(i.e. bovine serum albumin is BSA, Thyroglobulin is Thy, Chicken 
ovalbumin is Oval preceded with a single initial i.e. B for bovine or P for 
porcine to identify its species.
2. In all cases conjugate, antigen, serum, affinity column, the 
protein name is followed by the numerical site of linkage to the 
cyclopenta[a]phenanthrene followed by the atom of attachment.
3. Protein conjugate
Is the cyclopenta[a]phenanthrene modified protein 
and the word conjugate is used when the chemistry or physical 
characteristics of this product is discussed.
4. Protein antigen
Where a protein conjugate has been applied to an 
assay, and its roll is that of the target antigen; then the label applied to this 
conjugate is changed from conjugate to antigen.
4. Serum or antigen derived from a conjugate.
Where a serum is derived from an antigen (Protein
conjugate) and for the purposes of discussion the protein carrier is not an 
essential part of the discussion. The serum or antigen are labelled by the 
cyclopenta[a]phenanthrene numerical position of attachment and the atom to 
which the protein is ultimately linked
Examples:-
BSA-17-N-conj = Bovine serum albumin -17- oxime (anf/-15,16- 
dihydro-cyclopenta[a]phenanthren-17-one carboxymethyloxime) linked 
conjugate.
BSA-17-N-ant = Bovine serum albumin-17-oxime(anf/-15,16-dihydro- 
cyclopenta[a]phenanthren-17-one carboxymethyloxime) linked antigen
17-N-linked = Indicates that discussion of the conjugate, antigen or 
serum is being carried out, where the roll of the carrier is not an 
essential feature of the discussion.
Other conjugates of BSA include:-
BSA-16-0- Protein is attached to the 16-position via a hemisuccinate 
ester(15,16-dihydro-16-hydroxycyclopenta[a]phenanthren-17-one -16.- 
hemisuccinate)
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BSA-15-S- Protein is attached to the 15-position via a thioether 
linkage(15-(3-carboxyethylthio)-15,16-dihydrocyclopenta[a]- 
phenanthren -17-one).
BSA-11 -O- Protein is attached to the 11 -position via an ether 
linkage(11 -(3-carboxypropoxy)-15,16-dihydrocycIopenta[a]- 
phenanthren-17-one).
BSA-3-0- Protein is attached to the 3-position via an ether 
linkage(3-(3-carboxypropoxy)-15,16-dihydrocyclopenta[a]phenanthren- 
17-one).
18
[18] [30] [42]chrysene
[19] [31] m
OCHg
[20] [32]
[44]
OH
[21] [33]
HO [46][22]
[23] [47]
[10]
[24] [36]
[12] [25]
[14] [26] [38]
[15] [27]
[39]
[16]
HO[28] [40]
HO OH
[29] [53]1411
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[62][54]
[59]
[56]
[60] Androstenedione [ 641
----------  OH
[65][611
Benzo[a]pyrene
Benz[a]anthracene | [gg]
